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Abstract
 
Protein kinases have evolved as key players in the signaling processes that allow the 
mammalian cell to respond to environmental stimuli. Determination of the function of 
each the individual members of this large class of enzymes is aided by development of 
selective inhibitors. Most kinase inhibitors function through binding the highly conserved 
ATP-pocket and are often poorly selective as a result. This dissertation assesses two 
general strategies to improve kinase inhibitor selectivity. One strategy regards ATP-
competitive inhibitors which target distinct kinase folds, and an orthogonal strategy 
regards targeting inhibitor binding sites outside of the highly conserved ATP-pocket. 
First, the drug dasatinib is rationally altered to provide two sets of inhibitors which 
respectively bind distinct “inactive” kinase folds (DFG-out and c-helix out). Large scale 
selectivity profiling reveals that most of dasatinib’s kinase targets can adopt the DFG-
out conformation, while the c-helix out conformation appears less conserved. These 
results imply that targeting inactive conformations does not necessarily entail higher 
kinase inhibitor selectivity.  
Second, inhibitors that target regions outside of the ATP-pocket are developed using a 
bivalent approach. A fragment intended to target a region outside of the ATP-pocket is 
covalently tethered to an ATP-competitive inhibitor. Application of this strategy 
demonstrates the amount of selectivity that can be gained from targeting alternate 
pockets. In one example, we show that the site at which kinases bind their protein target 
can be modularly targeted for highly selective inhibition. In another example, the 
development of a highly selective c-Src inhibitor is achieved through targeting the 
phosphate binding-loop region. In an application of our c-Src selective inhibitor, it is 
xiv 
 
shown that selective inhibition is more effective than multi-kinase inhibition in the 
treatment of several cancer cell lines. 
Altogether this dissertation provides insight regarding the design of selective kinase 
inhibitors. One study reveals that ATP-competitive inhibitors that bind “inactive” kinase 
folds appear to be much less selective than previously suggested. A second study 
demonstrates that targeting sites outside of the ATP-pocket can provide very highly 
selective kinase inhibitors. 
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CHAPTER 1 
Chemical inhibition of protein kinases
The focus of the graduate research described herein has been the development of 
chemical tools for the investigation of structural features of protein kinases which may 
be exploited for selective inhibition.  
There are two separate-but-interrelated themes throughout the dissertation:  
1) How does binding an “inactive” fold influence kinase inhibitor selectivity? 
Chapters 2 and 3 describe the rational syntheses of ATP-competitive inhibitors which 
bind distinct inactive kinase forms (DFG-out and c-helix out). These compounds are 
based upon an inhibitor which is known to bind the active DFG-in form. This research 
allowed for an analysis of the selectivity differences between kinase inhibitors which 
respectively bind the DFG-in, DFG-out and c-helix out folds. It is revealed that all three 
conformations appear largely conserved across the kinome. One particular derivative 
displays exceptional activity in the treatment of several cancer cell lines.  
 2) How much selectivity may be gained by exploiting structural features outside of the 
canonical ATP-pocket? 
Chapters 4 and 5 are devoted to kinase inhibitors that interact with structural features 
outside of the ATP-pocket. Both chapters employ a common strategy using an ATP-
competitive “anchor” to tether another chemical fragment which is intended to interact 
with a site outside of the ATP-pocket. Chapter 4 highlights the level of selectivity that 
may be obtained through inhibitor interactions with the substrate-binding site. In an 
related approach, Chapter 5 discusses the development of the most highly selective 
cell-permeable inhibitor of c-Src kinase which is proposed to exploit an interaction with 
the phosphate-binding loop. 
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1.1 Protein kinases and their role in cell-signaling 
Eukaryotic life requires that all of the individual components of the cell 
intercommunicate in a manner that promotes healthy growth and division. Cell-signaling 
is a complex process which is regulated, in part, by protein phosphorylation.1,2 Protein 
phosphorylation cascades result from the activity of protein kinases, which are a family 
of enzymes with over 500 unique members encoded within the human genome.3 The 
process of reversible protein-phosphorylation catalyzed by protein kinases accounts for 
one of the most important post-translational modifications involved in eukaryotic cell 
signaling.4,5 While protein kinases account for only two percent of the human genome, it 
has been estimated that at least half of human proteins contain at least one site which 
undergoes a physiologically relevant phosphorylation6. Phosphorylation of protein 
targets has a variety of effects including, but not limited to, activation, translocalization 
and degradation.7,8 Many proteins contain several phosphorylation sites which allow for 
fine tuning of function.  
Protein phosphorylation events must be tightly regulated to ensure appropriate cellular 
response to the given environmental cues. Deregulation of protein kinase activity can 
significantly affect the morphology of a cell and eventually the surrounding tissue, which 
leads to a variety of diseases including cancer.9-11 Protein kinase inhibitors (PKIs) 
represent the largest class of new cancer drugs12,13 with six biologic examples and 
twenty small-molecule drugs currently approved by the FDA.  
 
1.2 Approaches to modulation of kinase activity 
Methods for the selective modulation of protein kinase activity are critical for 
understanding the individual roles for these enzymes in cellulo, and also how 
deregulation leads to disease. While genetic knockout/knockdown experiments provide 
highly selective removal of the desired target there are several drawbacks to this 
approach,14 but these shortcomings can be addressed using chemical inhibition (Figure 
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1.1). Chemical inhibition is attractive due to reversible and dose-dependent action with 
good spatiotemporal control. Furthermore, when selective small-molecule inhibition is 
used in combination with genetic techniques, meaningful insights that would be missed 
by employing either method independently can be obtained.15,16  
Genetic regulation Chemical regulation 
  
Advantages 
High selectivity (Few off-targets) 
Easily accessible, synthetically trivial 
Not limited to “drugable” targets 
Advantages 
Dose easily varied 
Rapid onset 
Reversible 
 
Figure 1.1. Strategies for the modulation of kinase activity. Figure adapted from reference 14. 
Unlike RNAi, development of selective small-molecule inhibitors is a challenging 
process. According to criteria set by Knapp et al17 there are only 25 inhibitors which can 
be defined as ‘high-quality’ kinase probes. Given that there are over 500 human kinases 
there is clearly an unmet research need. Most selective kinase inhibitors have been 
discovered serendipitously through high-throughput screening. Rational inhibitor design 
could greatly contribute to reducing this deficit. Development of selective kinase 
inhibitors also contributes to the foundation of drug discovery.18-20 
 
1.3 General features of small-molecule kinase inhibitors
Protein kinases can generally be categorized as phosphotransfersases. They contain 
respective binding sites for both adenosine triphosphate (ATP) and protein substrate. 
Upon binding both ATP and substrate, a kinase-assisted transfer of a phosphate unit 
from ATP to protein substrate occurs. Thus, in the design of small-molecule kinase 
4 
 
inhibitors there are two major sites that can be targeted (Figure 1.2). An overwhelming 
majority of small-molecule protein kinase inhibitors function through binding the ATP 
pocket.  
  
Figure 1.2. General structural features of A) the kinase domain and B) potential ligand binding sites 
within the kinase domain highlighted using space filling. Images were rendered using Pymol. PDBID: 
2ZV9 (A) and 2G1T (B). 
 The ATP-pocket is a hydrophobic cleft21 which has evolved to accommodate the 
heterocycle adenine, and thus small-molecule inhibitors have a natural inclination for 
occupation of this site. In contrast, the substrate-binding site has evolved to serve as an 
interface for protein-protein interaction. Small-molecule inhibitor binding of the 
substrate-binding site is generally unfavorable due to its flat and solvent-exposed 
nature.  
The selectivity of ATP-competitive 
kinase inhibitors has been observed 
to vary greatly (Figure 1.3).22-24 Most 
kinase inhibitor selectivity profiles fall 
somewhere in between the two 
extremes. While kinse inhibitor 
selectivity is not necessarily 
paramount for drug development, 
 
Figure 1.3. Spectrum of kinase inhibitor selectivity. 
Staurosporine (left) is a representative non-selective 
inhibitor, whereas lapatinib (right) is a representative 
selective inhibitor. 
A B 
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their use as probes necessitates high fidelity for the target of interest.17 Achieving high 
selectivity in this region is difficult due to the low sequence variability of this region.25 
ATP-competitive kinase inhibitors 
ubiquitously display interactions with 
the hinge region, which are to similar 
to those of adenine (Figure 1.4). 
Unlike adenine, many inhibitors 
exploit interactions with a 
hydrophobic pocket in the back of the 
ATP-binding site. Inhibitor binding of 
this back pocket can influence the 
positioning of structural features such 
as the activation loop and c-helix of 
the kinase. It has been proposed that 
interaction with this back pocket may improve inhibitor selectivity. 
 
1.4 DFG-out inhibitors 
Protein kinases dynamically interchange between active and inactive structural 
conformations.26 The first observed instance of a kinase in its inactive form was the co-
crystal structure of Abl kinase bound to the small-molecule inhibitor imatinib27,28 (Figure 
1.5). In this structure, the benzamide moiety of imatinib occupies a pocket that usually 
accommodates the phenylalanine residue of the DFG motif at the base of the activation 
loop. Binding this pocket results in a ‘DFG-flip’, and this perturbs the orientation of the 
aspartic acid (DFG) residue necessary for catalysis. Furthermore, displacement of the 
DFG phenylalanine (DFG) dismantles a series of hydrophobic residues referred to as 
the ‘regulatory spine.21,29 
 
 
Figure 1.4. Detailed interactions of a DFG-in inhibitor 
with the ATP-pocket. Shown is PP2 bound to c-Src 
(PDB: 2ZV9). Hydrogen bonds to residues within the 
hinge region are highlighted in cyan. 
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Figure 1.5. The first example of a kinase observed in the DFG-out conformation. A) Chemical structure of 
imatinib; and B) co-crystal structure of imatinib bound to Abl kinase. The DFG motif is highlighted in 
orange. Portions of the kinase have been removed for clarity. PDB: 1IEP. 
Imatinib was the first FDA approved kinase inhibitor and has generated considerable 
attention due to its success in the treatment of chronic myelogenous leukemia driven by 
the BCR-Abl oncogene.30-32 The clinical success of imatinib was largely credited to high 
selectivity for the ATP-binding site of the BCR-Abl kinase oncoprotein.24 The selectivity 
was assumed to be the result of binding a structural pose (DFG-out) that only BCR-Abl 
could assume. However, subsequent to these seminal findings it has been determined 
that at least 16% of all protein kinases can assume this fold33,34 (Figure 1.6). Despite 
these confounding observations, targeting the DFG-out conformation remains highly 
cited as a valid mechanism for improving kinase inhibitor selectivity.35-40  
The general features of DFG-out 
inhibitors are represented by the 
structure of sorafenib bound to 
BRAF kinase (Figure 1.7). As with 
most kinase inhibitors, DFG-out 
inhibitors usually have hydrogen 
bond interactions with the “hinge” 
region analogous to those of 
adenine. Additionally, as 
nomenclature would imply, the defining feature of DFG-out inhibitors is the flipping of 
the DFG motif at the base of the activation loop. The DFG flip is usually induced by  
 
Figure 1.6. Examples of kinases other than Abl that 
adopt DFG-out in the presence of a small-molecule 
inhibitor. 
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inhibitor occupation of the pocket that 
usually accommodates the displaced 
DFG phenylalanine. The flip of the 
activation loop disallows protein 
substrate binding, and this is why 
DFG-out is frequently referred to as 
an inactive form. Additionally, DFG-
out inhibitors routinely make 
hydrogen-bond interactions with the 
backbone of the activation loop and a 
glutamate sidechain of the c-helix at 
the back of the ATP-pocket. 
DFG-out inhibitors have received so much attention that a general method for the 
conversion of a DFG-in to a DFG out inhibitor has been developed, 41,42 and this method 
is graphically summarized in Figure 1.8. Briefly, assisted by x-ray co-crystal structures 
the authors rationally append a m-trifluoromethyl-benzamide moiety to a known DFG-in 
inhibitor. This serves to both 
occupy the back hydrophobic 
pocket of the ATP-binding site, 
and also provide a hydrogen bond 
donor interaction with the 
glutamate side chain of the c-
helix. The authors report four 
successful examples of 
application of this method. There is a limited examination of the selectivity of the 
respective pairs, and in general there is little difference in the profiles. The panels 
employed were relatively small which makes definitive conclusions difficult.  
Unexpectedly, DFG-out inhibitors have been observed to display different properties in 
cellulo relative to their DFG-in counterparts that are not due to selectivity differences 
(Figure 1.9). For example, Raf kinase has been observed to undergo dimerization upon 
 
Figure 1.7. General features of DFG-out inhibitors as 
represented by sorafenib bound to BRAF kinase. 
Hydrogen bonding interactions are represented as cyan 
dashes. The image was constructed using PDBID: 
1UWH. Part of the kinase has been removed for clarity. 
 
Figure 1.8. A general method for converting DFG-in to DFG-
out inhibitors, as initially proposed by Gray et al. 
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treatment with a DFG-in inhibitor,43 and DFG-out inhibitors have been shown to have a  
strikingly different influences on heterodimerization of BRAF kinase mutants.44 Another 
example is IRE1α’s kinase-controlled RNase.45 DFG-out inhibitors of the IRE1α kinase 
domain have been shown to allosterically modulate the activity of fused RNase domain. 
 
Figure 1.9. DFG-out inhibitors impact protein-protein differently than DFG-in inhibitors. 
 
Despite significant investment in the development of DFG-out inhibitors there has not 
been a thorough analysis of how their general properties might diverge from their DFG-
in counterparts. A side-by-side comparison has been made difficult because there has 
not been an appropriate set of inhibitors. Using a set from the aforementioned 
manuscript is not ideal because the DFG-out inhibitors are generally much more potent 
than their DFG-in parent. Chapter 2 describes a set of inhibitors which is aptly suited for 
such analyses. 
1.5 c-helix out inhibitors 
The ability of protein kinases to adopt 
both active and inactive conformations 
has allowed for a variety of methods for 
medicinal chemists to design small-
molecule inhibitors of a desired target. 
Small-molecule engagement of a 
specific structural conformation results 
in trapping of the protein in a local thermodynamic minimum that is associated with a 
given shape. There is increasing evidence that stabilization of a specific structural 
conformation using a small-molecule kinase inhibitor can influence biological activities 
that are not directly related to catalysis, such as participation in protein-protein 
DFG-in DFG-out c-helix out unknown 
afatinib 
bosutinib 
crizotinib 
dasatinib 
erlotinib 
gefinitinib 
pazopanib 
sunitinib  
axitinib 
imatinib 
nilotinib 
sorafanib 
ponatinib 
lapatinib ruxolitinib 
SU6656 
tofacitinib 
vemurafenib 
ibrutinib 
everolimus 
 
Table 1.1. Categorization of FDA approved small-
molecule kinase inhibitors by binding conformation. 
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interactions (PPIs).43,45,46 Therefore, a kinase inhibitor may have an effects beyond just 
turning the enzyme “off”. Design of inhibitors which can engage alternative 
conformations could serve as valuable tools to interrogate these ancillary PPIs. 
The current bias for kinase inhibitor development is 
represented by the categorization presented in Table 1.1. 
The majority of inhibitors bind the “active” DFG-in fold. 
Half as many inhibitors have been found the inactive 
DFG-out state. Only one FDA approved kinase inhibitor 
has been observed to bind the alternative c-helix out 
inactive conformation.47 Studies from our laboratory 
suggest that targeting the inactive DFG-out conformation 
of protein kinases is not a valid approach for improving 
selectivity (see chapter 2). Conversely, inhibitors which 
engage the c-helix out conformation have been observed 
to be highly selective for their given targets and this is 
represented by the selectivity profile of lapatinib (Figure 
1.10).36 
The c-helix out conformation is represented by the structure of c-Src kinase in its 
autoinhibited state in the presence of its regulatory domains48 (Figure 1.11). The 
authors suggest that clamping effect of the SH2 and SH3 domains upon the kinase 
domain results in a torsional forces which twist the c-helix outward from its catalytically 
conducive position. This autoinhibitory mechanism is believed to be shared by most 
other nonreceptor protein tyrosine kinases.49  
It has since been proposed that c-helix out is the biologically relevant inactive pose for 
most protein kinases, in contrast with DFG-out which is thought to be induced solely 
through small-molecule engagement. Small-molecule binding of the c-helix out pose is 
therefore particularly attractive because of the potential of influencing the regulatory 
domains with have cellular activities unrelated to catalysis. 
 
 
Figure 1.10. Selectivity profile 
of a lapatinib, a selected c-helix 
out kinase inhibitor. Data have 
been modified from Nat. Chem. 
Biol.
36
.  
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Figure 1.11. c-Src adopts c-helix out upon engagement of the regulatory SH2 and SH3 domains. A) c-
Src’s kinase domain (blue) in its autoinhibited state in the presence of its regulatory SH2 (red) and SH3 
yellow domains. AMPNP is bound in the ATP-binding site. B) A close-up image of the rotated c-helix 
showing the conserved Glu in a position not compatible with catalysis. DFG motif is observed in the DFG-
in conformation and is additionally highlighted in orange. Images constructed using PDBID: 2SRC. 
Small-molecule stabilization of the c-helix out conformation of the kinase domain has 
been shown to have a profound effect on the organization of the regulatory domains of 
c-Src46 (Figure 1.12). In one example a set of small-molecule inhibitors which 
preferentially bind to the c-helix out conformation of the kinase domain are shown to 
induce engagement of the SH2 and SH3 domains. Kinase inhibitors which influence the 
regulatory domains offer a unique mechanism of inhibition because the SH2 and SH3 
domains participate in many protein-protein interactions.  
In related studies, it has been found 
that while both DFG-in and c-helix out 
inhibitors efficiently diminish the 
catalytic activity of the kinase domain, 
they diverge in their ability to regulate 
dimerization of receptor tyrosine 
kinases.50,51 
 
Figure 1.12. Small-molecule binding of the c-helix out 
conformation results in organization of the SH2 and 
SH3 domains. 
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A typical binding mode for a c-helix out inhibitor is represented by Figure 1.13. Similar to 
most kinase inhibitors, c-helix out inhibitors generally have hydrogen bond interactions 
with the hinge region of the ATP-pocket. 
Similar to DFG-out inhibitors, c-helix out 
inhibitors also have a hydrophobic 
substituent which engages the back 
hydrophobic pocket. c-helix out inhibitors 
differ from DFG-out inhibitors because 
they lack a hydrogen bond interaction with 
the glutamate side chain of the c-helix. 
There is no general strategy currently available for converting a DFG-in to c-helix out 
inhibitor as there is for DFG-out inhibitors. This is a topic of discussion in Chapter 3. 
Development of this strategy has allowed for a cross-comparison of the DFG-in, DFG-
out, and c-helix out conformations in terms of general biochemical properties. 
 
1.6 Bisubstrate-competitive inhibitors 
Small-molecule strategies for inhibition of kinase activity mainly rely upon ATP- 
competitive inhibition of the catalytic domain52. Development of selective small-molecule 
kinase inhibitors remains a significant challenge due to the highly conserved nature of 
the ATP pocket.25,53,54 One particularly promising alternative strategy is the targeting of 
the less conserved substrate-binding site55-57 (for a review of this topic see reference 
58). Substrate-competitive inhibitors offer high selectivity,59,60 but generally suffer from 
poor potency due to the lack of a conventional small-molecule ligand pocket. 
Conversely, bisubstrate kinase inhibition attempts to compensate for the low potency of 
substrate-competitive inhibitors through covalent linkage to an ATP-competitive 
inhibitor. Theoretically, the merging of two inhibitors which have mutually exclusive 
binding sites should result in an inhibitor with improved potency relative to the parent 
compounds. Bisubstrate kinase inhibition has been of interest for some time61 yet there 
 
Figure 1.13. General features of a c-helix out 
inhibitor. 
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are sparse examples in which potency is dramatically improved upon merging the 
respective fragments. 
The bivalent inhibition strategy has a history that is closely tied to the transition-state 
inhibition theory. Unlike other enzymes such as proteases or phosphatases there is no 
covalent intermediate in the phosphotransferase reaction catalyzed by protein kinases. 
This makes targeting the phosphotransfer transition-state a considerable challenge. 
Rather than irreversibly trapping a catalytic cysteine, as is the case with phosphatase 
transition state mimetics, two inhibitor ligands must be tethered with a geometry that is 
representative of the phosphotransfer event. 
Inhibitors that interact with the substrate-binding site offer several potential promising 
outcomes that cannot be achieved solely with conventional ATP-competitive inhibitors. 
First, ligand binding of the substrate-binding site has been established to be coupled to 
dimerization and autophosphorylation as has been observed with PKR.62,63 Second, 
interference with protein-protein interactions associated with this site may have other 
interesting advantages that have yet to reveal themselves. 
 By definition, bisubstrate kinase 
inhibitors simultaneously interact with 
both the ATP and substrate-binding 
sites. Bisubstrate PKI inhibitors can be 
divided into three general classes 1) 
ATP-peptide conjugates 2) Adenine-
peptide conjugates and 3) ATP-
competitive inhibitor-peptide 
conjugates (Figure 1.14). The latter 
are the primary focus of Chapter 5 and 
thus will solely be discussed here.  
The biochemical potency of 
bisubstrate kinase inhibitors has been reported to range from low nanomolar to high 
micromolar. The ATP-competitive fragment is usually the largest contributor to affinity.  
 
Figure 1.14. General classes of bisubstrate kinase 
inhibitors.  
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A synergistic increase in potency upon covalent linkage of the respective inhibitors is 
expected due to a lower entropic penalty for inhibitor binding,64 although this is not 
always observed in practice. Conjugation of the two fragments does not always 
appreciably increase potency with respect to the two individual components (Table 1.2). 
The lack of synergistic improvement in potency is frequently attributed to suboptimal 
linker length.65 
Table 1.2 summarizes data extracted from a list 
of references from a recent review focused on 
bisubstrate inhibition of protein kinases.58 All 
citations which included data for both the final 
and parent ATP-competitive fragment are listed.  
As expected, most examples show an increase 
in potency relative to the ATP-competitive 
parent. Two examples surprisingly show 
instances in which the parent compound is 
actually made worse. 
The most promising advantage of bisubstrate 
protein kinase inhibitors over their ATP-
competitive counterparts is improved selectivity. However bisubstrate inhibitor selectivity 
is often only minimally investigated. In a recent review on bisubstrate inhibition58 there 
were only four examples66,70,73,74 in which a bisubstrate inhibitor was profiled against a 
panel of greater than thirty kinases (Table 1.3), and all other references included panels 
of less than six. A panel of thirty kinases represents only six percent of the human 
kinome. Furthermore the compounds that were profiled against large panels displayed 
relatively poor selectivity, and all fail to meet the definition of a “quality kinase probe”17.  
The four examples of bisubstrate inhibitors that were subjected to large kinase panels 
(Table 1.3) were all inhibitors specifically designed for PKA. In three of the citations, a 
highly positively charged peptide was linked to an ATP-competitive inhibitor, and this 
may explain the low selectivity. The general tendencies of basophilic kinases were 
exploited rather than the individual preferences of their target. The one reference 
Reference Fold improvement 
of conjugate vs 
parenta 
Enkvist et al66 698 
Ho et al67 0.51  
Meyer et al68 93 
Loog et al69 1,180 
Enkvist et al70 137,000 
Hines et al65 0.23 
Nam et al71 33 
Loog et al72 1,020 
 
Table 1.2. Analysis of potency 
improvement for conjugates versus parent 
compounds. 
a) Varying metrics were used between 
authors to determine affinity so ‘fold 
improvement’ is used in order to normalize 
the value. ATP-competitive parents are in 
general more potent so this was selected 
to be the representative ‘parent’. 
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(Shomin et al74) that deviated from this model, and tailored the peptidic inhibitor 
specifically to the target, achieved the highest selectivity.  There has been little 
examination of the selectivity of bisubstrate inhibitors designed for non-basophilic 
kinases such as tyrosine kinases.  
In summary, the high selectivity boasted by bisubstrate kinase inhibition has not been 
fully validated. Chapter 4 describes a modular method for the synthesis of bisubstrate 
inhibitors for tyrosine kinases. Also in this chapter, an optimized bisubstrate inhibitor for 
c-Src kinase is submitted to selectivity profiling to demonstrate an unprecedented 
improvement in selectivity relative to its ATP-competitive parent. 
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CHAPTER 2 
Rational design of DFG-out inhibitors
This chapter begins to address the question of “How does binding an “inactive” fold 
influence kinase inhibitor selectivity?” Specifically, this chapter regards the targeting of 
the DFG-out inactive kinase conformation. (For an introduction to DFG-out inhibitors 
see Chapter 1.4.) Derivatives of a DFG-in inhibitor (dasatinib) are created to target the 
DFG-out fold. Creation of these analogs allows for a head-to-head comparison of 
inhibitor selectivity with dasatinib. Using a large kinase panel, we determine if targeting 
the DFG-out conformation is a valid strategy for improving inhibitor selectivity. To date, 
this work represents the most extensive analysis of the impact of binding the inactive 
DFG-out fold on inhibitor selectivity. Additionally, one DFG-out derivative is discovered 
to have exceptionally high activity in the treatment of aggressive breast cancer cell 
lines.  
2.1 Introduction 
 The DFG-out conformation has long been stated to be non-conserved across protein 
kinases. Therefore it has been assumed that targeting the DFG-out fold should entail 
high inhibitor selectivity. Despite this assumption, an increasing number of kinases have 
been observed to adopt the DFG-out 
conformation. These observations led to the 
development of the hypothesis that most, if 
not all, kinases are capable of adopting the 
DFG-out conformation. Toward this end the 
promiscuous kinase inhibitor dasatinib 
(Figure 2.1) was rationally augmented to provide analogs designed to target the DFG-
out fold.  
 
Figure 2.1. Chemical structure of dasatinib. 
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2.2 Results and Discussion 
In order to assess how binding the DFG-
out conformation influences kinase 
inhibitor selectivity, a complementary pair 
of inhibitors needed to be developed. A 
strategy which has previously been 
applied toward transforming a DFG-in 
inhibitor into a DFG-out inhibitor was 
employed.2,3 The drug dasatinib,4,5 a pan-
kinase DFG-in inhibitor, was selected as a 
starting point. Briefly, the structure of 
dastanib bound to Abl6 was overlayed with 
several other structures of Abl complexed 
with DFG-out inhibitors (such as imatinib7, 
Figure 2.2A). This overlay revealed a 
distinct molecular overlap between 
dasatinib and the DFG-out inhibitors via a 
common phenyl ring. The juxtaposition 
suggested that incorporation of a benzamide moiety into dasatinib would result in an 
inhibitor which would bind the DFG-out fold.  
A model compound that incorporated this benzamide feature was synthesized (Figure 
2.2B). In order to make comparisons with dasatinib it was necessary for the DFG-out 
analog to be comparable in binding affinity. We selected two kinases that are already 
known to adopt the DFG-out fold and conducted an activity-based phosphorylation 
assay to assess inhibitor potency. It was found that compound 2.1 strongly inhibited 
both Abl and Src kinase, which are also potently bound by the parent dasatinib 
scaffold.8  
The activity of compound 2.1 was subsequently determined against a panel of the top 
twenty-five kinase targets of dasatinib8. All kinases selected for profiling exhibited high 
affinity for DFG-out compound 2.1 (Figure 2.3). As a control, five kinases which poorly 
 
 
Figure 2.2. Design of a dasatinib derivative that 
will bind the DFG-out conformation. A) Overlay of 
dasatinib (yellow) and imatinib (orange) 
respectively bound to c-Abl (PDBIDS: 2GQG 
&1IEP); and B) Chemical structure for model 
compound 2.1 along with inhibition constants for c-
Src and homologous kinase Abl derived from an 
activity based assay
1
.. 
A 
B 
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bind dasatinib were also included in the panel; compound 2.1 did not display 
appreciable affinity for these kinases (data not shown). Altogether, these data begin to 
imply that most kinases that are targets of dasatinib can adopt the DFG-out fold. 
Targeted kinase inhibitor therapy has revealed that cancer cells are prone to acquisition 
of mutations which confer resistance to small-molecule inhibitors9-12. Compound 2.1 and 
dasatinib were assayed against a representative “gatekeeper mutation” in c-Src kinase, 
a mutation that has been observed in many forms of cancer. While dasatinib retains 
micromolar affinity (Figure 2.4), compound 2.1 disappointingly displayed negligible 
binding to the mutant kinase (data not shown).  
Compound 2.1 was minimally 
altered to incorporate features 
commonly found in other DFG-out 
inhibitors. Specifically, a m-
trifluoromethyl substituent was 
incorporated into in the benzamide 
moiety (compound 2.2), and a 
methyl group was incorporated in 
the central phenyl ring (compound 
2.3). These features can be found 
in a similar position in inhibitors 
such as nilotinib and imatinib.  
Both of these chemical changes 
positively contributed to inhibition of the gatekeeper mutant (Figure 2.4). Compound 2.3 
 
Figure 2.3. Selectivity profile for compound 2.1 using a single-point binding assay. Compound 2.1 was 
screened at a final concentration of 1 µM. Kinases were selected based upon affinity for dasatinib with the 
kinases displaying the highest potency listed on the left. For tabulated data see experimental section.  
 
 Ki (nM) 
Compound  R =  Src 
wt 
Abl 
wt 
Src 
T341I 
Src 
T341M 
dasatinib  n/a  < 0.6  < 3.4 1,586  3,300  
2.2  H  < 0.6  < 3.4 56  403  
2.3  Me  < 0.6 < 3.4 2.2 3.1  
 
Figure 2.4. Biochemical kinase inhibition data for 
dasatinib and two DFG-out derivatives. from an activity-
based continuous kinase inhibition assay. 
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is one of the most potent inhibitors of this important resistance mutation to date. 
Currently, ponatinib13 (which has recently been clinically withdrawn) is the only viable 
option for treating the gatekeeper mutation, so the discovery of 2.3 can be regarded as 
a finding of potential therapeutic significance. 
After obtaining the encouraging initial 
results for the DFG-out analogs, it 
was desired to confirm that they were 
indeed binding the proposed 
structural conformation. Compound 
2.2 provided an adequate resolution 
(2.61 Å) structure bound to c-Src 
(Figure 2.5). Compound 2.2 was 
observed to bind c-Src with a clearly 
flipped DFG motif. The m-
trifluormethyl benzamide moiety of 
2.2 correlates with density in the DFG-out pocket, and the DFG motif is adequately 
resolved in the predicted inactive conformation. 
After binding the DFG-out fold was structurally confirmed, compounds 2.2 and 2.3 were 
profiled14 against a large 
panel of 131 kinases 
alongside dasatinib. In 
agreement with the 
preliminary profiling of 
2.1, the DFG-out 
inhibitors were not more 
selective than dasatinib 
(Figure 2.6). To the contrary, compound 2.3 was found to be as poorly selective as 
dasatinib (S(35) = 0.20). Altogether, these data indicate that binding the DFG-out fold 
does not significantly improve kinase inhibitor selectivity.  
 
Figure 2.5. X-ray co-crystal structure of compound 2.2 
bound to c-Src kinase (2.61 Å resolution). The DFG 
motif in addition to the c-helix Glu and catalytic Lys are 
highlighted in orange. Data kindly provided by Frank 
Kwarcinski (Soellner Lab). 
   
dasatinib 2.2 2.3 
Figure 2.6. Kinome profiling of dasatinib, 2.2, and 2.3 using a single 
point binding assay. All compounds were screened at a final 
concentration of 500 nM. A tabulated list of binding data is included in 
the experimental section.  
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Given the high biochemical similarity of compound 2.3 and dasatinib, it was surprising to 
observe differences in the treatment of several cell lines (Table 2.1). Compound 2.3 was 
more effective than dasatinib in treating two aggressive breast cancer cell lines (MDA-
MB-453 and MDA-MB-23) in 2-dimensional cell culture models. Further investigation of 
compound 2.3 in three-dimensional culture conditions revealed an amplified 
performance of compound 2.3 relative to dasatinib (twenty-fold advantage). Cell culture 
under 3-D conditions is considered to be more representative of in vivo conditions.  As a 
crude toxicity model human mammary epithelial (HME) cells were also treated. The 
Therapeutic Index (T.I.) was significantly improved for 2.3 relative to dasatinib (T.I. = 
200, and 132 respectively). In this case T.I. is defined as HME GI50/MDA-MB-231 (3D) 
GI50.  
 GI50 (µM) 
compound MDA-MB-453 
(2D) 
MDA-MB-231 
(2D) 
MDA-MB-231 
(3D) 
HME 
(2D) 
dasatinib 6.17 0.15 0.043 5.7 
2.3 0.04 0.08 0.002 0.4 
 
Table 2.1. Treatment of breast cancer cell lines using compound 2.3 and dasatinib. Data 
kindly provided by Michael Steffey (Soellner Lab). 
The divergence in in cellulo activity for dasatinib and compound 2.3 was somewhat 
puzzling. It is possible that factors within the cell may influence inhibitor binding that 
would not be detected using the isolated recombinant kinase assays employed for 
profiling. Additionally, it is also possible that compound 2.3 may have ATPase targets 
that dasatinib does not. In order to address both of these issues the in cellulo selectivity 
for ATP-binding proteins was determined using KiNativ profiling15 (Table 2.2). Briefly, 
the KiNativ assay employs a biotinylated acyl phosphate of ATP the irreversibly reacts 
specifically with conserved lysines within the ATP-binding site of protein kinases. Upon 
treatment with a small molecule, any reduction in labeling of a given kinase relative to 
control can be attributed to inhibitor binding.  The KiNativ probe is also known to label 
other ATPases in a similar fashion, which makes it particularly well suited for answering 
the current selectivity questions. 
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Kinase dasatinib 
Compound 
2.3 
EphA2 >96 68.7 
EphB2 >96 >96 
LYN >95 >95 
EphB4 >93 88.9 
ACK >92 79.9 
ABL,ARG >85 >85 
SRC >84 >84 
QSK >70 -13.1 
CSK 98.6 96.5 
FYN,SRC,YES 96.7 95.3 
CSK 96.5 94 
ZAK 93.7 93.9 
MAP2K5 88 40.5 
 
 
STLK5 78.7 -7.5 
KHS1 75.8 38.9 
TEC 73 64 
Wee1 69.2 21.9 
ILK 67.9 25.7 
p38a 67.9 95.2 
TESK1 65.6 12.7 
STLK5 59.5 -6.7 
MAP3K4 54.8 28.8 
MAP3K1 47.6 36.4 
KHS2 36.4 11.6 
GCK 32.8 41.8 
EGFR 18.8 46.1 
ROCK1,ROCK2 15.3 35.1 
p38b 2.4 76.6 
Table 2.2. Selected KiNativ profiling data for compound 2.3 and dasatinib. Both inhibitors were screened 
at a final concentration of 0.5 µM. The twenty-five kinases shown are ranked in terms of dasatinib 
affinity. 
 
The KiNativ data show that selectivity profiles for dasatinib and compound 2.3 largely 
overlap, which is in good agreement with biochemical profiling experiments. One 
difference does stand out though; compound 2.3 is a potent inhibitor of p38β kinase 
whereas dasatinib is not. It was considered that p38β inhibition might explain the 
improved performance of compound 2.3 
relative to dasatinib. This was briefly 
investigated in an experiment using a 
combination of dasatinib with BIRB-796 
(BIRB-796 is a well established inhibitor 
of p38β16) in the treatment MDA-MB-
231 cancer cells (Figure 2.7). The 
growth inhibition from the inhibitor 
combination was greater than what 
would mathematically be expected from 
additive inhibition. Thus we suggest that 
improved cellular performance of 
compound 2.3 relative to dasatinib is, in part, due to p38β inhibition.
 
 
Figure 2.7. Assessment of dual inhibitor treatment of 
a breast cancer cell line using dasatinib and a p38β 
inhibitor (BIRB-796). Data kindly provided by Mike 
Steffey. 
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2.3 Conclusions 
In this chapter we have compared the selectivity profiles of dasatinib and two 
derivatives which were designed to bind the DFG-out conformation of protein kinases. It 
was found that were few differences between the profile of dasatinib, compound 2.2, 
and compound 2.3. Overall these data are consistent with the hypothesis that targeting 
the DFG-out conformation is not a valid approach to improving kinase inhibitor 
selectivity.  
One of the novel DFG-out derivatives (compound 2.3) displayed a surprising increase in 
the effectiveness of treating cancer cells. In cellulo profiling revealed a minor selectivity 
difference between 2.3 and dastinib. Specifically 2.3 strongly inhibited p38β whereas 
dasatinib does not. In combination experiments it was shown that adding a p38β 
inhibitor to dasatinib treatment significantly improves performance in slowing breast 
cancer cell growth. 
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2.4 Experimental Section
 
GENERAL SYNTHETIC METHODS. Unless otherwise noted, all reagents were 
obtained via commercial sources and used without further purification. Tetrahydrofuran 
(THF) and dichloromethane (CH2Cl2) were dried over alumina under a nitrogen 
atmosphere. All 1H and 13C NMR spectra were measured with a Varian MR400, Varian 
VNMRS 500 or Inova 500 spectrometer. Mass Spectrometry (HRMS) was carried out by 
the University of Michigan Mass Spectrometry Facility (J. Windak, director). 
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SYNTHESIS OF COMPOUNDS 2.S-1- 2.3 
 
Scheme 2.S-1. Synthesis of compounds 2.1 - 2.3. 
 
 
Synthesis of 2.S-1: Compound 2.S-1 was synthesized using a literature protocol. 
Product yields and spectral properties agreed with those reported. 
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Synthesis of 2.S-2: Compound 2.S-2 was synthesized using a literature protocol. 
Product yields and spectral properties agreed with those reported. Spectral data.  1H 
NMR (500 MHz, Chloroform-d) δ 7.86 (d, J = 7.6 Hz, 2H), 7.77 (s, 1H), 7.56 (t, J = 7.4 
Hz, 1H), 7.54 – 7.45 (m, 2H), 7.33 (d, J = 2.0 Hz, 1H), 7.14 (t, J = 7.9 Hz, 1H), 6.80 (dd, 
J = 8.0, 1.9 Hz, 1H), 6.49 (dd, J = 8.0, 2.1 Hz, 1H), 3.75 (s, 2H). 13C NMR (100 MHz, 
cdcl3) δ 165.65, 147.30, 138.92, 135.12, 131.74, 129.75, 128.74, 126.94, 111.28, 
109.96, 106.77; HRMS-ESI (m/z): [M + H]+ calcd for C13H12N2O, 213.1022; found 
213.1035. 
 
Synthesis of 2.S-3: 3-nitroaniline (7.5 g, 54.3 mmol) was added to an oven-dried flask. 
Dichloromethane (271 mL) was added. The reaction mixture was then cooled to 0oC 
using an ice bath. 3-trifluoromethylbenzoyl chloride (12.4 g, 59.7 mmol) was then 
added, followed by diisopropylethylamine (8.42 g, 65.2 mmol). The reaction mixture was 
then allowed to warm to room temperature and stir overnight. Dichloromethane (270 
mL) was then added. The reaction mixture was then washed with 1 N HCl (270 mL), the 
aqueous layer was then back-extracted three times with dichloromethane (100 mL). The 
organic layers were then collected and dried over sodium sulfate. The solvent was then 
removed under reduced pressure. The crude reaction mixture was then purified via 
silica gel chromatography using a Biotage Isolera One to yield 16 g of compound 2.S-3 
as a light yellow solid (95 % yield). Spectral data. 1H NMR (400 MHz, DMSO-d6): δ 
10.92 (s, 1 H), 8.77-8.74 (m, 1 H), 8.32-8.26 (m, 2 H), 8.21-8.17 (m, 1 H), 7.98-7.92 (m, 
2 H), 7.80-7.74 (m, 1 H), 7.66-7.61 (m, 1 H); 19F NMR (376 MHz, dmso) δ -61.15; 
HRMS-ESI (m/z): [M + H]+ calcd for C14H9F3N2O3, 311.0638; found 311.0638. 
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Synthesis of 2.S-4: Compound 2.S-3 (2.3 g, 7.2 mmol) was added to an oven dried 
flask. Zinc dust (2.3 g, 34.8 mmol) was then added. The reaction vessel was evacuated 
using a vacuum pump and subsequently filled with N2; this was repeated for a total of 
three cycles. Tetrahydrofuran (24 mL) was added, followed by acetic acid (4 mL). The 
reaction mixture was then allowed to stir at room temperature for 48 hours. The crude 
reaction mixture was then filtered through celite. Solvent was removed under reduced 
pressure. The reaction mixture was then dissolved in ethyl actetate (100 mL) and 
washed with 1 N NaOH (100 mL), followed by a brine wash (100 mL). The organic layer 
was then dried over sodium sulfate. The solvent was removed under reduced pressure 
to provide a viscous yellow oil. The oil was triturated with an ether/hexanes mixture to 
provide compound 2.S-4 as a light yellow solid (90 % yield). Spectral data. 1H NMR 
(400 MHz, DMSO-d6): δ 10.15 (s, 1 H), 8.23-8.17 (m, 2 H), 7.93-7.89 (m, 1 H), 7.76-
7.70 (m, 1 H), 7.06-7.03 (m, 1 H), 6.97-6.91 (m, 1 H), 6.85-6.80 (m, 1 H), 6.32-6.27 (m, 
1 H), 5.09 (s, 2 H); HRMS-ESI (m/z): [M + H]+ calcd for C14H11F3N2O, 281.0896; found 
281.0905. 
 
Synthesis of 2.S-5: 4-methyl-3-nitroaniline (2.0 g, 13.1 mmol) was added to an oven-
dried flask. Tetrahydrofuran (66 mL) was added. The reaction mixture was then cooled 
to 0oC using an ice bath. 3-trifluoromethylbenzoyl chloride (2.742 g, 13.1 mmol) was 
then added, followed by diisopropylethylamine (2.039 g, 15.77 mmol). The reaction 
mixture was then allowed to warm to room temperature and stir overnight. 
Tetrahydrofuran was then removed via rotary vaporization. The crude mixture was then 
suspended in water, filtered, and then rinsed with water twice. After drying 4.1 g of 2.S-5 
as a light yellow solid was obtained (96 % yield). Spectral data. 1H NMR (400 MHz, 
DMSO-d6) δ 10.77 (s, 1H), 8.50 (d, J = 2.3 Hz, 1H), 8.31 – 8.22 (m, 2H), 7.97 (t, J = 9.4 
Hz, 2H), 7.77 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 1.23 (s, 3 H) ; 19F NMR (376 
MHz, dmso) δ -61.14.; HRMS-ESI (m/z): [M + H]+ calcd for C15H11F3N2O3, 325.0795; 
found 325.0794. 
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Synthesis of 2.S-6: Compound 2.S-5 (2.0 g, 6.2 mmol) and iron (1.72 g, 30.8 mmol) 
were added to an oven-dried flask. Ethanol (25 mL) and water (6.2 mL) were then 
added, followed by the addition of several drops of concentrated Hydrochloric Acid. The 
reaction mixture was then heated to reflux for 90 minutes. The reaction mixture was 
then allowed to cool to room temperature and filtered through celite. Ethanol was 
removed via rotary vaporization. The crude reaction was then suspended in water and 
filtered. After drying 1.4 g of 2.S-6 as an off-white solid was obtained (78 % yield). 
Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 10.11 (s, 1H), 8.24 – 8.15 (m, 2H), 7.90 
(d, J = 7.7 Hz, 1H), 7.72 (t, J = 7.9 Hz, 1H), 7.06 (s, 1H), 6.87 – 6.75 (m, 2H), 4.85 (s, 
2H), 1.99 (s, 3H); 19F NMR (376 MHz, dmso) δ -61.08; HRMS-ESI (m/z): [M + H]+ calcd 
for C15H13F3N2O, 295.1053; found 295.1061. 
 
 
Synthesis of 2.S-7: ethyl 2-aminothiazole-5-carboxylate (1.0 g, 5.8 mmol) and 4,6-
dichloro-2-methylpyrimidine (0.95 g, 5.8 mmol) were added to an oven dried flask. 
Dimethylformamide (20 mL) was then added. The reaction mixture was then cooled to 
0o C, and sodium hydride (0.510 g, 12.8 mmol) was added. The reaction was allowed to 
warm to room temperature and stir for an additional 3 hours. Excess base was 
quenched using ammonium chloride. The reaction was then suspended in water and 
filtered. After drying, 2.S-7 was obtained as a white solid (1.4g, 81% yield). Spectral 
data. 1H NMR (400 MHz, DMSO-d6) δ 12.30 (s, 1H), 8.07 (s, 1H), 6.88 (s, 1H), 4.24 (q, 
J = 7.1 Hz, 2H), 2.54 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, dmso) δ 
167.85, 162.83, 161.96, 159.07, 157.88, 145.84, 122.02, 104.11, 61.22, 25.61,14.70; 
HRMS-ESI (m/z): [M + H]+ calcd for C11H11ClN4O2S, 299.0364; found 299.0371. 
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Synthesis of 2.S-8: Compound 2.S-7 (1.4 g, 4.7 mmol) and sodium hydroxide (1.5 g, 
37.5 mmol) were added to an oven-dried round bottom flask. Methanol (11 mL) and 
water (4 mL) were then added. The reaction was stirred at room temperature for 48 
hours. Methanol was then removed under reduced pressure. The crude reaction mixture 
was then suspended in 1 N HCl and filtered. After drying 2.S-8 (0.95 g, 75 % yield) was 
obtained as a white solid. Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.03 (s, 1H), 
6.97 (s, 1H), 2.56 (s, 3H); 13C NMR (126 MHz, dmso) δ 167.79, 163.39, 162.56, 158.94, 
157.97, 145.28, 123.38, 104.03, 40.46, 40.29, 40.21, 40.13, 40.05, 39.96, 39.79, 39.62, 
39.46, 25.57; HRMS-ESI (m/z): [M + H]+ calcd for C9H7ClN4O2S, 271.0051; found 
271.0055. 
 
Synthesis of 2.S-9: Acid 2.S-8 (0.051 g, 0.188 mmol), aniline 2.S-2 (0.040 g, 0.188 
mmol), and HATU (0.079 g, 0.207 mmol) were added to an oven-dried round bottom 
flask. Dimethylformamide (0.9 mL) was then added, followed by DIEA (0.073 g, 0.565 
mmol). The reaction was allowed to stir at room temperature overnight. The reaction 
was then diluted in ethyl acetate (100 mL), and washed with water followed by brine. 
The organic layer was then dried over sodium sulfate. The crude reaction mixture was 
then purified via silica gel chromatography using a Biotage Isolera One (linear gradient 
40 → 100% EtOAc in hexanes) to yield 0.075 g of compound 2.S-9 as a white solid (86 
% yield).. 1H NMR (500 MHz, DMSO-d6) δ 12.20 (s, 1H), 10.28 (s, 1H), 10.24 (s, 1H), 
8.36 (s, 1H), 8.26 (t, J = 2.1 Hz, 1H), 7.99 – 7.92 (m, 2H), 7.61 – 7.40 (m, 5H), 7.30 (t, J 
= 8.1 Hz, 1H), 6.92 (s, 1H), 13C NMR (126 MHz, dmso) δ 167.85, 165.98, 161.76, 
160.03, 158.94, 157.96, 141.12, 139.86, 139.36, 135.38, 131.99, 129.12, 128.80, 
128.12, 116.38, 116.23, 113.03, 103.88, 25.64; [M + H]+ calcd for C22H17ClN6O2S, 
465.0985; found 465.0899. 
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Synthesis of 2.S-10: Acid 2.S-8 (0.075 g, 0.277 mmol), aniline 2.S-4 (0.078 g, 0.277 
mmol), and HATU (0.116 g, 0.305 mmol) were added to an oven-dried round bottom 
flask. Dimethylformamide (1.4 mL) was then added, followed by DIEA (0.143 g, 1.1 
mmol). The reaction was allowed to stir at room temperature overnight. The reaction 
was then diluted in ethyl acetate (100 mL), and washed with water followed by brine. 
The organic layer was then dried over sodium sulfate. The crude reaction mixture was 
then purified via silica gel chromatography using a Biotage Isolera One (linear gradient 
40 → 100% EtOAc in hexanes) to yield 0.035 g of compound 2.S-10 as a white solid 
(24 % yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 12.20 (s, 1H), 10.51 (s, 
1H), 10.27 (s, 1H), 8.37 (s, 1H), 8.31 – 8.24 (m, 3H), 7.95 (d, J = 7.8 Hz, 1H), 7.77 (t, J 
= 7.8 Hz, 1H), 7.47 (dd, J = 16.4, 8.0 Hz, 2H), 7.32 (t, J = 8.1 Hz, 1H), 6.93 (s, 1H), 2.58 
(s, 3H); 19F NMR (471 MHz, dmso) δ -61.09; HRMS-ESI (m/z): [M + H]+ calcd for 
C23H16ClF3N6O2S, 533.0769; found 533.0778. 
 
Synthesis of 2.S-11: Acid 2.S-8 (0.9 g, 3.3 mmol) was added to an oven-dried round 
bottom flask. Tetrahydrofuran (11 mL) was then added. The reaction was cooled to 0o 
C. Oxalyl chloride (0.5 g, 4.0 mmol) was added, followed by a drop of 
dimethylformamide. The reaction was allowed to warm to room temperature and stir for 
an additional twenty minutes. The crude mixture was then concentrated under reduced 
pressure. The crude reaction mixture was then again dissolved in tetrahydrofuran 
(11mL). Aniline 2.S-6 (1.0 g, 3.3 mmol) was then added followed by DIEA (0.43 g, 3.3 
mmol). The reaction was then allowed to stir overnight at room temperature. The crude 
reaction mixture was then purified via silica gel chromatography using a Biotage Isolera 
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One (linear gradient 40 → 100% EtOAc in hexanes) to yield 0.250 g of compound 2.S-
11 as a white solid (14 % yield).   Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 12.19 
(s, 1H), 10.45 (s, 1H), 9.90 (s, 1H), 8.30 – 8.11 (m, 3H), 7.93 (d, J = 7.8 Hz, 1H), 7.86 – 
7.71 (m, 2H), 7.56 (dd, J = 8.2, 2.3 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 6.91 (s, 1H), 2.56 
(s, 3H), 2.19 (s, 3H); 19F NMR (376 MHz, dmso) δ -61.10; HRMS-ESI (m/z): [M + H]+ 
calcd for C24H18ClF3N6O2S, 547.0925; found 547.0924. 
 
 
Synthesis of 2.1: To an oven dried flask was added 2.9 (0.040 mg, 0.086 mmol). 
Dioxane (0.29 mL) was then added, followed by morphiline (0.150 mg, 1.72 mmol). The 
reaction was then heated to 85 oC overnight. The reaction was allowed to cool to room 
temperature. Dioxane was removed under reduced pressure. The crude mixture was 
then suspended in ether and filtered. The crude solid was then washed with ether twice 
to afford the product as 5 mg of a light tan solid (11% yield). 1H NMR (400 MHz, DMSO-
d6) δ 11.48 (s, 1H), 10.24 (s, 1H), 10.10 (s, 1H), 8.27 – 8.19 (m, 3H), 7.97 – 7.90 (m, 
3H), 7.66 – 7.36 (m, 2H), 7.27 (t, J = 8.1 Hz, 1H), 6.03 (s, 1H), 3.79 (s, 2H), 3.46 (t, J = 
4.8 Hz, 6H), 2.40 (s, 3H); 13C NMR (126 MHz, dmso) δ 165.95, 165.62, 163.11, 163.05, 
160.38, 157.41, 141.17, 139.82, 139.54,135.39, 131.98, 129.06, 128.80, 128.12, 
127.27, 116.22, 116.15, 112.99, 83.18, 66.20, 63.75, 44.37, 43.28, 26.03; HRMS-ESI 
(m/z): [M + H]+ calcd for C26H25N7O3S, 514.1812; found 516.1816. 
 
Synthesis of 2.2: Compound 2.S-10 (0.035 g, 0.066 mmol) was added to an oven-
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dried round bottom flask. Dioxane (0.5 mL) was added. 1-(2-hydroxyethyl)piperazine 
(0.086 g, 0.657 mmol) was then added. The reaction was heated to reflux overnight. 
The reaction mixture was then concentrated under reduced pressure. The crude mixture 
was then purified using reverse-phase HPLC to afford 2.2 as a white solid (5 mg, 12% 
yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 11.47 (s, 1H), 10.48 (s, 1H), 
10.14 (s, 1H), 8.26 (s, 2H), 8.30 – 8.15 (m, 2H), 7.94 (d, J = 7.9 Hz, 1H), 7.76 (t, J = 7.8 
Hz, 1H), 7.49 – 7.39 (m, 2H), 7.29 (t, J = 8.1 Hz, 1H), 6.04 (s, 1H), 3.58 – 3.53 (m, 8H), 
2.40 (s, 3H); 19F NMR (471 MHz, dmso) δ -61.07; HRMS-ESI (m/z): [M + H]+ calcd for 
C29H29F3N8O3S, 627.2108; found 627.2107. 
 
Synthesis of 2.3: Compound 2.S-11 (0.250 g, 0.457 mmol) was added to an oven-
dried round bottom flask. Dioxane (1.5 mL) was added. 1-(2-hydroxyethyl)piperazine 
(1.190 g, 9.14 mmol) was then added. The reaction was heated to reflux overnight. The 
reaction mixture was then concentrated under reduced pressure. The crude mixture 
was then purified using reverse-phase Biotage C18 column to afford 2.3 as a white solid 
(25 mg, 9% yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 10.43 
(s, 1H), 9.74 (s, 1H), 8.29 – 8.20 (m, 2H), 8.17 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.82 – 
7.71 (m, 2H), 7.55 (dd, J = 8.3, 2.2 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.02 (s, 1H), 4.44 
(s, 1H), 3.48 (m, 4H), 3.28 (s, 8H), 2.38 (s, 3H), 2.18 (s, 3H); 19F NMR (376 MHz, dmso) 
δ -61.09; HRMS-ESI (m/z): [M + H]+ calcd for C30H31F3N8O3S, 641.2265; found 
641.2279. 
 
 
 
 
 
 
34 
 
SPECTRAL DATA FOR COMPOUNDS 2.S-2 – 2.3 
2.S-2: 
 
2.S-2 1H: 
 
2.S-2 13C: 
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2.S-3: 
 
2.S-3 1H: 
 
2.S-3 19F: 
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2.S-4: 
 
2.S-4 1H: 
 
2.S-4 19F: 
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2.S-5: 
 
2.S-5 1H: 
 
2.S-5 19F: 
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2.S-6: 
 
2.S-6 1H: 
 
2.S-6 19F: 
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2.S-7: 
 
2.S-7 1H: 
 
2.S-7 13C: 
 
 
 
 
40 
 
2.S8: 
 
2.S8 1H: 
 
2.S8 19F: 
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2.S-9: 
 
2.S-9 1H: 
 
2.S-9 13C: 
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2.S-10: 
 
2.S-10 1H: 
 
2.S-10 19F: 
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2.1: 
 
2.11H: 
 
2.1 13C: 
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2.2: 
 
2.2 1H: 
 
2.2 19F: 
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2.S11: 
 
2.S-11 1H: 
 
2.S-11 19F: 
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2.3: 
 
2.3 1H: 
 
2.3 19F: 
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BIOCHEMICAL CHARACTERIZATION 
General procedure for determination of inhibitor Ki. A continuous fluorescence 
assay1 was used to determine Ki. Reaction volumes of 100 µL were used in 96-well 
plates. 85 µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate 
inhibitor dilution (typically 5000, 1666, 555, 185, 61, 20, 6.8, 2.2, 0.76, 0 µM in DMSO) 
was then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et 
al)1 solution (1.8 mM in DMSO) was added. The reaction was initiated with 10 µL of 
ATP (1 mM in water), and reaction progress was immediately monitored at 405 nm (ex. 
340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 µM 
peptide substrate, 100 µM ATP, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM 
MgCl2, 0.01% Triton X-100.The initial rate data collected was used for determination of 
Ki values. For Ki determination, the kinetic values were obtained directly from nonlinear 
regression of substrate-velocity curves in the presence of various concentrations of the 
inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – LogEC50), X = 
log(concentration) and Y = binding; was used in the nonlinear regression. 
 
Analytical data for c-Src Ki determination. Each inhibitor Ki value was determined 
using at least three independent experiments; a representative inhibition curve is 
shown. 
 
 
 Avg Ki ≤ 0.6 nM 
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2.1 Avg Ki ≤ 0.6 nM 
 
 
 
2.2 Avg Ki ≤ 0.6 nM 
 
 
 
2.3 Avg Ki ≤ 0.6 nM 
 
 
Analytical data for c-Src T341I Ki determination. Each inhibitor Ki value was 
determined using at least three independent experiments, a representative inhibition 
curve is shown. 
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[ATP] = 25 µM  Avg Ki = 1,586 ± 427 nM 
 
 
 
2.1; [ATP] = 10 µM  Avg Ki ≥ 40,500 nM 
 
 
 
2.2; [ATP] = 25 µM  Avg Ki = 56 ± 14 
 
50 
 
 
 
2.3; [ATP] = 500µM Avg Ki = 1.9 ± 0.3 
 
 
Analytical data for c-Src T341M Ki determination. Each inhibitor Ki value was 
determined using at least three independent experiments, a representative inhibition 
curve is shown. 
 
 
[ATP] = 25 µM Avg Ki = 3,300  
 
 
 
2.1; [ATP] = 100 µM  Avg Ki ≥ 20,000  
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2.2; [ATP] = 25 µM Avg Ki = 404 ± 76 nM 
 
 
 
2.3 Avg Ki = 3.1 ± 1.7 nM 
 
Analytical data for c-Abl Ki determination. Each inhibitor Ki value was determined 
using at least three independent experiments, a representative inhibition curve is 
shown. 
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2.1; [ATP] = 5 mM  Avg Ki ≤ 3.4 nM 
 
 
 
2.2; [ATP] = 5 mM  Avg Ki ≤ 3.4 nM 
 
 
 
2.3; [ATP] = 5 mM Avg Ki ≤ 3.4 nM 
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DiscoveRx Kd determination. Dissociation constants for compounds 2.2, 2.3 and dasatinib 
were determined at DiscoveRx. 
A.  Tabulated Kd data. 
Compound  Src  Abl  Abl T315I-
nonphosphorylated 
Abl T315I-
phosphorylated 
dasatinib*  0.21  0.029  890   
2.2  0.53  2.2  >40,000   
2.3  2.7  2.9  66   
 
B. Representative binding curves. 
Src  
  
2.2 2.3 
 
Abl 
  
2.2 2.3 
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Abl T315I-nonphosphorylated 
 
 
2.2 2.3 
 
Abl T315I-phosphorylated 
  
2.2 2.3 
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KINOMEscan selectivity profiling 
Kinome profiling for compound 2.1 was performed by KINOMEScan (DiscoveRx, 
Fremont, CA). The compound was profiled at a concentration of 1 µM.  
A. 2.1 TREEspot analysis: 
 
2.1 
 
 
 
 
B. S-Scores for 2.1: 
S(35) = 0.25 
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C. Tabulated data for compound 2.1: 
KINOMEscan Gene Symbol 
Percent 
Control 
ABL1 (E255K)-phosphorylated 1.4 
ABL1 (F317I)-nonphosphorylated 0.3 
ABL1 (F317I)-phosphorylated 40 
ABL1 (F317L)-nonphosphorylated 0.65 
ABL1 (F317L)-phosphorylated 32 
ABL1 (H396P)-nonphosphorylated 1 
ABL1 (H396P)-phosphorylated 0.9 
ABL1 (M351T)-phosphorylated 30 
ABL1 (Q252H)-nonphosphorylated 1.9 
ABL1 (Q252H)-phosphorylated 1.6 
ABL1 (T315I)-nonphosphorylated 100 
ABL1 (T315I)-phosphorylated 84 
ABL1 (Y253F)-phosphorylated 0.35 
ABL1-nonphosphorylated 0.15 
ABL1-phosphorylated 0.6 
ABL2 0.5 
ACVR1 100 
ACVR1B 100 
ACVR2A 100 
ACVR2B 93 
ACVRL1 100 
ADCK3 100 
AKT1 100 
AKT2 98 
ALK 100 
AURKA 69 
AURKB 100 
AXL 91 
BLK 0.25 
BMPR2 82 
BMX 28 
BRAF 56 
BRAF (V600E) 32 
BRK 51 
BTK 68 
CDK11 100 
CDK2 89 
CDK3 94 
CDK7 100 
CDK9 86 
CHEK1 100 
CSF1R 0.2 
CSK 15 
CSNK1D 100 
CSNK1E 16 
CSNK1G2 32 
DCAMKL1 98 
DDR1 0.2 
DDR2 2.3 
DMPK 75 
DMPK2 90 
DYRK1B 76 
EGFR 85 
EGFR (E746-A750del) 70 
EGFR (G719C) 16 
EGFR (G719S) 32 
EGFR (L747-E749del, A750P) 55 
EGFR (L747-S752del, P753S) 58 
EGFR (L747-T751del,Sins) 34 
EGFR (L858R) 97 
EGFR (L858R,T790M) 59 
EGFR (L861Q) 38 
EGFR (S752-I759del) 32 
EGFR (T790M) 64 
EPHA1 100 
EPHA2 3.3 
EPHA3 18 
EPHA4 2 
EPHA5 2.4 
EPHA6 100 
EPHA7 80 
EPHA8 0.9 
EPHB1 7.9 
EPHB2 17 
EPHB3 100 
EPHB4 14 
EPHB6 6.4 
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ERBB2 89 
ERBB3 87 
ERBB4 51 
ERK1 100 
FAK 93 
FGFR1 100 
FGFR2 99 
FGFR3 100 
FGFR4 100 
FGR 1.3 
FLT1 3.6 
FRK 0.25 
FYN 0.3 
GAK 43 
GCN2 (Kin.Dom.2,S808G) 100 
GSK3B 92 
HCK 1.4 
IGF1R 100 
IKK-alpha 100 
IKK-beta 100 
INSR 60 
JAK2 (JH1domain-catalytic) 97 
JAK3 (JH1domain-catalytic) 98 
JNK1 100 
JNK2 82 
JNK3 94 
KIT 0 
KIT (A829P) 94 
KIT (D816H) 62 
KIT (D816V) 3.2 
KIT (L576P) 0.1 
KIT (V559D) 0 
KIT (V559D,T670I) 59 
KIT (V559D,V654A) 3.2 
KIT-autoinhibited 5.6 
LCK 0.4 
LIMK1 95 
LIMK2 83 
LKB1 100 
LOK 92 
LYN 0.9 
MAP3K4 100 
MAP4K2 98 
MAP4K3 96 
MAP4K4 100 
MAP4K5 86 
MAPKAPK2 100 
MARK3 94 
MEK1 100 
MEK2 93 
MEK3 91 
MEK4 100 
MEK5 12 
MET 100 
MKNK1 100 
MKNK2 100 
MLK1 87 
MRCKA 78 
MRCKB 100 
MST4 81 
NLK 78 
p38-alpha 36 
p38-beta 6 
PAK1 100 
PAK2 87 
PAK4 100 
PCTK1 100 
PDGFRA 6.6 
PDGFRB 0 
PDPK1 100 
PFCDPK1 (P.falciparum) 100 
PFPK5 (P.falciparum) 82 
PIK3C2B 77 
PIK3CA 90 
PIK3CG 89 
PIM1 100 
PIM2 88 
PIM3 100 
PKAC-alpha 100 
PKMYT1 96 
PKNB (M.tuberculosis) 64 
PLK1 100 
PLK3 100 
PLK4 62 
PRKCE 100 
RAF1 47 
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RET 44 
RET (M918T) 78 
RET (V804L) 95 
RET (V804M) 100 
RIOK2 95 
RIPK2 25 
ROCK1 64 
ROCK2 64 
RSK2 (Kin.Dom.1-N-terminal) 89 
SIK 19 
SIK2 19 
SLK 100 
SNARK 71 
SRC 0.1 
SRMS 85 
SRPK3 100 
STK36 100 
SYK 100 
TEC 11 
TESK1 81 
TGFBR1 100 
TGFBR2 66 
TIE2 100 
TNIK 99 
TNK2 100 
TNNI3K 5.1 
TRKA 62 
TSSK1B 100 
TXK 48 
TYK2 (JH1domain-catalytic) 100 
ULK2 94 
VEGFR2 51 
WEE1 100 
YANK3 90 
YES 0.45 
ZAK 5.6 
ZAP70 100 
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Luceome selectivity profiling 
Kinome profiling for compound dasatinib 2.2 and 2.3 was performed by KinaseSeeker™ 
(Luceome Biotechnologies, Tucson, AZ). The compounds were all profiled at a final 
inhibitor concentration of 500 nM. 
A. TREEspot analyses: 
 
dasatinib 
 
 
2.2 
 
 
2.3 
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B. S(35) Scores for compounds: 
dasatinib = 0.20 
compound 2.2 = 0.23 
compound 2.3 = 0.20 
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C. Tabulated Luceome selectivity profiling data for dasatinib, 2.2, and 2.3: 
 
Kinase %  control 
 
dasatinib 2.2 2.3 
ABL1 1.9 4.2 10.9 
ABL2 50.7 6.1 12.2 
AKT1 95.1 97.5 100 
AKT2 100 100 100 
AKT3 73.3 92.2 100 
AMPK-alpha1 93 100 100 
AMPK-alpha2 67.8 70.6 100 
AURKA 100 100 93.9 
AURKB 100 100 100 
AURKC 80.7 86.2 94.1 
AXL 27.4 30.5 100 
BIKE 100 97 100 
BLK 0 0 6.2 
BTK 35.5 73.9 26.4 
CAMK1 100 100 100 
CAMK1D 99.3 88.2 100 
CAMK1G 100 100 97.2 
CAMK2A 85.8 95.6 100 
CAMK2B 68.4 92.6 100 
CAMK2D 79.8 100 100 
CAMKK1 75 78 100 
CAMKK2 78.9 100 100 
CHEK1 90.9 100 100 
CSNK1D 100 100 100 
CLK1 100 100 100 
CLK2 100 100 100 
CSK 31.3 78.9 11.5 
DAPK1 100 100 97.4 
DAPK2 100 100 100 
DAPK3  100 100 100 
DDR1  84.8 85.6 1.1 
DDR2  51.8 49.2 9.1 
DMPK  100 100 100 
EPHA1  1.1 3.3 7.9 
EPHA2  1.3 1.1 68.9 
EPHA3  5.8 2.3 11.7 
EPHA4  0 0 2.7 
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EPHB2  0 0 4.4 
EPHB3  35.2 81.1 47.6 
EPHB4  1.8 2.1 4 
FGFR2  100 67.9 30.1 
FLT1  100 4.8 6.7 
FGFR1 57.2 62.2 56.7 
FLT3  36.8 41.5 91.5 
FYN  3.8 0.7 53.7 
GSK3A 100 67.7 100 
HCK  16.6 4.2 10 
IGF1R  75.7 64 94.5 
IKK-epsilon 100 100 100 
INSR  100 100 64.2 
ITK  42.3 50 100 
LIMK1  50 82.1 63.9 
LYN  5.9 5.9 54.1 
MARK1  100 100 100 
MARK2  100 100 100 
MARK3  100 100 100 
MARK4  100 100 100 
MELK  92 100 95.9 
MET  100 100 97 
MLK1  38.4 40.9 100 
MLK3  18.3 22.6 96.6 
MST2  83.3 61.5 97.6 
MUSK  86.4 20.6 60.6 
MYLK  75.4 94.8 100 
MYLK2  100 97 100 
PKMYT1 46.9 59.9 100 
p38-delta 100 100 100 
PAK1  100 100 100 
PDGFRA  21.3 31.9 79.1 
PDGFRB  38.4 37.5 57.8 
PDK1  100 100 100 
PHKG1  95.7 99.5 98.2 
PIM1  96.1 100 97.5 
PIM2  97.4 89.6 100 
PKAC-alpha 95.1 96.3 97.7 
PRKACB 78.1 96.7 100 
PRKCD 100 100 92.3 
PRKCE 100 100 100 
PRKCG 100 100 100 
PRKCH 100 100 100 
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PRKCQ 92.4 100 100 
PRKG1 100 100 97.4 
PKN3 92 83.8 67 
PRKX 72.8 89.3 100 
PLK4  12.4 0 100 
PRKD2  100 100 97.9 
PRKD3  100 100 100 
PTK2  100 100 100 
PTK2B  100 95.2 100 
PTK6  33.8 0.1 27 
RET  92.2 1 11.9 
RIPK2  0.1 37.2 51.8 
RSK1(Kin.Dom.1-N-terminal) 92.5 100 100 
RSK3(Kin.Dom.1-N-terminal) 100 94.6 100 
RSK2(Kin.Dom.1-N-terminal) 100 100 99.1 
RPS6KA4(Kin.Dom.1-N-
terminal) 100 87.2 100 
RPS6KA5(Kin.Dom.1-N-
terminal) 88.3 96.7 100 
RSK4(Kin.Dom.1-N-terminal) 100 100 100 
SGK2  74.3 91.3 96.4 
SGK3  100 100 100 
QSK 57 95.1 95 
SLK  100 96.2 95.3 
SNARK  81.3 89.8 100 
SNF1LK  12.9 28.8 10 
SNF1LK2  41.3 74 47.9 
SRC  8.8 10.6 16 
STK16  79.4 75 100 
STK33  100 100 100 
SYK  73.3 89.9 100 
TBK1  39.5 35.7 100 
TEC  41.6 86 28.8 
TESK1  49.1 94.1 78.3 
TESK2  45.1 93.7 50.4 
TIE1  100 27.4 64.9 
TIE2  100 33.3 15.2 
TNK2  24.8 91.9 39.6 
TNNI3K  25.9 12.7 20.1 
TRKB  100 70.6 54.8 
TRKC  100 77.8 48.3 
TXK  16.2 32.5 18 
VEGFR2  100 15.2 49.3 
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YANK2  100 100 88.2 
YES 8 0 12.7 
YSK1 100 100 98.6 
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CHAPTER 3 
Rational design of c-helix out inhibitors
This chapter continues to address the question of “How does binding an “inactive” fold 
influence kinase inhibitor selectivity?” The focus of this chapter is on inhibitors that bind 
the c-helix out inactive conformation of protein kinases (For an in-depth introduction to 
c-helix out inhibitors see Chapter 1.5) Unlike DFG-out inhibitors there is no known 
general method for converting a DFG-in inhibitor to a c-helix out inhibitor. A careful 
analysis reveals key differences between inhibitors which respectively bind the DFG-out 
and c-helix out inactive kinase forms, and a general method for selectively targeting the 
c-helix out fold was developed (Figure 3.1).  
 
3.1 Introduction 
 
Figure 3.1. General strategy for conversion of a DFG-in to c-helix out inhibitor. 
 
Binding the c-helix out conformation has an unknown influence on kinase inhibitor 
selectivity. In order to investigate this possibility it was decided that a general method 
for the synthesis of c-helix out kinase inhibitors would be useful. There is no method for 
creating c-helix out inhibitors analogous to the DFG-in to DFG-out conversion described 
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in Chapter 1.4. In an effort toward convertin a DFG-in inhibitor to a c-helix out inhibitor 
the general chemical features of the binding mode were analyzed.  
3.2 Results and discussion 
In general, c-helix out kinase inhibitors contain a chemical feature which encroaches 
upon the back of the ATP-pocket which forces the alpha-c helix out of its usual 
catalytically active position. DFG-out kinase inhibitors also occupy this back region. In 
order to bias inhibitor design toward binding the c-helix out conformation a comparison 
of DFG-out and c-helix out inhibitor binding modes was conducted (Figure 3.2). It was 
observed that DFG-out kinase inhibitors routinely have a hydrogen bond donor 
interaction with the conserved glutamate of the c-helix. It was hypothesized that 
elimination of this feature would bias inhibitor binding to the c-helix out conformation. A 
series of dasatinib derivatives were created based upon this assumption (Figure 3.3). 
 
 
Figure 3.2. General chemical features of DFG-out and c-helix out kinase inhibitors. A) Co-crystal 
structure of imatinib bound to Abl kinase in the DFG-out conformation with key hydrogen bonds displayed 
in cyan. PDB: 1IEP B) Co-crystal structure of lapatinib bound to EGFR in the c-helix out conformation. 
PDB: 1XKK.   
In order to initially characterize the impact that these substitutions had on inhibitor 
potency activity-based kinase assays were conducted (Figure 3.3). All compounds 
tested displayed excellent potency for the selected kinases. It is of some interest that all 
compounds were strong inhibitors of Abl because the c-helix out conformation has not 
been previously observed for this kinase. When tested against a commonly observed 
resistance mutation, all compounds displayed negligible inhibition, even less so than 
dasatinib. 
 
A B 
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Our laboratory has previously observed that 
incorporation of a methyl substituent in the 
central phenyl ring of dasatinib analogs 
confers significant potency for kinases 
bearing the “gatekeeper mutation”. A 
compound which included this feature was 
synthesized (compound 3.4) and was 
subsequently subjected to inhibition assays 
(Figure 3.4). Gratifyingly, a significant 
increase in potency in inhibition of the both 
gatekeeper mutants was observed.  
Despite the promising biochemical inhibition 
profile of compound 3.4 there was no 
evidence supporting that it binds the c-helix 
out conformation as it was intended to. 
Therefore co-crystallization with the kinase 
domains both Src and Abl with all new 
compounds was attempted. Compound 3.1 
provided acceptable crystals that diffracted 
at 2.45 Å and 2.9 Å respectively for Src and 
Abl. The structure of Src bound to compound 3.1 is shown in Figure 3.5. As expected, 
the density for the DFG motif clearly 
corresponds with what would be expected 
from a DFG-in conformation, additionally 
the c-helix is swung outward in order to 
accommodate the phenoxy substituent. It 
is noteworthy that this is the first 
observation of Abl kinase in the c-helix out 
conformation. 
 
 
 
 Ki (nM) 
Compound c-Src Abl Src 
T341M 
Src 
T341I 
3.1 ≤ 0.6  <0.2 ni ni 
3.2  ≤ 0.6  <0.2 ni ni 
3.3 ≤ 0.6  <0.2 ni ni 
dasatinib ≤ 0.6  <0.2 3,300 1,586  
 
Figure 3.3. Structures and biochemical 
inhibition assays for compounds 3.1-3.3. n.i. = 
no inhibition up to 125 µM inhibitor. 
 
 Ki (nM) 
Compound Src  Abl Src  
T341M 
Src  
T341I 
3.4 <0.6 <0.2 n.d. 32 
 
Figure 3.4. Activity-based kinase inhibition assays 
for compound 3.4. 
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Structural validation of compound 3.1 binding 
Abl in a c-helix out conformation implied that 
the selectivity of this set of inhibitors may be 
lower than other known c-helix out inhibitors. 
Compound 3.4 was subjected profiling against 
a diverse panel of 131 kinases using a single 
point binding assay1 (Figure 3.6). Compound 
3.4 was found to be more selective than 
dasatinib (S(35) score = 0.16 and 0.20 
respectively; S(35) is defined as the number 
of kinases that displayed ≤ 35% of competitor 
probe remaining bound). The most pronounced difference in the profiles 3.4 and 
dasatinib was loss of inhibition of the Eph family kinases for the c-helix out compound. 
These data generally suggest that the inhibitor binding of the c-helix out conformation 
may be a valid strategy to increase selectivity. 
The cellular performance of compound 3.4 was 
assessed in the MDA-MB-231 breast cancer cell 
line. This cell line is triple-negative for 
expression of the estrogen receptor, 
progesterone receptor and Her2/neu. The triple-
negative phenotype accounts for 15 percent of 
all types of breast cancer2 and has clinically 
been observed to have increased tumor size, 
likelihood of death, distant metastases and 
recurrence relative to non-triple-negative 
tumors3-6. The triple-negative tumors are also 
more difficult to treat because of the absence of 
the receptor targets, therefore new therapy 
options would be beneficial. 
 
Figure 3.5. Co-crystal structures of compound 
3.1 bound to Src kinase. Data kindly provided 
by Frank Kwarcinski (Soellner lab). 
 
Figure 3.6. Kinome selectivity profile for 
compound 3.4 using a single point binding 
assay. Compound 3.4 was screened at 500 
nM. Red circles indicate >65 % binding, 
and small green dots indicate kinases 
included in the panel that did not display 
any binding. For a tabulated list of binding 
data see experimental section. 
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Promisingly, compound 3.4 performed similarly to dasatinib (Table 3.1) in two-
dimensional cell culture. It has been observed that 3-dimensional cell culture can 
provide results that more closely align 
with what would be seen in vivo7, and so 
3.4 was tested under these conditions. It 
was reassuring to see that compound 
3.4 also appreciably inhibited cell 
growth under these conditions as well. 
3.3 Conclusions 
This chapter describes a method developed to transform a DFG-in kinase inhibitor to a 
c-helix out kinase inhibitor. Application of this method allowed for a comparison of the 
selectivity of DFG-in and c-helix out inhibitors derived from the same chemical scaffold. 
It appears that targeting the c-helix out inactive conformation does improve inhibitor 
selectivity, which is in contrast to the findings described in Chapter 2 with DFG-out 
inhibitors, Thus, the development of general strategy described above will likely be 
valuable for further generation of c-helix out kinase inhibitors. 
 
  
Compound MDA-MB-231  
(2D) 
GI50 (µM) 
MD-MB-231 
(3D) 
% inhibition 
(1 uM cpd) 
3.4 8.3 48.0  
dasatinib 6.5 50.7 
 
Table 3.1. Treatment of breast cancer cells using 3.4 
and dasatinib. Data kindly provided by Michael 
Steffey (Soellner lab). 
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3.4 Experimental section
GENERAL SYNTHETIC METHODS. Unless otherwise noted, all reagents were 
obtained via commercial sources and used without further purification. Tetrahydrofuran 
(THF) and dichloromethane (CH2Cl2) were dried over alumina under a nitrogen 
atmosphere. All 1H and 13C NMR spectra were measured with a Varian MR400, 
VNMRS 500 or Inova 500 spectrometer. Mass Spectrometry (HRMS) was carried out by 
the University of Michigan Mass Spectrometry Facility (J. Windak, director). 
SYNTHESIS OF COMPOUNDS 3.S1-3.4 
 
  
Scheme 3.S-1. Representative synthetic routes for final compounds 3.1 –3.4. 
 
 
Synthesis of 3.S-1: 2-((6-chloro-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxylic 
acid (44 mg, 0.162 mmol) and HATU (68 mg, 0.178 mmol) were added to an oven-dried 
round bottom flask. N,N-dimethylformamide (0.8 mL) was then added, followed by 
diisopropylethylamine (0.085 mL, 0.486 mmol). The reaction was allowed to stir at room 
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temperature for 45 min. 4-phenoxyaniline (30 mg, 0.162 mmol) was then added, and the 
reaction was allowed to stir overnight at room temperature. The reaction mixture was 
then precipitated by addition of water. The crude mixture was filtered, and the solid that 
was collected was then subjected to silica gel chromatography using a 30 → 100% ethyl 
acetate in hexanes gradient. Product 3.S-1 was isolated as tan solid. Spectral data. 1H 
NMR (400 MHz, DMSO-d6) δ 12.20 (s, 1H), 10.19 (s, 1H), 8.29 (s, 1H), 7.68 (d, J = 8.4 
Hz, 2H), 7.35 (t, J = 7.8 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 7.04 – 6.89 (m, 5H), 2.57 (s, 
3H). 13C NMR (100 MHz, DMSO-d6): 
13C NMR (126 MHz, dmso) δ 167.88, 161.69, 
159.87, 158.96, 157.94, 157.63, 152.65, 141.04, 134.94, 130.44, 123.55, 122.32, 
119.71, 118.50, 118.32, 103.85, 25.65; HRMS-ESI (m/z): [M + H]+ calcd for 
C21H16ClN5O2S, 438.0786; found 438.0792. 
 
Synthesis of 3.1: Compound 3.S-1 (10 mg, 0.023 mmol) was added to an oven-dried 
round bottom flask. Dioxane (0.228 mL) was then added, followed by 1-(2-
hydroxyethyl)piperazine) (0.028 mL, 0.228 mmol). The reaction was then refluxed 
overnight. The reaction was then allowed to cool to room temperature, and the dioxane 
was removed under reduced pressure. The crude residue was the purified using 
reverse-phase HPLC using a 5→95% acetonitrile in water gradient. Product 3.1 was 
isolated as 3 mg of a white solid (25% yield). Spectral data. 1H NMR (400 MHz, DMSO-
d6) δ 11.46 (s, 1H), 10.08 (s, 1H), 8.21 (s, 1H), 7.72 – 7.64 (m, 2H), 7.35 (dd, J = 8.6, 
7.3 Hz, 2H), 7.08 (t, J = 7.4 Hz, 1H), 7.04 – 6.92 (m, 4H), 6.03 (s, 1H), 3.29 (s, 3H), 3.21 
(s, 0H), 2.39 (s, 4H), 0.79 (s, 0H).  13C NMR (126 MHz, dmso) δ 165.66, 163.01, 
162.75, 160.24, 157.71, 157.41, 152.43, 141.04, 135.20, 130.42, 127.11, 123.49, 
122.18, 119.73, 118.44, 83.18, 52.83; 26.04. HRMS-ESI (m/z): [M + H]+ calcd for 
C27H29N7O3S, 532.2125; found 532.2118. 
 
Synthesis of 3.S-2: 4-nitrophenol (2.3 g, 16.5 mmol) and potassium carbonate (4.57 g, 
33.1 mmol) were added to an oven-dried round bottom flask. N,N-dimethylformamide 
(30 mL) was then added followed by benzyl bromide (2.0 mL, 16.5 mmol). The reaction 
mixture was then heated to 40o C overnight. The reaction mixture was then added to 
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120 mL of water. After filtration 3.S-2 was obtained as a light yellow solid (3.5 g, 15.3 
mmol, 92% yield). Spectral data. 1H NMR (400 MHz, Chloroform-d) δ 8.23 – 8.13 (m, 
2H), 7.47 – 7.31 (m, 5H), 7.06 – 6.97 (m, 2H), 5.15 (s, 2H). 13C NMR (125 MHz, 
Chloroform-d): δ 163.73, 141.66, 135.54, 128.83, 128.53, 127.54, 125.94, 114.89, 
70.70; HRMS-EI (m/z): calcd for C13H11NO3, 229.0739; found 229.0744. 
 
Synthesis of 3.S-3: Compound 3.S-2 (2.0 g, 8.7 mmol) and zinc (2.74 g, 42 mmol) 
were added to an oven-dried round bottom flask. Tetrahydrofuran (44 mL) was then 
added, followed by acetic acid (2 mL, 35 mmol). The reaction was stirred overnight 
under N2. The crude mixture was then filtered through celite. Tetrahydrofuran was 
removed under reduced pressure. The crude mixture was then subjected to silica gel 
chromatography (0→85% ethyl acetate in hexanes) to afford 1.24 g (6.22 mmol) of 3.S-
3 as a dark red oil (71% yield). Spectral data. 1H NMR (500 MHz, Chloroform-d) δ 7.47 
– 7.29 (m, 5H), 6.86 – 6.80 (m, 2H), 6.70 – 6.63 (m, 2H), 5.01 (s, 2H), 3.45 (s, 2H).  13C 
NMR (126 MHz, Chloroform-d) δ 147.23, 135.48, 132.76, 123.73, 123.02, 122.72, 
111.59, 111.32, 66.03; HRMS-ESI (m/z): [M + H]+ calcd for C13H13NO, 200.1070; found 
200.1071. 
 
Synthesis of 3.S-4: 2-((6-chloro-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxylic 
acid (18 mg, 0.075 mmol) and HATU (116 mg, 0.305 mmol) were added to an oven-
dried round bottom flask. N,N-dimethylformamide (1.385 mL) was then added, followed 
by diisopropylethylamine (0.194 mL, 1.1 mmol). The reaction was allowed to stir at room 
temperature for 45 min. 3.S-3 (55 mg, 0.277 mmol) was then added, and the reaction 
was allowed to stir overnight at room temperature. The reaction mixture was then 
precipitated by addition of water. The crude mixture was filtered, and the solid that was 
collected was then subjected to silica gel chromatography using a 30 → 100% ethyl 
acetate in hexanes gradient. Product 3.S-4 was isolated as a tan solid. Spectral data. 
1H NMR (500 MHz, DMSO-d6) δ 12.21 (s, 1H), 10.08 (s, 1H), 8.28 (s, 1H), 7.62 – 7.55 
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(m, 2H), 7.39 (ddd, J = 32.4, 24.7, 7.2 Hz, 5H), 7.05 – 6.97 (m, 2H), 6.93 (s, 1H), 5.09 
(s, 2H), 2.60 (s, 3H).  13C NMR (126 MHz, dmso) δ 167.87, 161.54, 159.67, 158.93, 
157.96, 155.08, 140.68, 137.59, 132.35, 128.84, 128.23, 128.12, 122.26, 115.27, 
103.85, 69.81, 25.64; HRMS-ESI (m/z): [M + H]+ calcd for C22H18ClN5O2S, 452.0942; 
found 452.0938. 
 
Synthesis of 3.2: Compound 3.S-4 (18 mg, 0.04 mmol) was added to an oven-dried 
round bottom flask. Dioxane (0.200 mL) was then added, followed by 1-(2-
hydroxyethyl)piperazine) (0.049 mL, 0.398 mmol). The reaction was then refluxed 
overnight. The reaction was then allowed to cool to room temperature, and the dioxane 
was removed under reduced pressure. The crude residue was the purified using 
reverse-phase HPLC using a 5→95% acetonitrile in water gradient. Product 3.2 was 
isolated as a white solid. Spectral data. HRMS-ESI (m/z): [M + H]+ calcd for 
C28H31N7O3S, 546.2282; found 546.2277. 
 
Synthesis of 3.S-5: 4-nitrophenol (2.3 g, 16.5 mmol) and potassium carbonate (4.57 g, 
33.1 mmol) were added to an oven-dried round bottom flask. N,N-dimethylformamide 
(30 mL) was then added followed by 3-chlorobenzyl chloride (2.1 mL, 16.5 mmol). The 
reaction mixture was then stirred at room temperature overnight. The reaction mixture 
was diluted in ether. The organic solution was washed twice with water, followed by a 
brine wash. The organic solution was dried over sodium sulfate. The solvent was 
removed under reduced pressure. The crude residue was subjected to silica gel 
chromatography (5→25% ethyl acetate in hexanes) to afford 1.0 g of 3.S-5 as a yellow 
solid (23% yield). Spectral data. 1H NMR (500 MHz, Chloroform-d) δ 8.26 – 8.20 (m, 
2H), 7.45 (s, 1H), 7.42 – 7.25 (m, 4H), 7.04 (d, J = 9.2 Hz, 2H), 5.15 (s, 2H). 13C NMR 
(126 MHz, Chloroform-d) δ 163.29, 141.85, 137.51, 134.76, 130.10, 128.65, 127.45, 
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125.99, 125.38, 114.83, 69.75; HRMS-EI (m/z): calcd for C13H10ClNO3, 263.0349; found 
263.0359. 
 
Synthesis of 3.S-6: Compound 3.S-5 (1.0 g, 3.8 mmol) and zinc (1.19 g, 18.2 mmol) 
were added to an oven-dried round bottom flask. Tetrahydrofuran (19 mL) was then 
added, followed by acetic acid (2 mL, 35 mmol). The reaction was stirred overnight 
under N2. The crude mixture was then filtered through celite. Tetrahydrofuran was 
removed under reduced pressure. The crude mixture was then subjected to silica gel 
chromatography (5→25% ethyl acetate in hexanes) to afford 1.24 g (6.22 mmol) of 3.S-
6 as a light red oil (71% yield). Spectral data. 1H NMR (400 MHz, Chloroform-d) δ 7.41 
(dt, J = 2.3, 1.1 Hz, 1H), 7.27 (q, J = 1.7 Hz, 3H), 6.83 – 6.74 (m, 2H), 6.67 – 6.58 (m, 
2H), 4.94 (s, 2H), 3.18 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 151.63, 140.45, 
139.62, 134.40, 129.79, 127.91, 127.43, 125.38, 116.37, 116.05, 69.94; HRMS-ESI 
(m/z): [M + H]+ calcd for C13H12ClNO, 234.0680; found 234.0680. 
 
Synthesis of 3.S-7: 2-((6-chloro-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxylic 
acid (13 mg, 0.047 mmol) and HATU (20 mg, 0.052 mmol) were added to an oven-dried 
round bottom flask. N,N-dimethylformamide (0.235 mL) was then added, followed by 
diisopropylethylamine (0.025 mL, 0.141 mmol). The reaction was allowed to stir at room 
temperature for 45 min. Compound 3.S-6 (11 mg, 0.047 mmol) was then added, and the 
reaction was allowed to stir overnight at room temperature. The reaction mixture was 
then precipitated by addition of water. The crude mixture was filtered, and the solid that 
was collected was then subjected to silica gel chromatography using a 30 → 100% ethyl 
acetate in hexanes gradient. The product 3.S-7 was isolated as a white solid. Spectral 
data. 1H NMR (400 MHz, DMSO-d6) δ 12.19 (s, 1H), 10.07 (s, 1H), 8.26 (s, 1H), 7.57 (d, 
J = 8.5 Hz, 2H), 7.48 (s, 1H), 7.38 (d, J = 6.8 Hz, 3H), 6.98 (d, J = 8.5 Hz, 2H), 6.91 (s, 
1H), 5.08 (s, 2H), 2.57 (s, 3H). 13C NMR (126 MHz, dmso) δ 167.88, 161.56, 159.70, 
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158.93, 157.95, 154.79, 140.74, 140.22, 133.54, 132.54, 130.81, 128.85, 128.16, 
127.73, 126.62, 122.27, 115.31, 103.85, 68.85, 25.67.; HRMS-ESI (m/z): [M + H]+ calcd 
for C22H17Cl2N5O2S, 486.0553; found 486.0546. 
 
Synthesis of 3.3: Compound 3.S-7 (10 mg, 0.023 mmol) was added to an oven-dried 
round bottom flask. Dioxane (0.230 mL) was then added, followed by 1-(2-
hydroxyethyl)piperazine) (0.028 mL, 0.228 mmol). The reaction was then refluxed 
overnight. The reaction was then allowed to cool to room temperature, and the dioxane 
was removed under reduced pressure. The crude residue was the purified using 
reverse-phase HPLC using a 5→95% acetonitrile in water gradient. Spectral data. 
HRMS-ESI (m/z): [M + H]+ calcd for C28H30ClN7O3S, 580.1892; found 580.1895. 
 
 
 
Synthesis of 3.S-8: 4-fluoro-2-methyl-1-nitrobenzene (1 g, 6.45 mmol), phenol (0.61 g, 
6.45 mmol), and potassium carbonate (2.67 g, 19.34 mmol) were added to an oven-
dried flask. N,N-dimethylformamide (21.5 mL) was then added and the reaction mixture 
was heated to 85oC overnight. The reaction mixture was cooled to room temperature 
and subsequently diluted with ethyl acetate. The organic solution was then washed with 
neutral water twice, followed by one wash with brine. The organic layer was then dried 
over sodium sulfate. The solvent was then removed under reduced pressure. The 
product was isolated as 2.1 g (86% yield) of an oil. Spectral data. 1H NMR (400 MHz, 
Chloroform-d) δ 8.07 – 7.99 (m, 1H), 7.46 – 7.30 (m, 2H), 7.22 (dt, J = 7.2, 1.3 Hz, 1H), 
7.10 – 7.00 (m, 2H), 6.87 – 6.74 (m, 2H), 2.58 (s, 3H). 13C NMR (126 MHz, Chloroform-
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d) δ 161.62, 154.86, 143.45, 137.10, 130.24, 127.46, 125.17, 120.53, 120.43, 115.05, 
21.42; HRMS-EI (m/z): calcd for C13H11NO3, 229.0739; found 229.0736. 
 
Synthesis of 3.S-9: Compound 3.S-8 (0.96 g, 4.19 mmol) was added to an oven-dried 
round bottom flask. Ethanol (16.75 mL) and water (4.2 mL) were then added followed by 
iron (1.17 g, 21 mmol). Several drops of concentrated hydrochloric acid were then 
added, and the reaction was refluxed for 90 minutes. After cooling to room temperature 
the crude reaction was filtered through celite. Ethanol was removed under reduced 
pressure. The crude residue was dissolved in ethyl acetate, and the organic solution 
was washed with water. The organic layer was then dried over sodium sulfate. The 
crude residue was subjected to silica gel chromatography (0→40% Ethyl acetate in 
hexanes). Removal of the organic solvent provided (0.37 g, 1.86 mmol) of product 3.S-9 
as a dark brown oil (44% yield).  Spectral data. 1H NMR (400 MHz, Chloroform-d) δ 
7.32 – 7.21 (m, 2H), 6.99 (td, J = 7.4, 1.1 Hz, 1H), 6.95 – 6.88 (m, 2H), 6.81 – 6.70 (m, 
2H), 6.64 (d, J = 8.4 Hz, 1H), 3.50 (s, 2H), 2.14 (s, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 159.03, 148.37, 140.89, 129.50, 123.97, 122.30, 121.95, 118.67, 
117.18, 115.85, 17.60; HRMS-ESI (m/z): [M + H]+ calcd for C13H13NO, 200.1070; found 
200.1075.  
 
Synthesis of 3.S-10: 2-((6-chloro-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxylic 
acid (75 mg, 0.28 mmol) and HATU (116 mg, 0.305 mmol) were added to an oven-dried 
round bottom flask. N,N-dimethylformamide (1.4 mL) was then added, followed by 
diisopropylethylamine (0.194 mL, 1.108 mmol). The reaction was allowed to stir at room 
temperature for 45 min. Compound 3.S-9 (59 mg, 0.28 mmol) was then added, and the 
reaction was allowed to stir overnight at room temperature. The reaction mixture was 
then dissolved in ethyl acetate and the organic solution was washed with water twice, 
followed by a brine wash. The crude mixture was then subjected to silica gel 
chromatography using a 0 → 100% ethyl acetate in hexanes gradient. Product 3.S-10 
was isolated as a tan solid. Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 12.18 (s, 
1H), 9.80 (s, 1H), 8.25 (s, 1H), 7.42 – 7.32 (m, 2H), 7.28 (d, J = 8.6 Hz, 1H), 7.11 (td, J 
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= 7.4, 1.2 Hz, 1H), 7.04 – 6.87 (m, 4H), 6.82 (dd, J = 8.6, 2.8 Hz, 1H), 2.56 (s, 3H), 2.18 
(s, 3H). 
 
Synthesis of 3.4: Compound 3.S-10 (40 mg, 0.089 mmol) was added to an oven-dried 
round bottom flask. Dioxane (0.9 mL) was then added, followed by 1-(2-
hydroxyethyl)piperazine) (0.11 mL, 0.885 mmol). The reaction was then refluxed 
overnight. The reaction was then allowed to cool to room temperature, and the dioxane 
was removed under reduced pressure. The crude residue was the purified using 
reverse-phase HPLC using a 5→95% acetonitrile in water gradient. Product 3.4 was 
isolated as 7 mg of a white solid (15% yield). Spectral data. 13C NMR (126 MHz, dmso) 
δ 165.78, 162.82, 162.68, 160.73, 157.38, 157.17, 154.90, 140.95, 136.59, 131.75, 
130.52, 128.77, 123.89, 120.66, 118.93, 116.62, 83.25, 70.16, 59.70, 52.45, 43.03, 
25.95, 18.38; HRMS-ESI (m/z): [M + H]+ calcd for C28H30ClN7O3S, 546.2282; found 
546.2286. 
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Analytical data for compounds 3.S-1 – 3.4 
3.S-1: 
 
3.S-1 1H: 
 
3.S-1 13C: 
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3.1: 
 
3.1 1H: 
 
3.1 13C: 
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3.S-2: 
 
3.S-2 1H: 
 
3.S-2 13C: 
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3.S-3: 
 
3.S-3 1H: 
 
3.S-3 13C: 
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3.S-4: 
 
3.S-4 1H: 
 
3.S-4 13C: 
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3.2: 
 
S3.2 1H: 
 
3.2 13C: 
 
  
85 
 
3.S-5: 
 
3.S-5 1H: 
 
3.S-5 13C: 
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3.S-6: 
 
3.S-6 1H: 
 
3.S-6 13C: 
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3.S-7: 
 
3.S-7 1H: 
 
3.S-7 13C: 
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3.3: 
 
3.3 1H: 
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3.S-8: 
 
S3 1H: 
 
S3 13C: 
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3.S-9: 
 
3.S-9 1H: 
 
3.S-9 13C: 
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3.S-10: 
 
3.S-10 1H: 
 
3.S-10 13C: 
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3.4: 
 
S3 1H: 
 
S3 13C: 
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Biochemical and cellular characterization 
General procedure for determination of inhibitor Ki. A continuous fluorescence 
assay8 was used to determine Ki. Reaction volumes of 100 µL were used in 96-well 
plates. 85 µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate 
inhibitor dilution (typically 5000, 1666, 555, 185, 61, 20, 6.8, 2.2, 0.76, 0 µM in 
DMSO) was then added. 2.5 µL of a substrate peptide (“compound 3” as described 
in Wang et al)8 solution (1.8 mM in DMSO) was added. The reaction was initiated 
with 10 µL of ATP (1 mM in water), and reaction progress was immediately 
monitored at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final 
concentrations of 30 nM enzyme, 45 µM peptide substrate, 100 µM ATP, 100 µM 
Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100.The initial 
rate data collected was used for determination of Ki values. For Ki determination, the 
kinetic values were obtained directly from nonlinear regression of substrate-velocity 
curves in the presence of various concentrations of the inhibitor. The equation Y = 
Bottom + (Top – Bottom)/(1 + 10^X – LogEC50), X = log(concentration) and Y = 
binding; was used in the nonlinear regression. 
 
Analytical data for c-Src Ki determination. Each inhibitor Ki value was determined 
using at least three independent experiments; a representative inhibition curve is 
shown. 
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3.3 Avg Ki ≤ 0.6 nM 
 
Analytical data for c-Abl Ki determination. Each inhibitor Ki value was determined 
using at least three independent experiments, a representative inhibition curve is 
shown. 
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3.4 Avg Ki ≤ 0.6 nM 
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3.1 Avg Ki ≤ 0.6 nM 
 
 
 
3.2 Avg Ki ≤ 0.6 nM 
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Analytical data for Src T341I Ki determination. Each inhibitor Ki value was 
determined using at least three independent experiments, a representative inhibition 
curve is shown. 
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3.3  
 
Analytical data for Src T341M Ki determination. Each inhibitor Ki value was 
determined using at least three independent experiments, a representative inhibition 
curve is shown. 
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DiscoveRx Kd determination 
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Luceome profiling 
Kinome profiling for compound 3.4 was performed by KinaseSeeker™ (Luceome 
Biotechnologies, Tucson, AZ). The compound was profiled at a final concentration of 
500 nM. 
 
A. TREEspot analysis: 
  
 
 
  
 
B. S-Scores: 
S (35) = 0.16 
 
 
 
 
 
100 
 
C. Tabulated data: 
KINOMEscan Gene Symbol Entrez Gene Symbol 
Percent 
Control 
ABL1-phosphorylated ABL1 8.1 
ABL2 ABL2 9 
AKT1 AKT1 100 
AKT2 AKT2 100 
AKT3 AKT3 100 
AMPK-alpha1 PRKAA1 100 
AMPK-alpha2 PRKAA2 100 
AURKA AURKA 91.4 
AURKB AURKB 100 
AURKC AURKC 96 
AXL AXL 100 
BIKE BMP2K 100 
BLK BLK 6.6 
BTK BTK 15.5 
CAMK1 CAMK1 100 
CAMK1D CAMK1D 100 
CAMK1G CAMK1G 93 
CAMK2A CAMK2A 100 
CAMK2B CAMK2B 100 
CAMK2D CAMK2D 100 
CAMKK1 CAMKK1 100 
CAMKK2 CAMKK2 100 
CHEK1 CHEK1 100 
CSNK1D CSNK1D 100 
CLK1 CLK1 100 
CLK2 CLK2 100 
CSK CSK 6.1 
DAPK1 DAPK1 100 
DAPK2 DAPK2 100 
DAPK3  DAPK3  100 
DDR1  DDR1  18.6 
DDR2  DDR2  28.9 
DMPK  DMPK  100 
EPHA1  EPHA1  14 
EPHA2  EPHA2  96.1 
EPHA3  EPHA3  63.7 
EPHA4  EPHA4  77.4 
EPHB2  EPHB2  100 
EPHB3  EPHB3  100 
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EPHB4  EPHB4  92.9 
FGFR2  FGFR2  100 
FLT1  FLT1  95.7 
FGFR1 FGFR1 100 
FLT3  FLT3  95.1 
FYN  FYN  21 
GSK3A GSK3A 100 
HCK  HCK  12.7 
IGF1R  IGF1R  100 
IKK-epsilon IKBKE 100 
INSR  INSR  97.6 
ITK  ITK  100 
LIMK1  LIMK1  8.1 
LYN  LYN  34.4 
MARK1  MARK1  100 
MARK2  MARK2  100 
MARK3  MARK3  100 
MARK4  MARK4  100 
MELK  MELK  100 
MET  MET  100 
MLK1  MLK1  100 
MLK3  MLK3  100 
MST2  MST2  100 
MUSK  MUSK  100 
MYLK  MYLK  100 
MYLK2  MYLK2  98.8 
PKMYT1 PKMYT1 100 
p38-delta MAPK13 100 
PAK1  PAK1  90.6 
PDGFRA  PDGFRA  74.9 
PDGFRB  PDGFRB  38.8 
PDK1  PDK1  100 
PHKG1  PHKG1  63.9 
PIM1  PIM1  99 
PIM2  PIM2  100 
PKAC-alpha PRKACA 98.2 
PRKACB PRKACB 100 
PRKCD PRKCD 100 
PRKCE PRKCE 100 
PRKCG PRKCG 100 
PRKCH PRKCH 100 
PRKCQ PRKCQ 96.6 
PRKG1 PRKG1 94.8 
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PKN3 PKN3 88.4 
PRKX PRKX 100 
PLK4  PLK4  100 
PRKD2  PRKD2  100 
PRKD3  PRKD3  100 
PTK2  PTK2  100 
PTK2B  PTK2B  100 
PTK6  PTK6  6.2 
RET  RET  100 
RIPK2  RIPK2  2.7 
RSK1(Kin.Dom.1-N-terminal) RPS6KA1 100 
RSK3(Kin.Dom.1-N-terminal) RPS6KA2  100 
RSK2(Kin.Dom.1-N-terminal) RPS6KA3  100 
RPS6KA4(Kin.Dom.1-N-terminal) RPS6KA4  96.5 
RPS6KA5(Kin.Dom.1-N-terminal) RPS6KA5 100 
RSK4(Kin.Dom.1-N-terminal) RPS6KA6  100 
SGK2  SGK2  100 
SGK3  SGK3  100 
QSK KIAA0999 91.1 
SLK  SLK  98.8 
SNARK  SNARK  100 
SNF1LK  SNF1LK  23.9 
SNF1LK2  SNF1LK2  84 
SRC  SRC  9.2 
STK16  STK16  100 
STK33  STK33  100 
SYK  SYK  100 
TBK1  TBK1  97 
TEC  TEC  22.2 
TESK1  TESK1  67.8 
TESK2  TESK2  23.4 
TIE1  TIE1  100 
TIE2  TIE2  100 
TNK2  TNK2  61.3 
TNNI3K  TNNI3K  77.6 
TRKB  TRKB  100 
TRKC  TRKC  100 
TXK  TXK  41.5 
VEGFR2  VEGFR2  100 
YANK2  YANK2  100 
YES YES1  6.3 
YSK1 STK25 100 
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CHAPTER 4 
A rational and modular approach to bisubstrate inhibition of protein kinases
This chapter addresses the “How much selectivity may be gained by exploiting 
structural features outside of the canonical ATP-pocket?” theme. The substrate site of 
Src kinase is targeted using a derivative of an optimal peptide substrate in a bisubstrate 
inhibition approach. It is shown that this strategy results in the most selective 
bisubstrate kinase inhibitor reported. Furthermore, the strategy appears to be modular 
and is used to develop a bisubstrate inhibitor of PDGFR kinase. Herein we report, using 
c-Src kinase as a model, a general bisubstrate inhibition approach in which modification 
of the peptide sequence drives the selectivity, which ultimately results in a potent and 
selective inhibitor of a kinase of interest. 
 
4.1 Introduction 
In Chapter 1.6 it is suggested that targeting the highly variable substrate binding site 
should provide kinase inhibitors with good selectivity. Substrate-competitive inhibitors 
frequently suffer from poor potency. It was decided to pursue a bisubstrate inhibition 
approach because it promises potency from the ATP-competitive fragment and 
selectivity from the substrate-competitive fragment. 
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4.2 Results and discussion 
 
 
Figure 4.1.. a) Structure of compound 4.1. b) Selectivity profile of compound 4.1 using a single-point 
binding assay. The compound was screened at 10 µM. Red circles are indicative of inhibitor binding to a 
given kinase > 35% control. Green circles indicate kinases included in the panel that did not display 
binding. c-Src is highlighted in blue. 
 
For the design of the bisubstrate inhibition strategy it was desired to have an ATP-
competitive inhibitor which targeted the model kinase c-Src, but would also be relatively 
promiscuous. An N1-phenyl pyrazolopyrimidine scaffold was selected because it fit the 
set criteria. Compound 4.11 was screened against a diverse panel of 200 kinases 
(KINOMEscan2, Figure 4.1). It was found that the compound bound a significant portion 
of the panel with appreciable affinity (52 kinases were ≥ 65% displaced from an 
immobilized ligand, see Experimental 
Section), thus it was deemed that this 
scaffold would be a considerable 
challenge in terms of attempting to 
improve its selectivity through 
application of a bisubstrate inhibition 
approach.  
Based upon previous work with Ser/Thr kinases3, it was envisioned that the selectivity 
of the promiscuous ATP-competitive inhibitor could be modulated via covalent linkage to 
a substrate-competitive peptide. It was necessary to decide how to conjugate the two 
respective components of the bisubstrate inhibitor, and a click-chemistry4 approach was 
 
Figure 4.2. General structure for bisubstrate inhibitors. 
For full structures see Experimental Section. 
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evaluated toward this end (Figure 4.2). The ATP-competitive pyrazolopyrimidine N1-
phenyl ring was modified to contain an alkyne handle5, and a peptide that was 
representative of a Src-optimal substrate sequence6 was modified such that the 
phosphorylatable tyrosine residue was replaced with 4-aminophenylalanine7 which 
could be acylated with an azido linker (See experimental section for peptide sequence).  
The linker length between the two fragments 
has been previously demonstrated to 
significantly influence the potency of 
bisubstrate inhibitors8. Molecular modeling 
was conducted using a structural overlay of a 
pyrazolopyrimidine bound to c-Src and a 
bisubstrate inhibitor bound c-Abl (c-Src has no 
reported structure with a ligand bound in the 
substrate-binding site) (Figure 4.S-1). The modeling indicated a distance of 11 Å 
between the two points of attachment of the proposed bisubstrate fragments. Linker 
lengths which bracketed the predicted optimal distance were evaluated. The short 
investigation of linker length revealed that affinity was greatly impacted by this feature 
(Table 4.1). The observed optimal linker length of n = 5 was in good agreement with 
what was expected from modeling.  
Bisubstrate inhibition should result in a 
synergistic increase in potency relative to 
the two individual nonconjugated 
components. Inhibition of c-Src by the 
respective ATP-competitive and substrate-
competitive fragments was evaluated to 
determine if synergistic inhibition was 
achieved in the merged product (Table 4.2). 
It was observed that the ATP-competitive compound (4.1) bound extremely poorly, 
which was not surprising given the high concentration of ATP used in the assay. The 
substrate-competitive fragment (4.5) bound with low micromolar affinity, which was 
Compound Linker 
length 
(n =) 
c-Src IC50 
(nM) 
4.2 3  159 
4.3 5  < 30 
4.4 7  121 
 
Table 4.1. Optimization of linker length for a 
c-Src bisubstrate inhibitor. Inhibitors were 
characterized using a continuous 
fluorescence assay. Assay conditions: 5 mM 
ATP, 45 µM peptide substrate. 
Compound Binding mode c-Src 
IC50 
(µM) 
4.1 ATP-
competitive  
>250 
4.5 Substrate-
competitive  
8.37 
 
Table 4.2: Biochemical characterization of the 
individual fragments of a bisubstrate inhibitor 
designed for c-Src. Inhibitors were characterized 
using a continuous fluorescence assay. Assay 
conditions: 5 mM ATP, 45µM peptide substrate. 
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expected for an inhibitor of this type under the given assay conditions. Altogether these 
data indicate that covalent conjugation of the individual components of the bisubstrate 
inhibitor results in a dramatic synergistic increase in potency. 
The high potency of bisubstrate inhibitor 4.3 did not allow for precise determination of its 
affinity for c-Src using an activity based assay, so it was decided to pursue alternate 
means of characterization. Affinity for a tight binding ligand which has been fluorophore-
labeled can be easily determined using TR-FRET. Inhibitor 4.3 was labeled on its N-
terminus with a fluorescent small molecule (Cy-5, see experimental section for full 
structure) to provide affinity probe 4.6. The Kd of the affinity probe was determined using 
TR-FRET and displayed low nanomolar affinity for c-Src (Figure 4.3). 
Fluorophore labeling of inhibitors is widely 
known to potentially modify the potency 
relative to the unlabeled counterpart. 
Therefore, a competition assay using probe 
4.6 was used to determine the affinity of 
inhibitor 4.3 for c-Src (Table 4.3). It was 
found that the unlabeled inhibitor 4.3 was 
approximately ten times more potent than 
affinity probe 4.6. To validate the binding 
assay a known ATP-competitive c-Src 
inhibitor, PP2, was also subjected to affinity determination. The observed value was 
similar to those previously reported and to an affinity value obtained using a 
commercially available kinase tracer (see Supporting Information). It was also of interest 
to determine if this assay would be useful for characterizing substrate-competitive 
inhibitors. Using substrate-competitive inhibitor MEB-4-151 in the TR-FRET assay 
yielded an affinity value very similar to what is obtained using activity based assays. We 
therefore propose that this inhibitor could be useful for finding other substrate-
competitive small molecules. 
 
 
Figure 4.3.  Measurement of the affinity of a 
fluorescently labeled bisubstrate probe 4.7 for c-
Src. Binding was determined using a TR-FRET 
assay. A representative run is shown. The probe 
was found to have an affinity of Kd = 6.3 ± 1.6 
nM. 
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After the affinity of inhibitor 4.3 was adequately 
characterized it was desired that the selectivity be 
determined. It was initially hypothesized that the 
substrate-competitive fragment would drive the 
selectivity of a bisubstrate inhibitor, and this needed to be validated. The peptide 
sequence used for the bisubstrate inhibitor 4.3 was derived from a substrate that is 
readily phosphorylated by c-Src but not by the structurally homologous kinase c-Abl. 
Based upon the known substrate selectivity, it was expected that compound 4.3 would 
be a poor inhibitor of c-Abl.  Biochemical assays revealed that compound 4.3 inhibits c-
Abl with an IC50 = 1,168 nM (see experimental section). The observed data were in 
good agreement with the proposed hypothesis; the compound inhibited c-Src with much 
greater affinity than c-Abl.  
There are few reports in which a bisubstrate 
inhibitor’s selectivity profile has been determined 
using a large kinase panel, and in general those 
that have been subjected to thorough evaluation 
display only modest improvement in selectivity 
relative to the parent components. In an effort to 
adequately determine the degree of selectivity 
that could be achieved using the described 
strategy compound 4.3 was submitted for 
selectivity profiling against a diverse panel of 
200 kinases (KinaseSeeker9, Figure 4.4). 
Compound 4.3 was found to be highly selective, 
with only two kinases found to be significantly 
bound (≤ 35% control), the target kinase, c-Src, and a related Src family kinase, Yes. It 
is noteworthy that three other SFKs (Fyn, Blk, Hck) were found to be modestly bound (≤ 
55% control) which would be expected by the redundant substrate preference of this 
Competitor Kd (nM) 
4.3 0.28 
PP2 22 
MEB-4-151 15, 566 
 
Table 4.3. Inhibitor Kd determination using 
probe 4.7. 
 
Figure 4.4. Selectivity profile for compound 
4.3 at 115 nM against a panel of 200 
kinases. determined using a binding assay 
(see supporting information for details). 
Only kinases that displayed ≤ 35% control 
are displayed. 
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family. To our knowledge this is the most selective SFK inhibitor, bisubstrate or 
otherwise, reported to date (S (35) = 0.010). 
Given the high selectivity of 4.3, further 
interrogation of the source of selectivity was a 
reasonable next inquiry. It was proposed that the 
selectivity is due to interactions between the 
substrate-binding site of the enzyme and residues 
within the peptide fragment. Inhibitor 4.3 was 
truncated to provide a bisubstrate inhibitor which 
contained only a 4-aminophenylalanine residue 
(Figure 4.5). Biochemical characterization of 
compound 4.7 revealed it to be much less 
selective than its related bisubstrate counterpart. 
Compound 4.7 displayed significant inhibition of c-
Abl and Hck (neither of which were >65% displaced in the selectivity panel). Altogether 
these data are suggestive that additional interactions within the substrate binding site 
are necessary to obtain high levels of both potency and selectivity. 
It was determined that the selectivity of 
compound 4.3 is driven by interactions within 
the substrate binding site, therefore it should 
be possible to tune the selectivity of the 
inhibitor by replacing the peptide fragment 
with a sequence that is representative for an 
optimal substrate for another kinase. In an 
effort to determine the modularity of this strategy another kinase found to be tightly 
bound by the parent pyrazolopyrimidine fragment was chosen to be targeted, PDGFRB 
(99.5% displacement from an immobilized ligand using 10 µM inhibitor 4.1, see 
supporting information). The same inhibitor development strategy was employed with 
the exception of the replacement of a substrate-competitive inhibitor whose sequence 
was based upon a reported substrate10 to provide compound 4.8 (see experimental 
 
 IC50 (nM) 
Cpd c-Src Hck Abl 
4.7 1,182 555 1,134 
 
Figure 4.5. Structure and biochemical 
characterization of a truncated c-Src 
bisubstrate inhibitor 4.7. Inhibitors were 
characterized using a continuous 
fluorescence assay. Assay conditions: 
100 µM ATP, 45 µM peptide substrate. 
 IC50 (µM) 
Compound 
(target) 
c-Src  Blk  PDGFRB  
4.3 
(c-Src) 
0.016  0.13  2.0  
4.8 
(PDGFRB) 
>10 
  
1.3
  
0.35  
 
Table 4.4. Biochemical characterization of a 
bisubstrate inhibitor designed to bind 
PDGFRB. For assay details see supporting 
information. 
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section for sequence). Significantly, compound 4.8 displayed good selectivity for 
PDGFR over c-Src, with no notable inhibition of c-Src up to 10 µM (Table 4.4). 
Clinically used kinase inhibitors commonly become ineffective upon a cancer patient’s 
development of a resistance mutation. One of the most commonly observed mutations 
is the “gatekeeper” mutation in the ATP-binding site11,12. This mutation results in loss of 
a key hydrogen bond required for the binding of most kinase inhibitors and also 
sterically occludes inhibitor binding. It was hypothesized that bisubstrate inhibitors 
would be less impacted relative to their ATP-competitive counterparts due to having 
additional interactions outside of the ATP pocket. Therefore we compared dasatinib13, a 
dual Src-Abl ATP-competitive inhibitor approved for treatment of patients whom develop 
resistance mutations in CML, to bisubstrate inhibitor 4.3 with respect to the T338I  
gatekeeper mutation in c-Src. Both inhibitors 
displayed decreased potency relative to the 
wild type kinase. Despite dasatinib being 
approximately six times more potent for the 
wild type kinase (see Supporting Information), 
it was found that inhibitor 4.3 was thirty times 
more potent versus the gatekeeper mutation 
(Figure 4.6) which represents a relative 180-
fold potency shift. It is therefore proposed that 
the bivalent nature of inhibitor 4.3 makes it 
less susceptible to mutations in the ATP-
binding site. To our knowledge this is the first 
examination of the influence of the gatekeeper 
mutation on a bisubstrate inhibitor which has an ATP-competitive fragment that would 
be predicted to clash with this residue (for an example of a bisubstrate inhibitor which 
evades T338I see reference 14). 
In order for a kinase inhibitor to be valuable as a cellular probe it must have adequate 
membrane permeability. In general, the utility of peptides has suffered considerably 
because of their poor cell permeability; therefore it was not surprising to observe that 
 
Figure 4.6. ATP-competitive vs. bisubstrate-
competitive inhibition of a clinically observed 
resistance mutation. IC50s were determined 
using the activity assay described in the 
Experimental section. 
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the c-Src selective bisubstrate inhibitor 4.3 had little effect in cell-based assays (See 
experimental section). Fortunately, several strategies have been developed to increase 
peptide permeability including incorporation of a poly-Arg tag. Compound 4.3 was 
modified to include a poly-Arg tag at its N-terminus to provide compound 4.3-R9. 
Addition of the Arg9 tag had little impact on its performance in biochemical inhibition 
assays (See experimental section). Treatment of HT29 cells with compound 4.3-R9 
resulted in dose-dependent growth inhibition (GI50 = 36 µM, See experimental section). 
Therefore, it is postulated that any inhibitor developed using the described strategy has 
good potential for application in whole-cell experiments. 
4.3 Conclusions 
Bisubstrate kinase inhibition has been of great interest due to the promise of selectivity 
offered by interactions with the substrate-binding site, but examples of such inhibitors 
that have been subjected to a large and diverse selectivity panel are rare. This work 
describes a rational approach to provide highly potent and selective bisubstrate kinase 
inhibitors in a modular fashion. Using c-Src as a model kinase, a bisubstrate inhibitor 
has been created which displays significantly higher potency than the respective 
individual components. It was also found that these bisubstrate inhibitors perform better 
than ATP-competitive inhibitors against a clinically observed resistance mutation. 
Importantly, when this inhibitor was subjected to a panel of 200 diverse kinases, only 
two kinses (c-Src and the related Src family kinase, Yes) showed significant affinity for 
the compound. It is also shown that replacing the peptide fragment with a sequence that 
is representative of a PDGFRB kinse substrate provides an inhibitor that potently 
inhibits PDGFRB but not c-Src, which is suggestive selectivity is driven by the peptidic 
substrate-competitive fragment. Furthermore, it is also shown that inhibitors generated 
using this strategy can be made cell permeable, which is encouraging for their 
application in whole-cell experiments. 
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4.5 Experimental section
 
SUPPLEMENTAL FIGURES 
 
 
Figure 4.S-1. Prediction of distance between N1-Phenylpyrazolopyrimidine (4.1) and a representative 
substrate peptide bound to a kinase based upon a molecular model. Pyrazolopyrimidine binding was 
modeled based upon a structure of PP2 bound to c-Src kinase (PDB 3GEQ). Peptide substrate binding 
was modeled based upon a structure of a bisubstrate inhibitor bound to c-Abl (PDB 2G1T), only the 
peptidic portion of the inhibitor is shown for clarity. The image shown was rendered using PyMol. 
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GENERAL SYNTHETIC METHODS. Unless otherwise noted, all reagents were 
obtained via commercial sources and used without further purification. Mass 
Spectrometry (HRMS) was carried out by the University of Michigan Mass Spectrometry 
Facility (J. Windak, director). 
SYNTHESIS OF COMPOUNDS 4.S-1 - 4.9 
 
Synthesis of 4.1: 4.1 was synthesized as previously described.1 
 
Synthesis of 4.S-1: 4.S-1 was synthesized as previously described.5 
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Scheme 4.S-1. General synthetic scheme for bisubstrate competitive kinase inhibitors 
using solid phase peptide synthesis. 
 
Peptide synthesis: Standard solid phase Fmoc peptide synthesis using rink amide 
resin was performed. Briefly, to a 10 ml peptide synthesis vessel was added 0.1 mmol 
of rink amide resin and 4 ml of deprotection solution (20% piperidine in NMP). The 
reaction was sealed and agitated for 30 min. The reaction solution was then removed 
via filtration and the resin was rinsed three times with NMP. Separately, a solution of 0.3 
mmol amino acid and 0.3 mmol HBTU in activator solution (5 % DIEA in NMP) was 
prepared; this solution was added to the vessel loaded with the pre-swelled rink amide 
resin. The vessel was sealed and agitated using a mechanical shaker for 30 min. The 
reaction solution was removed via filtration and the crude resin was rinsed three times 
with NMP. To the vessel containing the crude resin was added 4 ml deprotection 
solution (20% piperidine in NMP). The vessel was sealed and agitated using a 
mechanical shaker for 30 min. The reaction solution was drained and the crude resin 
was rinsed three times using NMP. The coupling-deprotection sequence was repeated 
with the amino acids necessary to afford the final desired peptides. After the final Fmoc 
deprotection, the terminal amine was acetylated using “Cap-mix A” (80% 
tetrahydrofuran, 10% acetic anhydride, 10% pyridine). 
Solid phase copper-catalyzed cycloadditions: To a 10 mL peptide synthesis vessel 
which was loaded with 0.1 mmol of resin (prepared as described in previous step) was 
added 0.3 mmol copper (I) iodide and 4 ml of a 25% diisopropylamine solution in NMP. 
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The reaction mixture was then agitated overnight at room temperature using a 
mechanical shaker. The reaction solution was drained and the crude resin was rinsed 
three times respectively using water, then NMP, and finally chloroform. The products 
were cleaved using a trifluoroacetic acid (TFA) solution (90% TFA, 5% water, 5% 
triisopropylsilane). TFA was then removed under reduced pressure. The crude reaction 
mixture was then dissolved in DMSO and purified using reverse phase HPLC (10% -> 
85% acetonitrile in water). 
Synthesis of Probe 4.6. The general protocol for peptide synthesis was followed with 
the exception being that a dye containing an acid handle for coupling was used to Cap 
the N-terminus. 
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I. ANALYTICAL DATA FOR COMPOUNDS 4.2–4.9. 
 
Spectral data for compound 4.2. HRMS-QTOF ESI+ (m/z): [M + H]+ calcd for 
C79H95ClN20O22, 1711.6691; found 1711.6655. 
 
 
Spectral data for compound 4.3. HRMS-QTOF ESI+ (m/z): [M + 2H]++ calcd for 
C81H99ClN20O22, 870.3538; found 870.3510. 
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Spectral data for compound 4.3-R9. HRMS-MALDI (m/z): [M -3Arg + H]+ calcd for 
C121H182ClN48O28, 2790.3981, found 2790.558. 
 
 
Spectral data for compound 4.4. HRMS-QTOF ESI+ (m/z): [M + 2H]++ calcd for 
C83H103ClN20O22, 884.3695; found 884.3687. 
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Spectral data for compound 4.5. HRMS-QTOF ESI+ (m/z): [M + H]+ calcd for 
C62H87N15O22, 1394.6223; found 1394.6251. 
Spectral data for compound 4.6. HRMS-QTOF ESI+ (m/z): [M + 2H]++ calcd for 
C111H133ClN22O22, 1081.9939; found 1081.9893. 
 
 
Spectral data for compound 4.7. HRMS-QTOF ESI+ (m/z): [M + H]+ calcd for 
C36H36ClN11O3, 706.2764, found 706.2755. 
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Spectral data for compound 4.8. HRMS-QTOF ESI+ (m/z): [M + 2H]++ calcd for 
C73H102ClN27O14, 808.8967; found 808.8958. 
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BIOCHEMICAL AND CELLULAR CHARACTERIZATION 
A. General procedure for determination of inhibitor IC50.  
A continuous fluorescence assay15 was used to determine IC50. Reaction volumes of 
100 µL were used in 96-well plates. 85 µL of enzyme in buffer was added to each well. 
2.5 µL of the appropriate inhibitor dilution (typically 5000, 1666, 555, 185, 61, 20, 6.8, 
2.2, 0.76, 0 µM in DMSO) was then added. 2.5 µL of a substrate peptide (“compound 3” 
as described in Wang et al16) solution (1.8 mM in DMSO) was added. The reaction was 
initiated with 10 µL of ATP (1 mM in water), and reaction progress was immediately 
monitored at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 
30 nM enzyme, 45 µM peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 
10 mM MgCl2, 0.01% Triton X-100; the concentration of ATP varied from 0.1 – 5 mM, 
and the concentrations are specified for each experiment in the following section. The 
initial rate data collected was used for determination of IC50 values. For IC50 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of the inhibitor. The 
equation Y=Bottom + (Top-Bottom)/(1+10^(X-LogEC50)) was used in the nonlinear 
regression. 
 
B. Analytical data for c-Src IC50 determination.  
Each inhibitor IC50 value was determined using at least three independent experiments; 
a representative inhibition curve is shown. 
 
 
4.2 Avg IC50 = 159 ± 28 nM 
 [ATP] = 5 mM 
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4.3 Avg IC50 ≤ 8.4 nM  
 [ATP] = 5 mM 
 
 
 
4.4 Avg IC50 = 121 ± 50 nM 
 [ATP] = 5 mM 
 
 
 
4.7 Avg IC50 = 1,182 ± 275 nM 
 [ATP] = 100 µM 
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4.5 Avg IC50 = 8,372 ± 861 nM 
 [ATP] = 5 mM 
 
C.  Analytical data for T338I c-Src IC50 determination. Each inhibitor IC50 value was 
determined using at least three independent experiments; a representative inhibition 
curve is shown. 
 
 
4.3 Avg IC50 = 953 ± 82 nM 
 [ATP] = 100 µM 
 
 
 
dasatinib Avg IC50 = 50,395 ± 18,520 nM 
 [ATP] = 100 µM 
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D. Analytical data for Hck IC50 determination. Each inhibitor IC50 value was 
determined using at least three independent experiments; a representative inhibition 
curve is shown. 
  
4.3 Avg IC50 = 37 ± 14 nM 
 [ATP] = 5 mM 
 
 
 
4.7 Avg IC50 = 555 ± 73 nM 
 [ATP] = 100 µM 
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E. Analytical data for c-Abl IC50 determination. Each inhibitor IC50 value was 
determined using at least three independent experiments; a representative inhibition 
curve is shown. 
 
 
4.3 Avg IC50 = 1,168 ± 731 nM 
 [ATP] = 5 mM 
 
 
 
4.7 Avg IC50 = 1,134 ± 374 nM 
 [ATP] = 100 µM 
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F. General procedure for determination of Kd  for Cy-5 labeled bisubstrate 
inhibitor (4.6).  
A Time Resolved FRET (TR-FRET) assay was used to determine Kd. Well volumes of 
20 µL were used in 384-well plates. 10 µL of a solution of 6xHis-enzyme and Eu3+ 
labeled Anti-6xHis antibody in buffer was added to each well. 5 µL of the appropriate 
probe dilution in buffer (typically 5000, 1666, 555, 185, 61, 20, 6.8, 2.2, 0.76, 0 nM in 
buffer) was then added. 5 µl buffer was then added. The plate was then centrifuged for 
30 seconds at 4,000 rpm. The plate was then allowed to incubate at room temperature 
for 30 minutes in an area devoid of light. TR-FRET emission was then determined 
respectively at 650 and 620 nM (ex. 360 ± 40 nm). A 570 ± 100 nm emission filter was 
used. 20 measurements were collected per data point with 100 µsec of delay time and 
200 µsec of data collection. Wells had final concentrations of 5 nM enzyme, 2 nM Eu3+ 
labeled Anti-6xHis antibody, 50 mM Tris buffer (pH 8.0), 100 mM NaCl, 0.1% BSA, an 
varying  concentrations of probe 4.6,. For Kd determination, the kinetic values were 
obtained directly from nonlinear regression of probe-binding curves. The equation 
Y=Bmax*X/(Kd+X) was used in the nonlinear regression. 
G. Analytical data for c-Src Kd determination of 4.6. 
 
Probe 4.6 Avg Kd = 6.3 ± 1.6 nM 
 
H. General procedure for competition-assay based determination of inhibitor Kd. 
A Time Resolved FRET (TR-FRET) competition assay was used to determine Kd. 
Reaction volumes of 20 µL were used in 384-well plates. 10 µL of a solution of 6xHis-
enzyme and Eu3+ labeled Anti-6xHis antibody in buffer was added to each well. 5 µL 
solution of probe 4.6 in buffer was added (final concentrations for individual experiments 
[4.6] 
126 
 
are specified below). 5 µL of the appropriate inhibitor dilution (typically 5000, 1666, 555, 
185, 61, 20, 6.8, 2.2, 0.76, 0 nM in buffer) was then added. The plate was then 
centrifuged for 30 seconds at 4,000 rpm. The plate was then allowed to incubate at 
room temperature for 30 minutes in an area devoid of light. TR-FRET emission was 
then determined respectively at 650 and 620 nM (ex. 360 ± 40  nm). A 570 ± 100 nm 
emission filter was used. 20 measurements were collected per data point with 100 µsec 
of delay time and 200 µsec of data collection. Reactions had final concentrations of 5 
nM enzyme, 2 nM Eu3+ labeled Anti-6xHis antibody, 50 mM Tris buffer (pH 8.0), 100 
mM NaCl, 0.1% BSA. For Kd determination, the kinetic values were obtained directly 
from nonlinear regression of probe-binding curves in the presence of various 
concentrations of the competing ligand. The equation Y=Bottom + (Top-
Bottom)/(1+10^(X-LogEC50)) was used in the nonlinear regression. 
I. Analytical data for c-Src inhibitor Kd determination using probe 4.6. Each ligand 
EC50 value was determined using at least three independent experiments; a 
representative binding curve is shown. 
 
 
4.3 Avg Kd = 280 ± 76 pM 
 [fluorescent probe 4.6] = 400 nM 
 
 
 
PP2 Avg Kd = 22 ± 7 nM 
 [fluorescent probe 4.6] = 40 nM 
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MEB-4-151 Avg Kd = 15,567 ±  4,304 nM 
 [fluorescent probe 4.6] = 40 nM 
 
J. Analytical data for c-Src inhibitor Kd determination using kinase Tracer 236. A 
modified protocol which employed kinase Tracer 236 (final concentrations for individual 
experiments are specified below). Each ligand EC50 value was determined using at least 
three independent experiments; a representative binding curve is shown. 
 
 
4.3 Avg Kd = 187 pM 
 [tracer 236] = 250 nM 
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PP2 Avg Kd = 8.9 ± 2.7 nM 
 [tracer 236] = 50 nM 
 
 
 
MEB-4-151 Avg Kd ˃ 330,000 
 [tracer 236] = 50 nM 
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K. Cancer cell growth inhibition assays. 
General procedure:  
1. Cell culture and seeding:  Cells are dispersed from flasks and collected by 
centrifugation (125xg for 5 minutes at room temperature). An aliquot of the 
resuspended cells is mixed with trypan blue solution and the cell number is 
quantified using a hemacytometer. In general, depending on the growth rate of 
the untreated cells, the cells will be plated at 5.0 – 7.5 x 103 cells per well. 100 µL 
of the cell mixture will be added to each well so the concentration should be 10X 
the cells per well in cells per mL. The cells are plated into sterile, clear bottom 96 
well plates and cultured under normal growth conditions overnight prior to dosing 
with compound. 
2. Dosing: The 100% DMSO compound stocks need to be prepared to 100X the 
final concentration that is desired in the assay. 3 µL of the DMSO stock solution 
is then added to 297 µL of the cell growth media to give a DMSO concentration 
of 1%. The cell media is removed by aspiration for adherent cells and replaced 
with 100 µL per well of the cell growth media containing the compound. In 
general each compound concentration is dosed in triplicate wells. The plates are 
returned to normal culture conditions for 24 – 72 hours.  
3. Assay: After the required incubation period the plates are removed from the 
incubator and 10 µL per well of WST-1 reagent is added. The plates are returned 
to the incubator and the color change is visually monitored for 0.5 – 2 hours. 
When sufficient color change has occurred the plates are shaken on a plate 
shaker for 60 seconds and read in the appropriate plate reader.  
4. Data Analysis: The reference absorbance reading is subtracted from the 
formazan absorbance and the data is plotted as a percentage of the vehicle (1% 
DMSO alone). Data analysis and curve fitting was performed using Graphpad 
Prism. For each cell line, there were n = 3 data points for each concentration. 
Each dose response curve was performed at least twice, providing n ≥ 6 for each 
data point. 
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Figure 4.S-2. Treatment of HT-29 colon cancer cells with 4.3-R9.  
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Luceome IC50 determination 
IC50s for compounds 4.3 and 4.8 were determined using KinaseLite™ (Luceome 
Biotechnologies, Tucson AZ).  
A. Tabulated Luceome IC50 data: 
                                      IC50 (µM) 
Test Compound  SRC  BLK  PDGFRB  
4.3  0.016 ± 0.005  0.13 ± 0.021  2.0 ± 1  
4.8  >10  1.3 ± 0.1  0.35  0.07  
 
B. Representative Luceome IC50 curves: 
  
Figure 4.S-3. Representative Src IC50 plots for A) Cpd 4.3 and B) Cpd 4.8 
 
  
Figure 4.S-4. Representative Blk IC50 plots for A) Cpd 4.3 and B) Cpd 4.8 
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Figure 4-S-5. Representative PDGFRB IC50 plots for A) Cpd 4.3 and B) Cpd 4.8 
 
 
Figure 4.S-6. Representative Src IC50 plot for dasatinib. 
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KINOMEscan profiling 
Kinome profiling for compound 4.1 was performed by KINOMEscan (DiscoveRx, 
Fremont, CA). The compound was profiled at a concentration of 10 µM.  
A. 4.1 TREEspot analysis: 
 
4.1 
 
 
 
 
B. S-Scores for 4.1: 
S(35) = 0.252 
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C. Tabulated data for compound 4.1: 
KINOMEscan Gene Symbol % control 
ABL1(E255K)-phosphorylated 36 
ABL1(F317I)-nonphosphorylated 100 
ABL1(F317I)-phosphorylated 76 
ABL1(F317L)-nonphosphorylated 100 
ABL1(F317L)-phosphorylated 44 
ABL1(H396P)-nonphosphorylated 20 
ABL1(H396P)-phosphorylated 52 
ABL1(M351T)-phosphorylated 90 
ABL1(Q252H)-nonphosphorylated 73 
ABL1(Q252H)-phosphorylated 51 
ABL1(T315I)-nonphosphorylated 100 
ABL1(T315I)-phosphorylated 87 
ABL1(Y253F)-phosphorylated 57 
ABL1-nonphosphorylated 59 
ABL1-phosphorylated 49 
ABL2 27 
ACVR1 20 
ACVR1B 62 
ACVR2A 50 
ACVR2B 8.6 
ACVRL1 15 
ADCK3 64 
AKT1 99 
AKT2 99 
ALK 100 
AURKA 90 
AURKB 94 
AXL 69 
BLK 0.75 
BMPR2 100 
BMX 37 
BRAF 22 
BRAF(V600E) 18 
BRK 3.2 
BTK 66 
CDK11 44 
CDK2 83 
CDK3 100 
CDK7 97 
CDK9 76 
CHEK1 100 
CSF1R 40 
CSK 92 
CSNK1D 85 
CSNK1E 0.35 
CSNK1G2 78 
DCAMKL1 99 
DDR1 28 
DDR2 61 
DMPK 81 
DMPK2 21 
DYRK1B 79 
EGFR 4.4 
EGFR(E746-A750del) 8.2 
EGFR(G719C) 0.45 
EGFR(G719S) 1.6 
EGFR(L747-E749del, A750P) 6.4 
EGFR(L747-S752del, P753S) 6.2 
EGFR(L747-T751del,Sins) 6.6 
EGFR(L858R) 9.6 
EGFR(L858R,T790M) 80 
EGFR(L861Q) 5.7 
EGFR(S752-I759del) 6.2 
EGFR(T790M) 33 
EPHA1 13 
EPHA2 51 
EPHA3 66 
EPHA4 44 
EPHA5 54 
EPHA6 64 
EPHA7 100 
EPHA8 15 
EPHB1 75 
EPHB2 66 
EPHB3 16 
EPHB4 60 
EPHB6 31 
ERBB2 56 
ERBB3 48 
ERBB4 31 
ERK1 92 
FAK 92 
FGFR1 92 
FGFR2 86 
FGFR3 100 
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FGFR4 100 
FGR 5.2 
FLT1 83 
FRK 5.8 
FYN 7 
GAK 4.7 
GCN2(Kin.Dom.2,S808G) 90 
GSK3B 100 
HCK 3.3 
IGF1R 100 
IKK-alpha 100 
IKK-beta 100 
INSR 81 
JAK2(JH1domain-catalytic) 97 
JAK3(JH1domain-catalytic) 92 
JNK1 94 
JNK2 84 
JNK3 91 
KIT 1 
KIT(A829P) 86 
KIT(D816H) 96 
KIT(D816V) 6.8 
KIT(L576P) 1.8 
KIT(V559D) 0.5 
KIT(V559D,T670I) 79 
KIT(V559D,V654A) 37 
KIT-autoinhibited 89 
LCK 0.5 
LIMK1 77 
LIMK2 85 
LKB1 88 
LOK 81 
LYN 21 
MAP3K4 89 
MAP4K2 94 
MAP4K3 96 
MAP4K4 97 
MAP4K5 100 
MAPKAPK2 100 
MARK3 83 
MEK1 65 
MEK2 65 
MEK3 96 
MEK4 100 
MEK5 7.9 
MET 100 
MKNK1 100 
MKNK2 100 
MLK1 96 
MRCKA 55 
MRCKB 70 
MST4 80 
NLK 13 
p38-alpha 90 
p38-beta 73 
PAK1 100 
PAK2 78 
PAK4 99 
PCTK1 100 
PDGFRA 38 
PDGFRB 0.5 
PDPK1 96 
PFCDPK1(P.falciparum) 13 
PFPK5(P.falciparum) 80 
PIK3C2B 100 
PIK3CA 91 
PIK3CG 12 
PIM1 100 
PIM2 77 
PIM3 100 
PKAC-alpha 37 
PKMYT1 65 
PKNB(M.tuberculosis) 100 
PLK1 100 
PLK3 91 
PLK4 67 
PRKCE 100 
RAF1 20 
RET 7.6 
RET(M918T) 3.6 
RET(V804L) 82 
RET(V804M) 97 
RIOK2 100 
RIPK2 0.25 
ROCK1 77 
ROCK2 83 
RSK2(Kin.Dom.1-N-terminal) 79 
SIK 12 
SIK2 18 
SLK 77 
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SNARK 79 
SRC 0.15 
SRMS 74 
SRPK3 100 
STK36 33 
SYK 80 
TEC 100 
TESK1 23 
TGFBR1 68 
TGFBR2 3.1 
TIE2 89 
TNIK 83 
TNK2 52 
TNNI3K 75 
TRKA 69 
TSSK1B 91 
TXK 1.1 
TYK2(JH1domain-catalytic) 100 
ULK2 98 
VEGFR2 100 
WEE1 100 
YANK3 78 
YES 11 
ZAK 33 
ZAP70 100 
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Luceome selectivity profiling 
Kinome profiling for compound 4.3 was performed by KinaseSeeker™ (Luceome 
Biotechnologies, Tucson, AZ). The compound was profiled at a concentration of 115 
nM. 
A. Compound 4.3 TREEspot analysis: 
 
4.3 
 
 
 
 
 
B. S-Scores for 4.3: 
S(35) = 0.010 
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C. Tabulated Luceome selectivity profiling data for compound 4.3: 
Kinase Family % Activity Remaining 
ABL1 TK 100.0 
ABL2 TK 96.5 
AKT1 AGC 100.0 
AKT1(FL) AGC 96.8 
AKT2 AGC 98.4 
AKT2(S474A) AGC 94.7 
AKT2(S474D) AGC 94.9 
AKT2(T309A,S474A) AGC 94.4 
AKT2(T309D,S474D) AGC 90.9 
AKT3 AGC 100.0 
AMPK-a1 CAMK 99.7 
AMPK-a2 CAMK 100.0 
AURKA Other 100.0 
AURKB Other 100.0 
AURKC Other 96.3 
AXL TK 100.0 
BIKE Other 96.5 
BLK TK 42.4 
BTK TK 100.0 
CAMK1 CAMK 99.9 
CAMK1D CAMK 99.1 
CAMK1G CAMK 100.0 
CAMK2A CAMK 100.0 
CAMK2B CAMK 97.1 
CAMK2D CAMK 100.0 
CAMKK1 Other 100.0 
CAMKK2 Other 100.0 
CHEK1 CAMK 96.9 
CK1D CK1 100.0 
CLK1 CMGC 100.0 
CLK2 CMGC 100.0 
CSK TK 95.3 
DAPK1 CAMK 100.0 
DAPK2 CAMK 100.0 
DAPK3 CAMK 97.4 
DDR1 TK 95.0 
DDR2 TK 96.3 
DMPK AGC 100.0 
EPHA1 TK 100.0 
EPHA2 TK 100.0 
EPHA3 TK 100.0 
EPHA4 TK 100.0 
EPHB2 TK 100.0 
EPHB3 TK 90.3 
EPHB4 TK 98.9 
FGFR2 TK 100.0 
FLT1 TK 100.0 
FLT2 TK 92.5 
FLT3 TK 100.0 
FYN TK 37.7 
GSK3a CMGC 100.0 
HCK TK 54.7 
IGF1R TK 92.1 
IKK-e Other 97.3 
INSR TK 100.0 
ITK TK 100.0 
LIMK1 TKL 100.0 
LYN TK 78.4 
MARK1 CAMK 90.1 
MARK2 CAMK 100.0 
MARK3 CAMK 100.0 
MARK4 CAMK 100.0 
MELK CAMK 100.0 
MET TK 100.0 
MLK1 TKL 100.0 
MLK3 TKL 100.0 
MST2 STE 81.0 
MUSK TK 100.0 
MYLK CAMK 88.0 
MYLK2 CAMK 100.0 
p38-g CMGC 97.0 
PAK1 STE 100.0 
PAK1(T423A) STE 100.0 
PAK1(T423E) STE 99.2 
PDGFRA TK 100.0 
PDGFRB TK 100.0 
PDK1 AGC 100.0 
PHKG1 CAMK 90.0 
PIM1 CAMK 88.3 
PIM2 CAMK 100.0 
PKAC-a AGC 98.9 
PKAC-b AGC 100.0 
PKC-d AGC 94.9 
PKC-e AGC 98.7 
PKC-g AGC 100.0 
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PKC-h AGC 100.0 
PKC-t AGC 84.0 
PRKD2 CAMK 100.0 
PRKD3 CAMK 93.3 
PKG1 AGC 100.0 
PKN3 AGC 74.7 
PLK4 Other 96.5 
PKX AGC 100.0 
PTK2 TK 100.0 
PTK2B TK 92.7 
PTK6 TK 76.7 
RET TK 91.9 
RIPK2 TK 95.5 
RPS6KA1/RSK1 AGC 94.4 
RPS6KA2/RSK3 AGC 100.0 
RPS6KA3/RSK2 AGC 100.0 
RPS6KA4/MSK2 AGC 82.4 
RPS6KA5/MSK1 AGC 98.0 
RPS6KA6/RSK4 AGC 98.8 
SGK2 AGC 95.1 
SGK3 AGC 100.0 
SNF1LK CAMK 87.7 
SNF1LK2 CAMK 84.9 
SIK3 CAMK 96.3 
SLK STE 100.0 
SNARK CAMK 77.1 
SRC TK 15.9 
STK16 Other 78.5 
STK33 CAMK 97.5 
SYK TK 98.7 
TBK1 Other 100.0 
TEC TK 100.0 
TESK1 TKL 100.0 
TESK2 TKL 85.7 
TIE1 TK 100.0 
TIE2 TK 95.0 
TNK2 TK 100.0 
TNNI3K TKL 97.6 
TRKB TK 97.0 
TRKC TK 100.0 
TKX TK 63.4 
VEGFR2 TK 100.0 
YANK2 AGC 100.0 
YES1 TK 17.4 
YSK1 STE 88.2 
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CHAPTER 5  
Development of a highly selective c-Src kinase inhibitor
This chapter additionally addresses the “How much selectivity may be gained by 
exploiting structural features outside of the canonical ATP-pocket?” theme. This chapter 
regards targeting features proximal to the ATP-pocket. Using a tethering approach 
similar to that described in Chapter 4 it is discovered that building toward the p-loop 
region of c-Src provides a highly selective inhibition. This selective probe is also used to 
demonstrate that dual Src-Abl inhibition is ineffective in some breast cancer cell lines. 
5.1 Introduction 
The non-receptor tyrosine kinase c-Src plays a vital role in many facets of cell 
physiology, regulating diverse processes including cell division, motility, adhesion, 
angiogenesis, and survival.1,2 c-Src was the first proto-oncogene to be identified and is 
frequently over-expressed in cancers2. Furthermore, the extent of this over-expression 
typically correlates with malignant potential and patient survival.1,2 Recently, c-Src was 
identified as the major resistance factor to Herceptin, a first line therapy for Her2+ 
breast cancer.3  Despite the significant attention devoted to c-Src inhibitor discovery, 
there are no highly selective probes for c-Src suitable for chemical genetic experiments 
in native systems.4,5,6 
To fully understand the role of c-Src in oncogenesis, specific probes of c-Src function 
are required. Herein, we describe the development of the first highly selective and cell-
permeable inhibitor of c-Src. Our approach involves modifying an existing non-selective 
inhibitor to interact with an adjacent pocket formed by the phosphate-binding loop of c-
Src. This approach represents an underutilized method for improving kinase inhibitor 
selectivity that is likely generalizable across many kinase families.7  We have developed 
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the most selective c-Src inhibitor to date and, using this inhibitor, we demonstrate that 
selective inhibition of c-Src is significantly more efficacious than multi-kinase inhibition in 
cell culture. Finally, using our probe we show that inhibition of a common off-target 
kinase of c-Src inhibitors, c-Abl, is pro-oncogenic in a breast cancer cell model. 
5.2 Results and discussion 
We started our work by examining PP2, a well-
known inhibitor reported to be highly selective for c-
Src.8  The description of PP2 as selective arises 
from a 2007 report in which several kinase inhibitors 
were profiled against a panel of 73 kinases, most of 
which were Ser/Thr kinases.9  Despite over 1,000 
subsequent biological studies using PP2 as a tool, 
no broader kinome profiling of PP2 has been 
reported. To test PP2’s selectivity more definitively, 
the inhibitor was screened against a diverse panel 
of 200 kinases using an in vitro ATP-site 
competition binding assay (KINOMEScan10) at a 
concentration of 10 µM. In contrast to previous 
reports,9  
PP2 is classed as non-selective from these data 
(S35 = 0.41, Figure 5.1). S35 is calculated by 
dividing the number of kinases with less than 35% 
of control by the total number of kinases tested. In 
the KINOMEScan panel, 56 kinases showed 
greater than 95% displacement from an immobilized 
ligand by PP2 (24 kinases had >99% displacement). Based on our results, PP2 is less 
selective than dasatinib, a well-studied and promiscuous tyrosine kinase inhibitor (in this 
 
Figure 5.1 A. Structure of PP2. B. 
Kinome dendrogram of PP2 selectivity 
profiling at 10 µM. c-Src is colored blue 
and off-target kinases of PP2 are 
colored red. Dendrogram was 
generated using TREEspot software 
tool with 10% cutoff. Green circles 
denote kinases kinases included in 
panel that show no binding below 
cutoff. Dendrogram reprinted with 
permission from KINOMEscan. 
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panel S35 = 0.27).11 Given this lack of selectivity, interpretation of the results from the 
numerous reports using PP2 in biological studies are complicated by inhibition of many  
other kinases. For example, PP2 has been 
used to demonstrate that c-Src activity 
modulates ErbB2 and ErbB3 phosphorylation 
state in breast cancer.12  However, our profiling 
shows that PP2 significantly inhibits both 
ErbB2 and ErbB3. For the complete profiling 
data for PP2, see the Supporting Information. 
Based on co-crystal structures of PP2 bound to 
c-Src and Src-family kinases,13,14 we 
hypothesized that PP2 could be modified to 
obtain a selective inhibitor. Specifically, a 
pocket formed by the phosphate-binding loop 
(P-loop, also known as the glycine-rich loop) 
was identified in c-Src that did not appear in 
homologous kinases, including c-Abl (for molecular models of this pocket, see the 
Supporting Information). c-Abl is a tyrosine kinase with high sequence similarity to c-Src 
(69% across the entire kinase domain) and nearly identical ATP-binding pockets. No 
clinical or pre-clinical inhibitors of c-Src have been reported that do not also inhibit c-
Abl.11 Therefore, c-Abl was chosen 
as our initial test for inhibitor 
selectivity. From our analyses of co-
crystal structures of dasatinib bound 
to both c-Src and c-Abl, c-Src has a 
more “open” P-loop compared to c-
Abl (Figure 2). Likewise, in co-
crystal structures of imatinib with c-
 
Figure 5.2. Alignment of structures with 
dasatinib bound to c-Src (PDB code: 3QLG) 
and c-Abl (2GQG). c-Src is colored light 
green with P-loop of c-Src highlighted yellow. 
c-Abl is colored light blue with P-loop of c-Abl 
highlighted red. Dasatinib is shown in space 
fill model. 
 
Scheme 5.1. Synthesis and biochemical characterization 
of benzyl triazole compound 5.2.  
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Src and c-Abl the P-loop of c-Src 
is “open” while the P-loop of c-
Abl is “closed” (Supporting 
Information Figure S1).  
To obtain molecules that could 
interact with the P-loop pocket of 
c-Src, a PP2 analog containing 
an aryl alkyne handle was 
synthesized. PP2~alkyne (5.1) is 
a modest inhibitor of c-Src (Ki = 
1.4 µM). Based on our proposed 
molecular docking model (see 
Supporting Information Figure 
S2), PP2~alkyne scaffold was 
elaborated using benzyl azide 
and  
either Cu- or Ru-based click 
chemistry15  to form 1,4- or 1,5-
disubstituted benzyl triazoles, 
respectively. Consistent with our 
model, the 1,4-disubstituted 
benzyl triazole is not an effective 
inhibitor of c-Src (see Supporting 
Information), while the 1,5-disubstituted benzyl triazole (5.2) has increased binding 
affinity for c-Src (Ki = 207 nM). Significantly, compound 5.2 did not inhibit c-Abl activity 
up to 125 µM (Scheme 5.1).  
In an effort to further improve potency, a limited number of analogs (compounds 5.3–
5.6) were synthesized (Table 5.1). From this series of compounds, meta-substituted 
Table 5.1. Summary of Ki values obtained for compounds 
5.1–5.6.  
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biphenyl 4 was the only compound that had improved binding (lower Ki) to c-Src. 
Compound 5.4 is a potent inhibitor (Ki = 44 nM) of c-Src and does not inhibit c-Abl up to 
125 µM. The binding affinity of compound 4 for c-Src is comparable to that of PP2 (Ki = 
33 nM). However, PP2 is also an effective c-Abl inhibitor (Ki = 325 nM). 
Compound 5.4 was screened against a diverse 
kinase panel (KINOMEscan10) using an in vitro ATP-
site competition binding assay at a concentration of 
10 µM (Figure 5.3). From this panel, we found that 
compound 4 was remarkably selective. Only three 
kinases (c-Src, c-Raf, and B-Raf) exhibited >95% 
displacement from an immobilized ligand by 
compound 5.4 (only c-Src had >99% displacement). 
Detailed selectivity profiling results can be found in 
the Supporting Information.  
Using this same method,10 Kd measurements were 
obtained for c-Src and 6 homologous kinases that 
are members of the Src kinase family and not found 
in the panel (Table 5.2). Obtaining selectivity across 
this conserved kinase family has been a challenging 
task with only a handful of compounds identified that 
can discriminate between them.16,17 The Kd for c-Src 
(86 nM) was in good agreement with the Ki we 
obtained in our biochemical activity assay. 
Compound 5.4 is selective between Src family 
members, with >2-fold selectivity over both Lck and 
Fgr, 8-fold selectivity over c-Yes, and >40-fold selectivity over Lyn, Hck, and Fyn (Table 
5.2).  
 
Figure 5.3. A. Structure of compound 
4. B. Kinome dendrogram of 
compound 4 selectivity profiling at 10 
µM. c-Src is colored blue and off-target 
kinases of compound 4 are colored 
red. Dendrogram was generated using 
TREEspot software tool with 10% 
cutoff. Green circles denote kinases 
kinases included in panel that show no 
binding below cutoff.  Dendrogram 
reprinted with permission from 
KINOMEscan. 
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Interactions with the P-loop of kinases have previously been reported to modulate 
selectivity in kinase–ligand interactions.18-20 Typically, these interactions are not due to 
the primary sequence of the P-loop, but rather due to distributed contributions 
throughout the kinase catalytic domain.19 To probe the selectivity of compound 4, the P-
loop of c-Src (residues 273-281, chicken c-Src numbering) was replaced with the P-loop 
residues of c-Abl. Compound 5.4 bound c-Src-TM (Q275G, C277Q, F278Y) with similar  
potency to that of wild-type c-Src (Ki = 175 nM). This 
suggests that the primary sequence of the P-loop is not 
solely responsible for the observed selectivity. Studies 
aimed at better understanding compound 5.4’s impressive 
selectivity are in progress. 
To serve as an effective probe in biological studies, the 
probe must function in cells. Compound 5.4 was incubated 
with murine embryonal fibroblast (MEF) cells exogenously 
expressing full-length c-Src. The change in 
phosphorylation of c-Src Tyr-416 was measured using 
specific antibodies in a sandwich ELISA.21  In this assay, 
compound 5.4 has an IC50 = 1.9 µM indicating that our probe is cell permeable and 
inhibits c-Src activity in cells (See experimental section).  
In the kinome profiling of compound 5.4, B-Raf and c-Raf were inhibited along with c-
Src. To assess whether compound 5.4 has Raf inhibitory activity in cellulo, 
phosphorylation changes in Erk, a downstream substrate of B-Raf and c-Raf, were 
measured. In SK-BR-3 cells stimulated with EGF to activate the Raf pathway, treatment 
of 100 µM compound 5.4 had no effect on p-Erk levels (see Experimental Section). 
From these results, we assume that cellular inhibition of B-Raf and/or c-Raf is not 
significant.22   
We were interested in whether selective c-Src inhibition would be as efficacious as 
multi-kinase inhibition.23  To test this, our selective probe 5.4 was compared to the non-
Table 5. 2. Kd values obtained 
by KINOMEscan for Src family 
kinases with compound 5.4. 
kinase Kd (nM) 
c-Src 86 
Lck 160 
Fgr 240 
Yes 720 
Lyn 3200 
Hck 4400 
Fyn >40,000 
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selective inhibitor PP2. PP2 has a nearly identical biochemical Ki for c-Src and has 
been extensively used in cell culture experiments. Four different cancer cell lines were 
examined,24 each of which have been shown to be growth dependent upon c-Src 
activity.25  In all cancer cell lines tested, compound 5.4 is more efficacious than PP2 
(Table 5.3). Addressing the debate about whether selective inhibition offers any 
advantage for kinase inhibitor therapeutics has been complicated by a lack of truly 
selective kinase inhibitors.23 In our studies, selective inhibition leads to improved cellular 
efficacy.  
The most profound differences between compound 5.4 and PP2 were found in cell lines 
derived from breast cancer tumors. Recent work has shown that, in contrast to its role in 
hematopoietic cancers, c-Abl activity in breast cancer is anti-oncogenic.26 That is, 
inhibition of c-Abl in breast cancer increases disease progression. We hypothesized that 
the increased efficacy of compound 5.4 could be due, in part, to removal of c-Abl 
inhibition. To test this hypothesis, the efficacy of compound 5.4 was examined in 4T1 
cells, which are frequently used as a late-stage model of metastatic breast cancer.  
Schiemann and co-workers have previously 
demonstrated that expression of a 
constitutively active c-Abl gene is sufficient 
to prevent growth of 4T1 cells in 3D 
culture.27 The efficacy of c-Src inhibitors 
has not previously been reported in 4T1 
cell culture, however, we found that 4T1 
cell growth in 3D culture is dependent upon 
c-Src activity using compound 5.4 (Figure 
5.4). To determine whether inhibition of c-
Abl can mitigate the efficacy of compound 
5.4, a highly specific inhibitor of c-Abl, 
GNF-2,28 was used. When GNF-2 and compound 5.4 are dosed together, the decrease 
in 4T1 growth observed with compound 5.4 alone was significantly abrogated (Figure 
Table 5.3. Biochemical and characterization of 
PP2 and compound 5.4.  
 
PP2 Compound 4 
Ki, c-Src 0.033 µM 0.044 µM 
GI50, HT-29 48 µM 11 µM 
GI50, SK-BR-3 > 100 µM 12 µM 
GI50, MCF7 > 100 µM 11 µM 
GI50, MDA-MB-453 14 µM 6.0 µM 
GI50, NIH-3T3 17 µM > 100 µM 
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5.4). Avoiding inhibition of off-target kinases that have anti-oncogenic activities is an 
important and frequently neglected advantage of selective inhibition. In addition to c-Abl, 
we anticipate there are other kinases inhibited by PP2 whose native activity is anti-
oncogenic.  
The results with 4T1 cellular inhibition highlight the potential utility of c-Src inhibitors in 
breast cancer therapy. Indeed, the identification of c-Src as a major resistance pathway 
to Herceptin therapy has re-invigorated the clinical exploration of c-Src inhibitors as a 
breast cancer therapy.3 Unfortunately, 
there are no c-Src inhibitors in pre-clinical 
development or clinical use that are not 
also inhibitors of c-Abl.4,11 Our data (and 
others26,27) indicate that inhibition of c-Abl 
should be avoided in breast cancer. 
Furthermore, development of highly 
selective c-Src inhibitors for therapeutic 
use should be pursued (rather than dual-
Src/Abl and/or pan-kinase inhibitors). 
Cancer cell profiling was performed by the National Cancer Institute (NCI 60 panel).29  
Consistent with published reports for inhibition of c-Src using genomic techniques,25 
compound 5.4 was cytostatic (and not cytotoxic). At a single concentration of 10 µM, 
mean growth across 57 cell lines tested was 71%. Seven cell lines showed <50% 
growth. There is good correlation between two of the cell lines, HT-29 and MCF7, where 
full dose-response curves were obtained in our laboratory (vide supra). For complete 
information on the NCI 60 panel with compound 5.4, see the Supporting Information. 
Along with dramatic increases in cellular efficacy against cancer cell lines, toxicity to a 
non-cancer cell line, NIH-3T3, was significantly reduced with selective c-Src inhibition 
(Table 5.2). With compound 5.4, no growth inhibition up to 100 µM is observed while 
PP2 has a GI50 of 17 µM for NIH-3T3 cells. PP2 is actually more effective at slowing the 
 
Figure 5.4. 4T1 cell proliferation in 3D culture. 
Growth inhibition occurs with treatment of 10 µM 
compound 4. Addition of 3 µM of a specific c-Abl 
inhibitor (GNF-2) mitigates effects of compound 
5.4. *, p-value = <0.005. 
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growth of non-cancerous NIH-3T3 cells than 3 of the 4 cancer cell lines examined. The 
reduced toxicity to healthy cells afforded by compound 5.4 is yet another advantage of 
selective inhibition. 
 
5.3 Conclusions 
Despite being the first oncogene discovered, and playing a central role in many cancer 
signaling pathways, there have been no reports of a truly selective c-Src inhibitor that 
can be used in cellular studies. Using a novel approach of extending into the P-loop 
pocket of c-Src, we have developed a highly selective probe for c-Src activity.  
Moreover, we have shown distinct advantages to selective inhibition. Studies using 
compound 5.4 to improve our understanding of c-Src signaling in cancer are in 
progress. 
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5.4 Experimental Section 
 
SUPPLEMENTARY FIGURES FOR MANUSCRIPT 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.S1. Model image of compound 5.2 bound to c-Src (starting 
structure from PDB code 3DQW). Model was generated using MOE 
(Chemical Computing Group) software. The benzyl triazole 
functionality of compound 5.2 is observed to make significant 
interactions with the P-loop pocket of c-Src. 
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(M) 
Figure 5.S-2. c-Src autophosphorylation assay. For detailed 
information, see Supporting Information page S52. 
Table 5.S-1. Biochemical characterization of analogs designed to 
increase interaction in the P-loop pocket of c-Src. 
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GENERAL SYNTHETIC METHODS. Unless otherwise noted, all reagents were 
obtained via commercial sources and used without further purification. Tetrahydrofuran 
(THF) and dichloromethane (CH2Cl2) were dried over alumina under a nitrogen 
atmosphere. All 1H and 13C NMR spectra were measured with a Varian MR400 or Inova 
500 spectrometer. Mass Spectrometry (HRMS) was carried out by the University of 
Michigan Mass Spectrometry Facility (J. Windak, director). 
 
SYNTHESIS OF COMPOUNDS 5.S-1 - 5.6 
 
 
 
Synthesis of 5.S-1:  2-((4-chlorophenyl)(methoxy)methylene)malononitrile (4.3 g, 19.7 
mmol) (prepared as described previously)1 was added to an oven-dried flask. Ethanol 
(100 mL) was then added, followed by triethylamine (5.0 g, 49.2 mmol), and 3-
bromophenyl hydrazine hydrochloride (4.4 g, 3.2 mmol). The reaction mixture was 
heated to reflux for 40 minutes. Approximately half of the solvent was then removed 
under reduced pressure. The reaction mixture was then suspended in water (150 mL) 
and filtered. After drying, the reaction afforded 5.S-1 as a tan solid (4.0 g, 54% yield). 
Spectral data. 1H NMR (500 MHz, DMSO-d6): δ 7.88-7.85, (m, 2 H), 7.51 (t, J = 8.06 
Hz, 1 H), 7.68-7.65 (m, 1 H), 7.63-7.60 (m, 1 H), 7.59-7.56 (m, 2H), 7.53-7.48 (m, 1 H), 
7.03 (s, 2 H); 13C NMR (100 MHz, DMSO-d6): δ 153.71, 149.87, 139.01, 134.33, 
Scheme 5.S1. Synthesis of PP2~alkyne (5-1). 
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131.77, 131.36, 130.27, 129.38, 128.13, 127.47, 123.79, 122.41, 115.68, 71.85; HRMS-
ESI (m/z): [M + H]+ calcd for C16H10BrClN4, 372.9850; found 372.9849. 
Synthesis of 5.S-2: Compound 5.S-1 (4.0 g, 10.7 mmol) was added to an oven-dried 
flask, followed by formamide (75 mL). The reaction mixture was heated to a gentle 
reflux for 2.5 hours. The reaction mixture was then allowed to cool to room temperature. 
The product was subsequently precipitated with water (120 mL). The crude mixture was 
filtered to yield 3.3 g (76% yield) of compound 5.S-2 as a light tan solid. Spectral data. 
1H NMR (500 MHz, DMSO-d6): δ 8.53 (s, 1 H), 8.41 (s, 1 H), 8.31-8.28 (m, 1 H), 7.79-
7.76 (m, 2 H), 7.66-7.62 (m, 2 H), 7.50-7.57 (m, 2 H); 13C NMR (100MHz, DMSO-d6): δ 
158.84, 157.21, 155.25, 145.48, 140.36, 134.50, 131.61, 131.24, 130.71, 129.65, 
129.25, 123.37, 122.19, 119.86, 99.33; HRMS-ESI (m/z): [M + H]+ calcd for 
C17H11BrClN5; 399.9959, found 399.9956. 
Synthesis of 5.S-3: Compound 5.S-2 (3.1 g, 7.7 mmol), Pd(PPh3)2Cl2 (272 mg, 0.4 
mmol), and CuI (74 mg, 0.4 mmol) were added to an oven-dried round-bottom flask. 
The reaction vessel was evacuated using a vacuum pump and subsequently filled with 
N2; this was repeated for a total of three cycles. N,N-dimethylformamide (50 mL) was 
then added, followed by ethynyltrimethylsilane (1 g, 10 mmol) and triethylamine (2.4 g, 
23.2 mmol). The reaction mixture was then heated to 60oC and stirred overnight. The 
mixture was then allowed to cool to room temperature and was precipitated using water 
(250 mL). The resulting solid was filtered, and then washed with water (20 mL). The 
residual solid was purified via silica gel chromatography using a Biotage Isolera One 
(linear gradient 20% → 100% EtOAc in hexanes) to yield 2.4 g (74% yield) of compound 
5.S-3 as a light tan solid.  Spectral data. 1H NMR (500 MHz, DMSO-d6): δ 8.41 (s, 1 H), 
8.35 (s, 1 H), 8.32-8.28 (m, 1 H), 7.79-7.75 (m, 2 H), 7.65-7.61 (m, 2 H), 7.56 (t, J = 8.1 
Hz, 1 H), 7.44-7.41 (m, 1 H), 0.26 (s, 9 H); 13C NMR (100 MHz, DMSO-d6): δ 158.80, 
157.08, 155.06, 145.25, 139.23, 134.41, 131.29, 130.67, 130.09, 129.60, 123.52, 
123.33, 121.59, 104.87, 99.29, 95.34, 79.61, 0.26; HRMS-ESI (m/z): [M + H]+ calcd for 
C22H20ClN5Si, 418.1249; found 418.1254. 
Synthesis of 5.1:  Compound 5.S-3 (2.3 g, 6.6 mmol) was added to an oven-dried 
flask.  Tetrahydrofuran (28 mL) was then added followed by a 1 M solution of 
tetrabutlyammonium fluoride  in THF (6.6 mL). The reaction mixture was allowed to stir 
at room temperature for 1 hour. 1 N HCl (6.6 mL) was added. The organic solvent was 
then removed under reduced pressure. The reaction mixture was then suspended in 
water (100 mL), and subsequently filtered. The residual solid was rinsed twice with 
water (20 mL). After drying, 1.3 g (68% yield) of compound 5.1 was obtained as a light 
tan solid.  Spectral data. 1H NMR (500 MHz, DMSO-d6): δ 8.42-8.40 (m, 2 H), 8.31-
8.27 (m, 1 H), 7.80-7.75 (m, 2 H), 7.66-7.62 (m, 2 H), 7.60-7.56 (m, 1 H), 7.48-7.44 (m, 
1 H), 4.34 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 158.83, 157.15, 155.12, 145.27, 
139.24, 134.42, 131.31, 130.71, 130.17, 129.74, 129.63, 123.89, 122.89, 121.63, 99.25, 
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83.30, 81.98; HRMS-ESI (m/z): [M + H]+ calcd for C19H12ClN, 346.0854; found 
346.0856. 
 
 
Synthesis of 5.S-4: Benzyl bromide (1.0 g, 5.9 mmol) was added to an oven-dried 
flask. Dioxane (22 mL) and water (7 mL) were added, followed by sodium azide (1.9 g, 
29 mmol). The reaction mixture was heated to 65oC overnight. After the reaction was 
cooled to room temperature dioxane was removed under reduced pressure. The 
aqueous phase was then extracted with ethyl acetate (7 mL) three times. The organic 
layers were then collected and dried over sodium sulfate. After filtration, removal of 
solvent afforded 5.S-4 (0.7 g, 90% yield) as a light yellow oil. Spectral data. 1H NMR 
(500 MHz, CDCl3): δ 7.44-7.33 (m, 5 H), 4.36 (s, 2 H); 
13C NMR (100 MHz, CDCl3): δ 
135.47, 128.89, 128.35, 128.28, 54.80; HRMS-EI (m/z): calcd for C7H7N3, 133.0640; 
found 133.0640. 
 
Synthesis of 5.S-5: 4-(bromomethyl)-1,1'-biphenyl (247 mg, 1.0 mmol) was added to 
an oven-dried flask. Dioxane (3.8 mL) and water (1.2 mL) were then added, followed by 
sodium azide (325 mg, 5.0 mmol). The reaction mixture was heated to 60oC overnight. 
After the reaction was cooled to room temperature dioxane was removed under reduced 
pressure. The aqueous phase was then extracted with ethyl acetate (5 mL) three times. 
The organic layers were then collected and dried over sodium sulfate. After filtration, 
removal of solvent afforded 5.S-5 (188 mg, 90% yield) as a light yellow solid. Spectral 
data. 1H NMR (400 MHz, DMSO-d6): δ 7.69-7.62 (m, 4 H), 7.46-7.41 (m, 4 H), 7.37-7.31 
(m, 1 H), 4.46 (s, 2 H); 13C NMR (100 MHz, DMSO-d6): δ 140.40, 140.03, 135.22, 
129.50, 129.40, 128.04, 127.42, 127.12, 53.71; HRMS-ESI (m/z): calcd for C13H11N3, 
209.0953; found 209.0961. 
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Synthesis of 5.S-6: 3-(bromomethyl)-1,1'-biphenyl (247 mg, 1.0 mmol) was added to 
an oven-dried flask. Dioxane (3.8 mL) and water (1.2 mL) were then added, followed by 
sodium azide (325 mg, 5.0 mmol). The reaction mixture was heated to 60oC overnight. 
After the reaction was cooled to room temperature dioxane was removed under reduced 
pressure. The aqueous phase was then extracted with ethyl acetate (5 mL) three times. 
The organic layers were then collected and dried over sodium sulfate. After filtration, 
removal of solvent afforded 5.S-6 (180 mg, 86% yield) as a light yellow oil. Spectral 
data. 1H NMR (500 MHz, CDCl3): δ 7.64-7.58 (m, 3 H), 7.56 (s, 1 H), 7.52-7.46 (m, 3 
H), 7.42-7.37 (m, 1 H), 7.35-7.31 (m, 1 H), 4.44 (s, 2 H); 13C NMR (100 MHz, CDCl3): δ 
141.92, 140.64, 135.93, 129.29, 128.85, 127.58, 127.21, 127.13, 127.02, 126.98, 54.85; 
HRMS-EI (m/z): calcd for C13H11N3, 209.0953; found 209.0957. 
 
 
Synthesis of 5.S-7: tert-butyl (3-(hydroxymethyl)phenyl)carbamate2 (1.0 g, 4.5 mmol) 
was added to an oven-dried flask. The reaction vessel was evacuated using a vacuum 
pump and subsequently filled with N2. This procedure was repeated for a total of 3 
times. Dichloromethane (22 mL) was added. The reaction mixture was cooled with an 
ice bath. Diethylisopropylamine (0.7 g, 5.4 mmol) was added followed by 
methanesulfonyl chloride (0.56 g, 4.9 mmol). The reaction mixture was allowed to stir 
for 5 minutes, at which time the reaction was allowed to warm to room temperature. The 
reaction mixture was stirred for an additional 60 minutes at room temperature. The 
reaction was then diluted with dichloromethane (40 mL), washed with 1 N HCl (60 mL), 
followed by a wash with saturated NaHCO3 (60 mL). The organic layer was then dried 
over Na2SO4. The solvent was removed under reduced pressure, which resulted in a 
clear oil and was carried on without further purification. To the flask containing the crude 
intermediate was added sodium azide (1.5 g, 22.4 mmol), followed by a THF/water 
mixture (3:1, 20 mL). The reaction mixture was heated to 50oC overnight. The reaction 
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mixture was then allowed to cool to room temperature. 1 N NaOH was added (5 mL). 
The organic solvent was removed under reduced pressure. The aqueous layer was 
extracted with ethyl acetate (20 mL) three times. The organic layers were combined and 
dried over Na2SO4. The solvent was removed under reduced pressure, and resulted in 
clear oil that was carried on without further purification. To the flask containing the crude 
intermediate was added DCM (20 mL) and trifluoroacetic acid (6 mL). The reaction 
mixture was stirred at room temperature for 60 minutes. Solvent was removed under 
reduced pressure. Chloroform (40 mL) was added, and solvent was again removed 
under reduced pressure. The resulting oil was dissolved in ethyl acetate (40 mL) and 
was washed with 1 N NaOH (40 mL), and then brine (40 mL). The organic layer was 
then dried over Na2SO4. The crude reaction mixture was then purified by silica gel 
chromatography using a Biotage Isolera One (linear gradient 0 → 100% EtOAc in 
hexanes) to yield 266 mg (39% yield over three steps) of compound 5.S-7 as a light 
orange oil.   Spectral data. 1H NMR (500 MHz, CDCl3): δ 7.21-7.16 (m, 1 H), 6.75-6.66 
(m, 3 H), 4.26 (s, 2 H), 3.91 (br s, 2 H); 13C NMR (100 MHz, CDCl3): δ 146.31, 136.56, 
129.78, 118.60, 115.21, 114.82, 54.77; HRMS-EI (m/z): calcd for C7H8N4, 148.0749; 
found 148.0749. 
 
 
Synthesis of 5.S-8: 3-(azidomethyl)aniline (44 mg, 0.3 mmol) was added to an oven-
dried flask. Dichloromethane (1 mL) was then added. The reaction was cooled in an ice 
bath. Benzoyl chloride (42 mg, 0.3 mmol) was then added, followed by triethylamine (39 
mg, 0.4 mmol). The reaction was allowed to warm to room temperature and stir 
overnight. The reaction was then diluted with dichoromethane (20 mL) and washed with 
water (20 mL). The aqueous phase was then back-extracted with dichloromethane three 
times (20 mL each). The organic layers were collected and dried over sodium sulfate. 
The crude reaction mixture was then purified by silica gel chromatography using a 
Biotage Isolera One (linear gradient 0 → 100% EtOAc in hexanes). 5.S-8 was isolated 
as a yellow solid (68 mg, 85% yield). Spectral data. 1H NMR (400 MHz, DMSO-d6): δ 
10.30 (s, 1 H), 7.95-7.91 (m, 2 H), 7.83-7.81 (m, 1 H), 7.74-7.70 (m, 1H), 7.59-7.47 (m, 
3H), 7.35 (t, J = 7.83 Hz, 1 H), 7.09-7.05 (m, 1 H), 4.43 (s, 2 H) ; 13C NMR (100 MHz, 
DMSO-d6): δ 166.07, 140.00, 136.53, 135.27, 132.06, 129.42, 128.82, 128.11, 124.00, 
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120.47, 120.44, 54.16; HRMS-APCI (m/z): [M + H]+ calcd for C14H12N4O, 253.1084; 
found 253.1088. 
 
Synthesis of 5.S-9: 3-(azidomethyl)aniline (44 mg, 0.3 mmol) was added to an oven-
dried flask. Dichloromethane (1 mL) was then added. The reaction was cooled in an ice 
bath. Phenylisocyanate (36 mg, 0.3 mmol) was then added. The reaction was allowed 
to warm to room temperature and stir overnight. Solvent was removed under reduced 
pressure. The crude reaction mixture was dissolved in DMSO (1 mL), and purified by 
reverse-phase HPLC (25 →90% acetonitrile in water) to yield 45 mg (56% yield) of the 
product as a white solid. Spectral data. 1H NMR (500 MHz, DMSO-d6): δ 8.76 (s, 1 H), 
8.67 (s, 1 H), 7.53-7.51 (m, 1 H), 7.47-7.43 (m, 2 H), 7.41-7.37 (m, 1 H), 7.33-7.25 (m, 3 
H), 6.99-6.94 (m, 2 H), 4.42 (s, 2 H); 13C NMR (100 MHz, DMSO-d6): δ 152.91, 140.51, 
140.03, 136.67, 129.61, 129.23, 122.33, 122.19, 118.65, 118.27, 54.13; HRMS-APCI 
(m/z): [M + H]+ calcd for C14H13N5O, 268.1193; found 268.1195. 
 
 
Synthesis of 5.2: Compound 5.1 (18 mg, 0.05 mmol) and Cp*RuCl(COD) (2 mg, 0.005 
mmol) were added to a flame-dried round-bottom flask. The reaction vessel was 
evacuated using a vacuum pump and subsequently filled with N2, this procedure was 
repeated for a total of 3 times. THF (1 mL) and 5.S-4 (7 mg, 0.05 mmol) were then 
added. The reaction mixture was allowed to stir at room temperature overnight. THF 
was removed under reduced pressure. The crude mixture was then dissolved in DMSO 
(1 mL), and then purified by reverse-phase HPLC (linear gradient of 25 → 90% CH3CN 
in H2O) to yield 12 mg (48% yield) of compound 5.2 as a white solid.  Spectral data. 
1H 
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NMR (500 MHz, DMSO-d6): δ 8.37-8.30 (m, 3 H), 8.07 (s, 1 H), 7.76-7.71 (m, 2 H), 
7.68-7.61 (m, 3 H), 7.47-7.42 (m, 1 H), 7.28-7.20 (m, 3 H), 7.10-7.05 (m, 2 H), 5.76 (s, 2 
H); 13C NMR (100 MHz, DMSO-d6): δ 158.81, 157.09, 155.13, 145.26, 139.43, 137.55, 
136.35, 134.43, 133.76, 131.30, 130.69, 130.46, 129.62, 129.10, 128.23, 127.78, 
127.35, 126.69, 121.95, 120.84, 99.21, 51.70; HRMS-ESI (m/z): [M + H]+ calcd for 
C26H19ClN8, 479.1494; found 479.1489. 
 
 
Synthesis of 5.3: Compound 5.1 (18 mg, 0.05 mmol) and Cp*RuCl(COD) (2 mg, 0.005 
mmol) were added to a flame-dried round-bottom flask. The reaction vessel was 
evacuated using a vacuum pump and subsequently filled with N2, this procedure was 
repeated for a total of 3 times. THF (1 mL) and 5.S-5 (9 mg, 0.05 mmol) were then 
added. The reaction mixture was allowed to stir at room temperature overnight.  THF 
was removed under reduced pressure. The crude mixture was then dissolved in DMSO 
(1 mL), and then purified by reverse-phase HPLC (linear gradient of 25 → 90% CH3CN 
in H2O) to yield 10 mg (35% yield) of compound 5.3 as a white solid.  Spectral data. 
1H 
NMR (500 MHz, DMSO-d6): δ 8.41-8.37 (m, 1 H), 8.32 (s, 1 H), 8.30-8.28 (m, 1 H), 8.10 
(s, 1 H), 7.73-7.67 (m, 3 H), 7.57-7.53 (m, 6 H), 7.52-7.49 (m, 1 H), 7.44-7.40 (m, 2 H), 
7.37-7.32 (m, 1 H), 7.21-7.18 (m, 2 H), 5.79 (s, 2 H); 13C NMR (100 MHz, DMSO-d6): δ 
158.81, 157.10, 155.12, 145.30, 139.99, 139.80, 139.46, 137.59, 135.49, 134.42, 
133.76, 131.29, 130.66, 130.52, 129.61, 129.34, 128.10, 128.00, 127.82, 127.34, 
126.97, 126.85, 122.01, 120.87, 99.24, 51.41; HRMS-ESI (m/z): [M + H]+ calcd for 
C32H23ClN8, 555.1087; found 555.1805. 
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Synthesis of 5.4: Compound 5.1 (18 mg, 0.05 mmol) and Cp*RuCl(COD) (2 mg, 0.005 
mmol) were added to a flame-dried round-bottom flask. The reaction vessel was 
evacuated using a vacuum pump and subsequently filled with N2, this procedure was 
repeated for a total of 3 times. THF (1 mL) and 5.S-6 (9 mg, 0.05 mmol) were then 
added. The reaction mixture was allowed to stir at room temperature overnight.  THF 
was removed under reduced pressure. The crude mixture was then dissolved in DMSO 
(1 mL), and then purified by reverse-phase HPLC (linear gradient of 25 → 90% CH3CN 
in H2O) to yield 12 mg (42% yield) of compound 5.4 as a white solid.  Spectral data. 
1H 
NMR (400 MHz, DMSO-d6): δ 8.37-8.32 (m 2H), 8.28 (s 1H), 8.90 (s 1H), 7.71-7.65 (m 
3H), 7.63-7.58 (m 2H), 7.52-7.45 (m 2H) 7.39-7.25 (m 7H), 7.03-7.08 (s 1H), 5.87-5.79 
(s 2H); 13C NMR (100 MHz, DMSO-d6): δ 158.79, 157.04, 155.12, 145.23, 140.90, 
139.94, 139.45, 137.60, 136.98, 134.41, 133.84, 131.26, 130.63, 130.48, 129.80, 
129.60, 129.23, 127.97, 127.85, 126.89, 126.77, 126.62, 126.47, 125.97, 121.88, 
120.94, 99.22, 51.84; HRMS-ESI (m/z): [M + H]+ calcd for C32H23ClN8, 555.1807; found 
555.1804. 
 
Synthesis of 5.5: Compound 5.1 (18 mg, 0.05 mmol) and Cp*RuCl(COD) (2 mg, 0.005 
mmol) were added to a flame-dried round-bottom flask. The reaction vessel was 
evacuated using a vacuum pump and subsequently filled with N2, this procedure was 
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repeated for a total of 3 times. THF (1 mL) and 5.S-8 (10 mg, 0.05 mmol) were then 
added. The reaction mixture was allowed to stir at room temperature overnight.  THF 
was removed under reduced pressure. The crude mixture was then dissolved in DMSO 
(1 mL), and then purified by reverse-phase HPLC (linear gradient of 25 → 90% CH3CN 
in H2O) to yield 14 mg (45% yield) of compound 5.5 as a white solid.  Spectral data. 
1H 
NMR (500 MHz, DMSO-d6): δ 10.23 (s, 1 H), 8.38-8.33 (m, 2 H), 8.31 (s, 1 H), 8.10 (s, 1 
H), 7.87-7.84 (m, 2 H), 7.73-7.66 (m, 4 H), 7.63-7.59 (m, 2 H), 7.59-7.54 (m, 2 H), 7.51-
7.46 (m, 3 H), 7.22 (t, J = 7.82 Hz, 1 H), 6.84-6.81 (m, 1 H), 5.76 (s, 2 H); 13C NMR (100 
MHz, DMSO-d6): δ 165.93, 158.79, 157.08, 155.14, 145.22, 140.10, 139.47, 137.66, 
136.91, 135.18, 134.38, 133.75, 131.99, 131.30, 130.65, 130.47, 129.60, 129.34, 
128.73, 128.05, 127.82, 126.73, 122.48, 121.95, 120.94, 119.92, 118.83, 99.20, 51.75; 
HRMS-ESI (m/z): [M + H]+ calcd for C33H24ClN9O, 598.1865; found 598.1866. 
 
Synthesis of 5.6: Compound 5.1 (18 mg, 0.05 mmol) and Cp*RuCl(COD) (2 mg, 0.005 
mmol) were added to a flame-dried round-bottom flask. The reaction vessel was 
evacuated using a vacuum pump and subsequently filled with N2, this procedure was 
repeated for a total of 3 times. THF (1 mL) and 5.S-9 (11 mg, 0.05 mmol) were then 
added. The reaction mixture was allowed to stir at room temperature overnight.  THF 
was removed under reduced pressure. The crude mixture was then dissolved in DMSO 
(1 mL), and then purified by reverse-phase HPLC (linear gradient of 25 → 90% CH3CN 
in H2O) to yield 14 mg (44% yield) of compound 5.6 as a white solid.  Spectral data. 
1H 
NMR (500 MHz, DMSO-d6): δ 8.73 (s, 1 H), 8.59 (s, 1 H), 8.38-8.32 (m, 3 H), 8.10 (s, 1 
H), 7.73-7.66 (m, 3 H), 7.64-7.60 (m, 2 H), 7.49-7.46 (m, 1 H), 7.41-7.35 (m, 3 H), 7.27-
7.22 (m, 2 H), 7.17-7.12 (m, 2 H), 6.97-6.92 (m, 1 H), 6.68-6.64 (m, 1 H), 5.73 (s, 2 H); 
13C NMR (100MHz, DMSO-d6): δ 158.81, 157.10, 155.14, 152.73, 145.26, 140.63, 
139.99, 139.46, 137.65, 137.14, 134.39, 133.75, 131.30, 130.66, 130.48, 129.61, 
129.18, 127.79, 126.71, 122.25, 121.97, 120.87, 120.46, 118.56, 117.71, 116.49, 99.21, 
51.70;  HRMS-ESI (m/z): [M + H]+ calcd for C33H25ClN10O; 613.1974, found 613.1971. 
161 
 
 
Synthesis of 5.S10: Compound 5.1 (45 mg, 145 µmol) was added to an oven dried 
microwave vial, followed by copper iodide and 1 ml DMF containing 2 equivalents of 
5.S-4 (39 mg, 290 µmol). The reaction was heated to 75oC in a microwave reactor for 
45 min. After the reaction was cooled to room temperature, water (5 mL) was added to 
precipitate product. The reaction was then filtered, rinsed with water twice, followed by a 
hexanes wash. The crude precipitate was then chromatographed via silica gel 
chromatography using a Biotage Isolera One (linear gradient of 40→100% EtOAc in 
DCM) to yield 45 mg of 5.S-10 (65% yield) as a white solid. Spectral data. 1H NMR 
(400 MHz, DMSO-d6): δ 8.74 (s, 1 H), 8.68-8.65 (m, 1 H), 8.37 (s, 1 H), 8.23-8.18 (m, 
1H), 7.80-7.74 (m, 3 H), 7.64-7.56 (m, 3 H), 7.40-7.28 (m, 5 H), 5.64 (s, 1 H); 13C NMR 
(100 MHz, DMSO-d6): δ 158.84, 157.10, 155.07, 146.53, 145.06, 139.62, 136.42, 
134.36, 132.10, 131.47, 130.75, 130.22, 129.65, 129.25, 128.62, 128.34, 123.59, 
122.58, 120.92, 117.91, 99.20, 53.51; HRMS-ESI (m/z): [M + H]+ calcd for C26H19ClN8, 
479.1494; found 479.1495. 
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IV. SPECTRAL DATA FOR COMPOUNDS 5.1–5.6. 
 
5.S-1:  
 
5.S-1 1H:  
 
5.S-1 13C: 
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5.S-2: 
 
5.S-2 1H:  
 
5.S-2 13C: 
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5.S-3:  
 
5.S-3 1H:  
 
5.S-3 13C: 
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5.1:  
 
5.1 1H:  
 
5.1 13C: 
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5.S-4:  
 
5.S-4 1H:   
 
5.S-4 13C: 
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5.S-5:  
 
5.S-5 1H:  
 
5.S-5 13C: 
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5.S-6:  
 
5.S-6 1H:  
 
5.S-6 13C: 
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5.S-7: 
 
5.S-7 1H: 
 
5.S-7 13C: 
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5.S-8:  
 
5.S-8 1H: 
 
5.S-8 13C: 
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5.S-9:  
 
5.S-9 1H:  
 
5.S-9 13C: 
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5.2:  
 
5.2 1H:  
 
5.2 13C: 
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3:  
 
5.3 1H:  
 
5.3 13C: 
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5.4:  
 
5.4 1H:  
 
5.4 13C: 
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5.5:  
 
5.5 1H:  
 
5.5 13C: 
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5.6:  
 
5.6 1H:  
 
5.6 13C: 
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5.S-10:  
 
5.S-10 1H:  
 
5.S-10 13C: 
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V. BIOCHEMICAL CHARACTERIZATION 
General procedure for determination of inhibitor Ki. A continuous fluorescence 
assay30 was used to determine Ki. Reaction volumes of 100 µL were used in 96-well 
plates. 85 µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate 
inhibitor dilution (typically 5000, 1666, 555, 185, 61, 20, 6.8, 2.2, 0.76, 0 µM in DMSO) 
was then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et 
al)31 solution (1.8 mM in DMSO) was added. The reaction was initiated with 10 µL of 
ATP (1 mM in water), and reaction progress was immediately monitored at 405 nm (ex. 
340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 µM 
peptide substrate, 100 µM ATP, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM 
MgCl2, 0.01% Triton X-100.The initial rate data collected was used for determination of 
Ki values. For Ki determination, the kinetic values were obtained directly from nonlinear 
regression of substrate-velocity curves in the presence of various concentrations of the 
inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – LogEC50), X = 
log(concentration) and Y = binding; was used in the nonlinear regression. 
Analytical data for c-Src Ki determination. Each inhibitor Ki value was determined 
using at least three independent experiments, a representative inhibition curve is 
shown. 
5.1: 
 
 
Avg Ki =  1,452 ± 562 nM 
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5.2: 
  
Avg Ki = 207 ± 13 nM 
 
5.3: 
  
Avg Ki ≥ 60 µM 
 
5.4: 
  
Avg Ki = 44  ± 11 nM 
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5.5: 
 
 
Avg Ki = 37 ± 21 µM 
 
5.6: 
  
Avg Ki ≥ 60 µM 
 
5.S10: 
 
 
Avg Ki ≥ 60 µM 
 
181 
 
PP2: 
 
 
Avg Ki = 33 ± 7 nM 
 
Analytical data for c-Abl Ki determination. Each inhibitor Ki value was determined 
using three independent experiments, a representative inhibition curve is shown. 
5.1: 
 
 
Avg Ki = 7,150 ± 3,390 µM 
 
5.2: 
  
Avg Ki ≥ 60 µM 
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5.4: 
 
 
Avg Ki ˃ 125 µM 
 
PP2: 
 
 
Avg Ki = 325 ± 8 nM 
 
Analytical data for c-Src-TM (Q275G, C277Q, F278Y) Ki determination. Each 
inhibitor Ki value was determined using three independent experiments, a 
representative inhibition curve is shown. 
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5.4: 
 
 
Avg Ki = 175 ± 21 nM 
 
 
 
 
 
 
 
Analytical data for phosphorylated c-Src Ki determination. Each inhibitor Ki value 
was determined using three independent experiments, a representative inhibition curve 
is shown. 
5.4: 
 
 
Avg Ki = 49 ± 11 nM 
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Analytical data for three-domain c-Src Ki determination. Each inhibitor Ki value was 
determined using three independent experiments, a representative inhibition curve is 
shown. 
5.4: 
  
Avg Ki = 46 ± 22 nM 
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VI. MOLECULAR MODELS 
Molecular visualization of c-Src and c-Abl structures was performed using PyMol v.1.4 
(Schrodinger). The starting structure for c-Src was 3DQW and the starting structure for 
c-Abl was 2G21. 
A. PP2 bound to c-Src. 
P-loop (residues 273–281) is denoted in red:  
 
B. PP2 bound to c-Abl. 
P-loop (residues 248–256) is denoted in red:  
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C. Overlay of c-Src and c-Abl structures with PP2 bound. 
c-Src P-loop is denoted in yellow and c-Abl P-loop is denoted in red:  
 
 
 
D. Molecular modeling of inhibitors bound to c-Src 
Molecular modeling was performed using MOE 2011.05 (Chemical Computing Group). 
The starting structure for c-Src was 3DQW and the starting structure for c-Abl was 2G2I.  
Structures of PP2 bound to Src-family kinases were used to obtain a model of PP2 
bound to both c-Src and c-Abl (main text Figure 2). 
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E. Model image of PP2~alkyne (5.1) bound to c-Src: 
 
 
F. Model image of compound 5.2 bound to c-Src: 
 
G. Model image of compound 5.4 bound to c-Src: 
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H. Molecular modeling of inhibitors bound to homologous kinases. 
Molecular modeling was performed using MOE 2011.05 (Chemical Computing Group). 
The starting structure for c-Src was 3DQW, the starting structure for c-Abl was 2G2I, the 
starting structure for Hck was 2HK5, and the starting structure for Lck was 1QPE.  
Compound 5.4 was docked into c-Src structure and protein alignment performed by 
PyMol v.1.4 (Schrodinger). Kd values were obtained from KINOMEscan (DiscoveRx) as 
reported on page S49 of Supporting Information. 
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X. KINOME PROFILING OF PP2 AND COMPOUND 5.4. 
 
Kinome profiling for PP2 and compound 5.4 was performed by KINOMEScan 
(DiscoveRx, Fremont, CA). Both compounds were profiled at a concentration of 10 M.  
 
A. PP2 TREEspot analysis: 
1% of control:  10% of control:  35% of control: 
   
 
B. S-Scores for PP2: 
S(1) = 0.147 
S(10) = 0.313 
S(35) = 0.448 
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C. Tabulated data for PP2: 
 
Kinase % of control 
 
Kinase % of control 
ABL1(E255K)-phosphorylated 0.8 
 
JNK1 66 
ABL1(F317I)-nonphosphorylated 6.6 
 
JNK2 20 
ABL1(F317I)-phosphorylated 23 
 
JNK3 12 
ABL1(F317L)-nonphosphorylated 3.4 
 
KIT 0 
ABL1(F317L)-phosphorylated 18 
 
KIT(A829P) 97 
ABL1(H396P)-nonphosphorylated 0.05 
 
KIT(D816H) 52 
ABL1(H396P)-phosphorylated 0.35 
 
KIT(D816V) 0.45 
ABL1(M351T)-phosphorylated 32 
 
KIT(L576P) 0.9 
ABL1(Q252H)-nonphosphorylated 2.6 
 
KIT(V559D) 0 
ABL1(Q252H)-phosphorylated 0.9 
 
KIT(V559D,T670I) 84 
ABL1(T315I)-nonphosphorylated 92 
 
KIT(V559D,V654A) 30 
ABL1(T315I)-phosphorylated 84 
 
KIT-autoinhibited 73 
ABL1(Y253F)-phosphorylated 0.5 
 
LCK 0.4 
ABL1-nonphosphorylated 2.6 
 
LIMK1 52 
ABL1-phosphorylated 0.55 
 
LIMK2 100 
ABL2 6.8 
 
LKB1 86 
ACVR1 0 
 
LOK 44 
ACVR1B 10 
 
LYN 9.2 
ACVR2A 2.8 
 
MAP3K4 100 
ACVR2B 2.4 
 
MAP4K2 84 
ACVRL1 4.4 
 
MAP4K3 72 
ADCK3 84 
 
MAP4K4 70 
AKT1 100 
 
MAP4K5 79 
AKT2 97 
 
MAPKAPK2 100 
ALK 100 
 
MARK3 53 
AURKA 71 
 
MEK1 0.65 
AURKB 99 
 
MEK2 1.2 
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AXL 60 
 
MEK3 70 
BLK 0.75 
 
MEK4 70 
BMPR2 20 
 
MEK5 6.8 
BMX 21 
 
MET 87 
BRAF 14 
 
MKNK1 100 
BRAF(V600E) 9 
 
MKNK2 62 
BRK 0.1 
 
MLK1 81 
BTK 3.4 
 
MRCKA 8 
CDK11 29 
 
MRCKB 13 
CDK2 79 
 
MST4 74 
CDK3 100 
 
NLK 1.4 
CDK7 80 
 
p38-alpha 57 
CDK9 95 
 
p38-beta 13 
CHEK1 100 
 
PAK1 98 
CSF1R 13 
 
PAK2 75 
CSK 0.95 
 
PAK4 87 
CSNK1D 24 
 
PCTK1 94 
CSNK1E 0.1 
 
PDGFRA 28 
CSNK1G2 79 
 
PDGFRB 0.15 
DCAMKL1 96 
 
PDPK1 100 
DDR1 0.25 
 
PFCDPK1(P.falciparum) 0.25 
DDR2 0 
 
PFPK5(P.falciparum) 96 
DMPK 84 
 
PIK3C2B 100 
DMPK2 28 
 
PIK3CA 79 
DYRK1B 76 
 
PIK3CG 4.7 
EGFR 6.2 
 
PIM1 100 
EGFR(E746-A750del) 7.4 
 
PIM2 74 
EGFR(G719C) 3.4 
 
PIM3 100 
EGFR(G719S) 2.9 
 
PKAC-alpha 49 
EGFR(L747-E749del, A750P) 14 
 
PKMYT1 77 
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EGFR(L747-S752del, P753S) 12 
 
PKNB(M.tuberculosis) 81 
EGFR(L747-T751del,Sins) 6.3 
 
PLK1 100 
EGFR(L858R) 18 
 
PLK3 97 
EGFR(L858R,T790M) 57 
 
PLK4 32 
EGFR(L861Q) 5 
 
PRKCE 55 
EGFR(S752-I759del) 7.8 
 
RAF1 25 
EGFR(T790M) 2 
 
RET 0 
EPHA1 2.8 
 
RET(M918T) 0.55 
EPHA2 8.2 
 
RET(V804L) 75 
EPHA3 14 
 
RET(V804M) 76 
EPHA4 11 
 
RIOK2 67 
EPHA5 3.2 
 
RIPK2 0 
EPHA6 9.1 
 
ROCK1 76 
EPHA7 90 
 
ROCK2 44 
EPHA8 0.9 
 
RSK2(Kin.Dom.1-N-
terminal) 44 
EPHB1 3.6 
 
SIK 0.35 
EPHB2 29 
 
SIK2 1.4 
EPHB3 0.85 
 
SLK 77 
EPHB4 5.4 
 
SNARK 80 
EPHB6 4.6 
 
SRC 0.15 
ERBB2 3 
 
SRMS 42 
ERBB3 8.2 
 
SRPK3 100 
ERBB4 9.3 
 
STK36 41 
ERK1 95 
 
SYK 85 
FAK 78 
 
TEC 45 
FGFR1 58 
 
TESK1 36 
FGFR2 58 
 
TGFBR1 10 
FGFR3 88 
 
TGFBR2 0.5 
FGFR4 43 
 
TIE2 63 
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FGR 1.2 
 
TNIK 34 
FLT1 72 
 
TNK2 8 
FRK 0.3 
 
TNNI3K 23 
FYN 0.4 
 
TRKA 59 
GAK 3.8 
 
TSSK1B 29 
GCN2(Kin.Dom.2,S808G) 93 
 
TXK 0.2 
GSK3B 100 
 
TYK2(JH1domain-
catalytic) 91 
HCK 0.45 
 
ULK2 98 
IGF1R 100 
 
VEGFR2 71 
IKK-alpha 100 
 
WEE1 100 
IKK-beta 100 
 
YANK3 59 
INSR 72 
 
YES 1.5 
JAK2(JH1domain-catalytic) 73 
 
ZAK 68 
JAK3(JH1domain-catalytic) 100 
 
ZAP70 100 
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D. Compound 5.4 TREEspot analysis: 
 
1% of control:  10% of control:  35% of control: 
 
   
 
E. S-Scores for Compound 5.4: 
 
S(1) = 0.011 
S(10) = 0.033 
S(35) = 0.067 
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F. Tabulated data for Compound 5.4: 
 
KINOMEscan Gene Symbol Percent Control 
 
KINOMEscan Gene Symbol Percent Control 
ABL1(E255K)-phosphorylated 100 
 
LKB1 100 
ABL1(T315I)-phosphorylated 84 
 
MAP3K4 32 
ABL1-phosphorylated 100 
 
MAPKAPK2 99 
ACVR1B 55 
 
MARK3 93 
ADCK3 37 
 
MEK1 80 
AKT1 100 
 
MEK2 100 
AKT2 100 
 
MET 100 
ALK 100 
 
MKNK1 78 
AURKA 100 
 
MKNK2 90 
AURKB 96 
 
MLK1 100 
AXL 100 
 
p38-alpha 100 
BMPR2 100 
 
p38-beta 56 
BRAF 4.2 
 
PAK1 100 
BRAF(V600E) 1.7 
 
PAK2 95 
BTK 92 
 
PAK4 100 
CDK11 100 
 
PCTK1 85 
CDK2 83 
 
PDGFRA 76 
CDK3 100 
 
PDGFRB 36 
CDK7 92 
 
PDPK1 100 
CDK9 100 
 
PIK3C2B 95 
CHEK1 83 
 
PIK3CA 100 
CSF1R 99 
 
PIK3CG 58 
CSNK1D 99 
 
PIM1 100 
CSNK1G2 100 
 
PIM2 100 
DCAMKL1 100 
 
PIM3 100 
DYRK1B 100 
 
PKAC-alpha 100 
EGFR 65 
 
PLK1 87 
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EGFR(L858R) 71 
 
PLK3 74 
EPHA2 94 
 
PLK4 78 
ERBB2 43 
 
PRKCE 100 
ERBB4 99 
 
RAF1 3.2 
ERK1 100 
 
RET 100 
FAK 100 
 
RIOK2 74 
FGFR2 60 
 
ROCK2 100 
FGFR3 62 
 
RSK2(Kin.Dom.1-N-terminal) 92 
FLT3 100 
 
SNARK 91 
GSK3B 90 
 
SRC 0.55 
IGF1R 100 
 
SRPK3 100 
IKK-alpha 79 
 
TGFBR1 33 
IKK-beta 82 
 
TIE2 47 
INSR 85 
 
TRKA 100 
JAK2(JH1domain-catalytic) 84 
 
TSSK1B 83 
JAK3(JH1domain-catalytic) 79 
 
TYK2(JH1domain-catalytic) 84 
JNK1 87 
 
ULK2 99 
JNK2 100 
 
VEGFR2 73 
JNK3 100 
 
YANK3 98 
KIT 28 
 
ZAP70 100 
KIT(D816V) 20 
   KIT(V559D,T670I) 90 
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G. TREEspot comparison using scanEDGE (96 kinase) diverse panel (35% of 
control): 
 
PP2:     Compound 5.4: 
  
 
H. S-Score comparison using scanEDGE panel (96 diverse kinases): 
 
PP2    Compound 5.4 
 
S(1) = 0.07   S(1) = 0.01 
S(10) = 0.16   S(10) = 0.04 
S(35) = 0.31   S(35) = 0.07 
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VIII. KD DETERMINATION FOR COMPOUND 5.4. 
Kd measurements were performed using KINOMEscan technology (DiscoveRx, 
Fremont, CA). An 11-point 3-fold serial dilution of compound 5.4 was prepared in 100% 
DMSO at 100x final test concentration and subsequently diluted to 1x in the assay (final 
DMSO concentration = 2.5%). Kd was determined using a compound top concentration 
= 30,000 nM. A Kd value reported as 40,000 nM indicates that the Kd was determined to 
be >30,000 nM.  
 
Compound Name KINOMEscan Gene Symbol Kd (nM)  
KB-4-102 FGR 240  
KB-4-102 FYN 40000  
KB-4-102 HCK 4400  
KB-4-102 LCK 160  
KB-4-102 LYN 3200  
KB-4-102 SRC 86  
KB-4-102 YES 720  
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IX. CELLULAR CHARACTERIZATION. 
A. c-Src Autophosphorylation. This assay was performed by ProQinase GmbH 
(Freiburg, Germany). Murine embryonal fibroblast (MEF) cells were used that express a 
high level of exogenously introduced full-length Src. The high Src expression level 
results in a constitutive tyrosine autophosphorylation of Src at Tyr418. MEF-SRC cells 
were plated in DMEM supplemented with 10% FCS in multiwell cell culture plates. 
Compound incubation was done in serum-free medium. Quantification of Src 
phosphorylation was assessed in 96-well plates via ELISA using a phospho-Src specific 
antibody and a secondary detection antibody. Raw data were converted into percent 
phosphorylation and the IC50 value was determined using GraphPad Prism software. 
Each concentration has n = 2 data points and the graph below represents the average 
at each concentration. 
 
 
B. p-Erk AlphaScreen. SKBR3 cells (ATCC) were plated in 96-well plates at a 
density of 1.0–2.0 x 104 cells per well. The cells were grown to 80-90% confluency prior 
to overnight serum-starvation in DMEM, 0.1% BSA. The serum-free media was then 
removed and replaced with DMEM containing 100 M compound 5.4 (or PP2) in 1% 
DMSO. The cells were incubated for 60 min prior to addition of EGF (Sigma Aldrich). 
After incubation, the media was removed and 50 L AlphaScreen lysis buffer 
(PerkinElmer) was added to each well. The lysates were analyzed using the 
AlphaScreen SureFire Erk1/2 (p-Thr202/Tyr204) assay kit (PerkinElmer) according to 
the manufacturer’s protocol. For each compound, n = 4. 
C.  
 
(M) 
202 
 
 
Treatment of SKBR3 cells with 100 M compound 5.4 showed no change in p-Erk 
levels. As a positive control, treatment with 100 M lapatinib (a selective dual-
ErbB2/EGFR inhibitor) shows a large decrease in p-Erk levels. These data are 
consistent with compound 5.4 not inhibiting B-Raf or c-Raf in SKBR3 cells. Lapatinib 
reduces p-Erk levels by reducing p-ErbB2 and p-EGFR levels. 
 
 
In contrast to compound 5.4, PP2 shows a decrease in p-Erk levels upon treatment of 
100 M PP2 to SKBR3 cells. PP2 inhibits ErbB2 and EGFR (see kinome profiling 
section) and cellular inhibition of these kinases will lead to decreased p-Erk levels.  
 
C. Cancer cell growth inhibition assays. 
General procedure:  
1. Cell culture and seeding:  Cells are dispersed from flasks and collected by 
centrifugation (125xg for 5 minutes at room temperature). An aliquot of the 
resuspended cells is mixed with trypan blue solution and the cell number is 
quantified using a hemacytometer. In general, depending on the growth rate of 
the untreated cells, the cells will be plated at 5.0 – 7.5 x 103 cells per well. 100 µL 
of the cell mixture will be added to each well so the concentration should be 10X 
the cells per well in cells per mL. The cells are plated into sterile, clear bottom 96 
well plates and cultured under normal growth conditions overnight prior to dosing 
with compound. 
2. Dosing: The 100% DMSO compound stocks need to be prepared to 100X the 
final concentration that is desired in the assay. 3 µL of the DMSO stock solution 
is then added to 297 µL of the cell growth media to give a DMSO concentration 
of 1%. The cell media is removed by aspiration for adherent cells and replaced 
with 100 µL per well of the cell growth media containing the compound. In 
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general each compound concentration is dosed in triplicate wells. The plates are 
returned to normal culture conditions for 24 – 72 hours.  
3. Assay: After the required incubation period the plates are removed from the 
incubator and 10 µL per well of WST-1 reagent is added. The plates are returned 
to the incubator and the color change is visually monitored for 0.5 – 2 hours. 
When sufficient color change has occurred the plates are shaken on a plate 
shaker for 60 seconds and read in the appropriate plate reader.  
4. Data Analysis: The reference absorbance reading is subtracted from the 
formazan absorbance and the data is plotted as a percentage of the vehicle (1% 
DMSO alone). Data analysis and curve fitting was performed using Graphpad 
Prism. For each cell line, there were n = 3 data points for each concentration. 
Each dose response curve was performed at least twice, providing n ≥ 6 for each 
data point. 
 
C1. HT-29: 
 
 
C2. SK-BR-3: 
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C3. MCF7: 
 
 
C4. MDA-MB-453: 
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C5. NIH-3T3: 
 
D. NCI-60 cancer cell profiling: 
 
One-dose (10 M) cell profiling of compound 5.4 was performed by the NCI 
Developmental Therapeutics Program. The assigned NSC number for compound 5.4 is 
761450.  
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